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ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
SCHOOL OF MEDICINE 
 
Doctor of Medicine 
 
LONGITUDINAL ASSESSMENT OF CYSTIC FIBROSIS PULMONARY 
DISEASE USING CLINICAL, BIOCHEMICAL AND EMERGING 
MICROBIOLOGICAL TECHNIQUES 
 
by Thomas William Vaisey Daniels 
 
Cystic Fibrosis (CF) causes chronic lower respiratory tract infection 
leading to morbidity and mortality.  CF Pulmonary Exacerbations 
(CFPEs) cause accentuated symptoms and increase mortality.  The 
definition and aetiology of CFPEs has however proved elusive.  
Recently, culture independent techniques have shown that there is 
much greater diversity of bacteria than previously detected by 
culture dependent methods.  Building on this, in the work presented 
here, the bacteria in respiratory samples from adults with CF were 
studied over a 12 month period.  Each subject provided thrice weekly 
sputum samples for analysis by culture and culture independent 
microbiological methods.  Concurrently an in-depth assessment of 
their subjective and objective health using Visual Analogue Scales 
(VAS) and spirometry (FEV1) was undertaken.  Inflammation markers 
were also measured. 
   A total of 2061 samples from fourteen adults (mean age 30.2; mean 
FEV1% predicted 53.3%; 6 females; 8 ∆F508 homozygotes) were 
collected. Subjective VAS measures correlated with objective 
spirometric measures.  However, previously unsuspected complexity 
of subjective symptomatology was found.  Ribosomal clone sequence 
analysis identified 90 different species, including 15 not previously 
reported in CF lung disease.  Notably 44% of species detected were 
obligate anaerobes, and 72% were species previously associated with 
the human oro-pharynx. During the study period, subjects 
experienced 42 CFPEs requiring treatment.  New species were not 
seen to enter the bacterial community as aetiological agents for 
CFPEs.  However, whilst treatment for CFPEs caused a large fall in the 
proportion of anaerobic species, no significant change in the 
proportion of Pseudomonas aeruginosa was detected.  
    Significant and potentially important differences in bacterial 
community composition, structure and stability between subjects 
separated by gender, genotype and lung function were observed. 
Moreover, the presence of certain species correlated with subjects 
suffering frequent CFPEs. 
   The results presented here give new insights in to the complexity 
of symptoms and bacterial diversity in CF pulmonary disease. 
   iii 
List of Contents 
List of Contents.................................................................................................. iii 
List of Figures ....................................................................................................vi 
List of Tables.....................................................................................................viii 
DECLARATION OF AUTHORSHIP.................................................................ix 
Acknowledgements........................................................................................x 
Abbreviations.................................................................................................xi 
Chapter 1 -  Introduction................................................................................1 
1.1  CF Pulmonary Exacerbations...............................................................2 
1.1.1  Clinical Significance.......................................................................2 
1.1.2  Costs .............................................................................................3 
1.1.3  Definition .......................................................................................4 
1.1.4  Aetiology........................................................................................9 
1.1.5  Pulmonary Inflammation in Cystic Fibrosis..................................17 
1.2  Airway defence and CFTR gene.........................................................18 
1.2.1  Role of CFTR in airway defence against bacteria .......................18 
1.2.2  Role of CFTR deficiency in inappropriate immune response.......20 
1.2.3  CFTR as Bacterial Binding Site...................................................24 
1.2.4  Summary.....................................................................................25 
1.3  Microbiology Techniques....................................................................26 
1.3.1  Culture-based techniques............................................................27 
1.3.2  Techniques for Molecular analysis of microbial diversity.............31 
1.3.3  PCR techniques...........................................................................35 
1.3.4  Taxonomic Ambiguity of Bacteria................................................42 
1.4  Microbiology of Pulmonary Disease in CF..........................................42 
1.4.1  Recognised pathogens................................................................44 
1.4.2  CF as a Polymicrobial Pulmonary Disease..................................50 
1.5  Inflammation in Clinical CF Pulmonary Disease.................................61 
1.6  Summary............................................................................................62 
1.7  Hypothesis..........................................................................................62 
Chapter 2 -  Materials and Methods.............................................................63 
2.1  Clinical Trial........................................................................................63 
2.1.1  Study Duration.............................................................................63 
2.1.2  Sampling Frequency....................................................................64 
2.1.3  Inclusion and Exclusion Criteria ..................................................65 
2.1.4  Clinical Monitoring Form..............................................................67 
2.1.5  Sputum Sample Collection Methods............................................72 
2.2  Sputum Microbiology..........................................................................76 
2.2.1  Laboratory Culture Techniques ...................................................76 
2.3  Molecular Microbial Analysis ..............................................................78 
2.3.1  Nucleic Acid Extraction................................................................79 
2.3.2  In silico sequence analysis..........................................................82 
2.3.3  16S Ribosomal Clone Sequencing..............................................83 
2.4  Sputum Inflammatory Mediators.........................................................84 
2.4.1  Clinical Sampling Methods ..........................................................84 
2.4.2  Sputum Processing to Generate a Soluble Phase.......................85 
2.4.3  Inflammatory Mediator Analysis...................................................85 
2.5  Definitions...........................................................................................93 
2.6  Statistical Analysis..............................................................................95   iv 
2.7  Validation of Study Techniques ..........................................................97 
2.7.1  Visual Analogue Scales Repeatability Testing ............................97 
2.7.2  Sample Delivery Cold Chain........................................................97 
2.7.3  Duration of Transportation of Sample to Laboratory..................100 
2.7.4  Reproducibility, and Effects of Delays in Time to Freezer on 
Bacterial Diversity....................................................................................101 
2.7.5  Repeatability of Molecular Techniques......................................103 
2.7.6  Discussion.................................................................................104 
Chapter 3 -  Results Overview...................................................................105 
3.1  Overview...........................................................................................105 
3.1.1  Subject Demographics ..............................................................105 
3.2  Pulmonary Exacerbations.................................................................109 
3.3  Results of Bacterial Culture..............................................................111 
Chapter 4 -  Results: Clinical Monitoring....................................................114 
4.1  Analysis of Individual Components of Clinical Monitoring.................114 
4.1.1  Breathlessness VAS..................................................................117 
4.1.2  Cough VAS................................................................................118 
4.1.3  Sputum VAS..............................................................................118 
4.1.4  General Wellbeing VAS.............................................................118 
4.1.5  Spirometric Values ....................................................................119 
4.1.6  Correlations between components of Clinical Monitoring Form.120 
4.2  Individual Subjects’ Response Profile Plots......................................122 
4.2.1  Subject 01 .................................................................................122 
4.2.2  Subject 02 .................................................................................125 
4.2.3  Subject 03 .................................................................................128 
4.2.4  Subject 04 .................................................................................130 
4.2.5  Subject 05 .................................................................................133 
4.2.6  Subject 06 .................................................................................136 
4.2.7  Subject 07 .................................................................................139 
4.2.8  Subject 08 .................................................................................142 
4.2.9  Subject 09 .................................................................................145 
4.2.10  Subject 10 .................................................................................149 
4.2.11  Subject 11 .................................................................................152 
4.2.12  Subject 12 .................................................................................155 
4.2.13  Subject 13 .................................................................................158 
4.2.14  Subject 14 .................................................................................161 
4.3  Relationship between Clinical Monitoring and CFPEs......................164 
4.4  Summary of Clinical Monitoring and CFPE.......................................167 
4.5  Discussion of Clinical Monitoring......................................................168 
Chapter 5 -  Results: Periodic Sampling at Times of Clinical Stability .......171 
5.1  Bacterial Clone Sequence Analysis..................................................174 
5.1.1  Classification of Bacteria Detected by Clone Sequencing.........180 
5.2  TRFLP Sampling Overview ..............................................................180 
5.2.1  TRFLP.......................................................................................180 
5.2.2  Comparison of Bacterial Community Structure by Genotype ....186 
5.2.3  Comparison of Bacterial Community Structure by FEV.............188 
5.2.4  Comparison of Bacterial Community Structure by Gender........191 
5.3  Core/Satellite Analysis of Species Detected.....................................194 
5.4  Discussion........................................................................................196 
Chapter 6 -  Results: Flux around treated CF Pulmonary Exacerbations ..203 
6.1  Variations in Species Richness ........................................................205   v 
6.1.1  Single CFPE from Each Subject................................................205 
6.2  Variations in Species Evenness .......................................................208 
6.3  Variations in Flux between Samples.................................................211 
6.4  Variations in Key Species.................................................................212 
6.5  Multivariate Analysis.........................................................................216 
6.6  Discussion........................................................................................218 
6.6.1  Bacterial community structure ...................................................218 
Chapter 7 -  Inflammatory Mediators .........................................................222 
7.1.1  Inflammatory Mediators vs. Bacterial Community Measures.....225 
7.1.2  Inflammatory Mediators vs. Clinical Data ..................................228 
7.2  Discussion........................................................................................229 
Chapter 8 -  Discussion .............................................................................233 
8.1  Clinical Monitoring ............................................................................234 
8.1.1  Limitations of Clinical Monitoring...............................................238 
8.2  Sputum Culture.................................................................................243 
8.2.1  Limitations of Bacterial Culture..................................................244 
8.3  Inflammatory Mediators....................................................................244 
8.3.1  Limitations of Inflammatory mediators.......................................246 
8.4  Culture independent bacterial analysis.............................................247 
8.4.1  Periodic Stable Sampling ..........................................................247 
8.4.2  Culture Independent Microbiological Analysis of CFPEs...........255 
8.4.3  Polymicrobial diversity in the CF airways: beyond bacteria.......260 
8.4.4  Limitations of Culture Independent Techniques ........................263 
8.5  Future Directions ..............................................................................267 
8.6  Summary..........................................................................................272 
Chapter 9 -  Appendices............................................................................274 
9.1  Clinical Monitoring Form...................................................................274 
9.2  Histograms for Clinical Parameters ..................................................275 
9.3  Box and Whisker Plot for FEV6 Values for All Subjects ...................276 
9.3.1  Distribution of Spirometric Values..............................................277 
9.4  Individual Response Profile Plots .....................................................278 
9.4.1  Subject 01 .................................................................................278 
9.4.2  Subject 02 .................................................................................279 
9.4.3  Subject 03 .................................................................................280 
9.4.4  Subject 04 .................................................................................281 
9.4.5  Subject 05 .................................................................................282 
9.4.6  Subject 06 .................................................................................283 
9.4.7  Subject 07 .................................................................................284 
9.4.8  Subject 08 .................................................................................285 
9.4.9  Subject 09 .................................................................................286 
9.4.10  Subject 10 .................................................................................287 
9.4.11  Subject 11 .................................................................................288 
9.4.12  Subject 12 .................................................................................289 
9.4.13  Subject 13 .................................................................................290 
9.4.14  Subject 14 .................................................................................291 
9.5  Bacterial Clone Sequence Results ...................................................292 
Glossary..........................................................................................................294 
List of References...........................................................................................295 
  
  vi 
List of Figures 
Figure 1-1 - Diagnostic Criteria for diagnosing CFPEs .......................................6 
Figure 1-2 T-RFLP: example of polyacrylamide gel..........................................40 
Figure 1-3 Respiratory Infections in CF. ...........................................................43 
Figure 2-1 Sampling Frequency........................................................................64 
Figure 2-2 Effects of Time from expectoration to sample freezing..................102 
Figure 3-1 CFPE and Antibiotic Courses per Subject.....................................110 
Figure 3-2 Type of Treatment for CFPE by Subject........................................110 
Figure 3-3 Summary of organisms detected by selective culture ...................111 
Figure 3-4 Relationship between CFPEs Gp F streptococci by culture...........113 
Figure 4-1 Visual Analogue Box and Whisker plots........................................117 
Figure 4-2 FEV1 box and whisker plot by subject...........................................119 
Figure 4-3 Scatter plot correlations for four symptom domains.......................121 
Figure 4-4 Subject 01: Response Profile Plot for Sum of VASs......................123 
Figure 4-5 Subject 01: Response Profile Plot for FEV1 and FEV6 .................124 
Figure 4-6 Subject 02: Response Profile Plot for Sum of VASs......................126 
Figure 4-7 Subject 02: Response Profile Plot for FEV1 and FEV6 .................127 
Figure 4-8 Subject 03: Response Profile Plot for Sum of VASs......................129 
Figure 4-9 Subject 03: Response Profile Plot for FEV1..................................129 
Figure 4-10 Subject 04: Response Profile Plot for Sum of VASs....................132 
Figure 4-11 Subject 04: Response Profile Plot for FEV1................................132 
Figure 4-12 Subject 05: Response Profile Plot for Sum of VASs....................135 
Figure 4-13 Subject 05: Response Profile Plot for FEV1 and FEV6 ...............135 
Figure 4-14 Subject 06: Response Profile Plot for Sum of VASs....................137 
Figure 4-15 Subject 06: Response Profile Plot for FEV1 and FEV6 ...............138 
Figure 4-16 Subject 07: Response Profile Plot for Sum of VASs....................141 
Figure 4-17 Subject 07: Response Profile Plot for FEV1 and FEV6 ...............141 
Figure 4-18 Subject 08: Response Profile Plot for Sum of VASs....................144 
Figure 4-19 Subject 08: Response Profile Plot for FEV1 and FEV6. ..............144 
Figure 4-20 Subject 09: Response Profile Plot for Sum of VASs....................148 
Figure 4-21 Subject 09: Response Profile Plot for FEV1 and FEV6 ...............148 
Figure 4-22 Subject 10: Response Profile Plot for Sum of VASs....................151 
Figure 4-23 Subject 10: Response Profile Plot for FEV1 and FEV6 ...............151 
Figure 4-24 Subject 11: Response Profile Plot for Sum of VASs....................154 
Figure 4-25 Subject 11: Response Profile Plot for FEV1 and FEV6 ...............154 
Figure 4-26 Subject 12: Response Profile Plot for Sum of VASs....................157 
Figure 4-27 Subject 12: Response Profile Plot for FEV1 and FEV6 ...............157 
Figure 4-28 Subject 13: Response Profile Plot for Sum of VASs....................160 
Figure 4-29 Subject 13: Response Profile Plot for FEV1 and FEV6 ...............160 
Figure 4-30 Subject 14: Response Profile Plot for Sum of VASs....................163 
Figure 4-31 Subject 14: Response Profile Plot for FEV1 and FEV6 ...............163 
Figure 4-32 Summary of VAS scores for 12 CFPEs.......................................168 
Figure 4-33 Changes in Lung Function for 12 CFPE in 12 Subjects...............168 
Figure 5-1 Rank abundance for species detected by clone sequence............177 
 Figure 5-2 Bacterial Community Stability (Subj 1-8) ......................................183 
Figure 5-3 Bacterial Community Stability (Subj 9-14). ....................................184 
Figure 5-4 Mean bacterial species richness, by T-RFLP and culture..............184 
Figure 5-5 Similarity in bacterial profiles at times of stability...........................185 
Figure 5-6 Bacterial community evenness by CF genotype............................186 
Figure 5-7 Similarity in profiles by CF genotype (Sorensen Index).................187  
  vii 
Figure 5-8 Similarity in profiles by CF genotype.(Bray-Curtis Index)...............187 
Figure 5-9 Bacterial community evenness by Lung Function..........................189 
Figure 5-10 Similarity in profiles by Lung Function. ........................................190 
Figure 5-11 Species richness during clinical stability......................................191 
Figure 5-12 Bacterial community evenness during clinicla stability.................192 
Figure 5-13 Similarity Indexes during clinical stability.....................................193 
Figure 5-14 Principle Component Analysis by gender....................................194 
Figure 6-1. Bacterial species richness around treatment for CFPE ................205 
Figure 6-2 Box and whisker plot of species richness during CFPE.................207 
Figure 6-3 Bacterial Community Richness for Subject 09...............................207 
Figure 6-4. Bacterial community evenness during CFPE................................209 
Figure 6-5 Changes in bacterial community slope for Subject 09...................210 
Figure 6-6 Box plot of Sorensen Similarity Index during CFPE.......................212 
Figure 6-7 Proportion of P. aeruginosa and Prevotella spp. during CFPE......214 
Figure 6-8 Box plot of proportions of Prevotella spp. around CFPE................214 
Figure 6-9 Proportions of anaerobes and P. aeruginosa around CFPE..........215 
Figure 6-10 Proportion of Prevotella spp. for Subject 9 throughout study.......216 
Figure 9-1 Clinical Monitoring Form................................................................274 
Figure 9-2 Distribution of FEV1.......................................................................275 
Figure 9-3 Distribution of Age .........................................................................275 
Figure 9-4 FEV6 box and whisker plot............................................................276 
Figure 9-5 Histogram of FEV1 values for all subjects.....................................277 
  
  viii 
List of Tables 
Table 1-1. Clinical features association with CFPEs.................................................7 
Table 2-1 Media used for microbial culture of sputum samples................................78 
Table 2-2 Measures of Repeatability Testing for VASs.............................................97 
Table 2-3 Results of Specimen Delivery Cold Chain Auditing............................... ...99 
Table 2-4 Results of time to delivery audit................................................................101 
Table 2-5 Results of time to freezer analysis............................................................101 
Table 3-1 Baseline characteristics for individual subjects.........................................106 
Table 3-2 Baseline characteristics for all subjects....................................................106 
Table 3-3 Long term medications taken by subjects during study............................108 
Table 3-4 Pulmonary Exacerbations and antibiotics per subject..............................111 
Table 4-1 Distribution of Values for components of CMF.........................................115 
Table 4-2 Correlations between VAS scores and lung function...............................116 
Table 4-3 Subject 01: CMF Correlations..................................................................125 
Table 4-4 Subject 02: CMF Correlations..................................................................128 
Table 4-5 Subject 03: CMF Correlations..................................................................130 
Table 4-6 Subject 04: CMF Correlations..................................................................133 
Table 4-7 Subject 05: CMF Correlations..................................................................136 
Table 4-8 Subject 06: CMF Correlations..................................................................139 
Table 4-9 Subject 07: CMF Correlations..................................................................142 
Table 4-10 Subject 08: CMF Correlations................................................................145 
Table 4-11 Subject 09: CMF Correlations................................................................149 
Table 4-12 Subject 10: CMF Correlations................................................................152 
Table 4-13 Subject 11: CMF Correlations................................................................155 
Table 4-14 Subject 12: CMF Correlations................................................................158 
Table 4-15 Subject 13: CMF Correlations................................................................161 
Table 4-16 Subject 14: CMF Correlations................................................................164 
Table 4-17 CMF changes during CFPEs..................................................................166 
Table 4-18 Last period of stability prior to CFPE......................................................167 
Table 5-1 Sputum Sampling at Times of Clinical Stability........................................173 
Table 5-2 Semi-quantitative bacterial culture result.................................................179 
Table 5-3 Dominant species/bands by T-RFLP........................................................182 
Table 5-4 Species richness and similarity between samples...................................185 
Table 5-5 Bi-modal Division of Subjects by Lung Function......................................188 
Table 6-1 Antibiotics used in CFPEs analysed in chapter 6.....................................204 
Table 6-2 Classification of Subjects by Frequency of CFPE....................................205 
Table 6-3 Species richness before CFPE................................................................206 
Table 6-4 Comparison of median values for PCA bands.........................................218 
Table 7-1 Inflammatory Mediator results..................................................................224 
Table 7-2 Correlation between bacterial community and inflammatory mediators...227 
Table 7-3 Correlation between clinical measures and inflammatory mediators.......229 
Table 9-1 lassification of species identified by clone sequence analysis.................293 
 
  
  ix 




I, …THOMAS WILLIAM VAISEY DANIELS 
 
declare that the thesis entitled: 
 
LONGITUDINAL ASSESSMENT OF CYSTIC FIBROSIS PULMONARY 




and the work presented in the thesis are both my own, and have been 
generated by me as the result of my own original research.  I confirm that: 
 
 
￿  this work was done wholly or mainly while in candidature for a 
research degree at this University; 
 
￿  where any part of this thesis has previously been submitted for a 
degree or any other qualification at this University or any other 
institution, this has been clearly stated; 
 
￿  where I have consulted the published work of others, this is always 
clearly attributed; 
 
￿  where I have quoted from the work of others, the source is always 
given. With the exception of such quotations, this thesis is entirely my 
own work; 
 
￿  I have acknowledged all main sources of help; 
 
￿  where the thesis is based on work done by myself jointly with others, I 
have made clear exactly what was done by others and what I have 
contributed myself; 
 











  x 
Acknowledgements 
I would not have been able to complete this thesis without the advice and 
encouragement of my two main supervisors, Dr. Mary Carroll and Dr. Kenneth 
Bruce.  The work would also not have been possible without the vision, courage 
and financial support of The Anna Trust (Tisbury House, Tisbury, Salisbury). In 
addition there are others to who I owe a tremendous debt of gratitude for their 
roles in enabling me to complete this work.  They include:  
•  The participants, for who this work is undertaken, and without whom this 
work would have been impossible.  Their interest, enthusiasm, hard work 
and positive outlook in the face of adversity has been an inspiration. 
•  Ms. Fransisca Stressmann, Kings College London, for the huge amount 
of T-RFLP analysis that is included in this thesis. 
•  Dr. Geraint Rogers, Kings College London, for advice and assistance. 
•  Dr. Alan Walker at The Wellcome Trust Sanger Research Institute, 
Cambridge, for 16S bacterial clone sequence analysis 
•  Dr. Chris Van der Gast at the Centre for Ecology and Hydrology, Oxford, 
for statistical advice 
•  Dr. Janice Shute at the University of Portsmouth, for advice and 
assistance with inflammatory mediator analysis 
•  Mr. Andrew Tuck and all the staff at the HPA Microbiology Laboratory 
Southampton General Hospital, for their sample handling and sputum 
culture work. 
•  Mr. Richard Bedwell of OTR Couriers, for whom the participants had 
great affection 
•  Dr. Peter Henderson of Pisces Conservation Ltd, Pennington, Hampshire 
for statistical advice 
Finally, I would like express my deep debt of gratitude to my wife, Dominique, 
and my two sons, for their love, support and encouragement throughout the last 
few years. 
 
  Dr. Thom Daniels 
March 2010 
  
  xi 
Abbreviations 
ABPA –   Allergic Bronchopulmonary Aspergillosis 
ASL –   Airway Surface Liquid 
BAL –   Broncho-Alveolar Lavage 
Bcc –   Burkholderia cepacia Complex 
BMI –   Body mass index 
BSA -   Bovine Serum Albumin 
cDNA -   complimentory DNA 
CF –   Cystic Fibrosis 
CFF –   Cystic Fibrosis Foundation 
CFPE –   Cystic Fibrosis Pulmonary exacerbation 
CFRD –   CF Related Diabetes 
cfu –   colony forming units 
Cif –   CFTR inhibitory protein 
Cl
-  -   Chloride 
Cm -   Centimetre
 
CMF –   Clinical Monitoring Form 
COPD –   Chronic Obstructive Pulmonary Disease 
DEPC -   Diethyl Pyrocarbonate 
DGGE –   Deanturing Gradient Gel Electrophoresis 
DMSO –   Dimethylsulphoxide 
DNA –   Deoxyribo-Nucleic Acid 
dNTP -   deoxynucleotide triphosphate 
DTT –   dithiothreitol 
ECP –   eosinophilic Cationic Protien 
EDN –   Eosinophil Derived Neurotoxin 
ELISA –   Enzyme linked immunosorbanta assay 
ENaC –   Epithelial Sodium (Na) Channel 
ETT –   Endotracheal Tube 
FEV1 –   Forced expiratory Volume in One Second 
FEV1% predicted –   FEV1 as a percentage of the predicted value using 
European Coal Steel Standards 
FISH –   Fluorescent In Situ Hybridisation 
FVC –   Forced Vital Capacity 
g -   g force 
g -   gram 
G+C –   Guanine and Cytosine 
GES -   Guanidinium thiocyanate-EDTA-Sarkosyl  
GWB -   General Wellbeing 
H2O2 -   Hydrogen peroxide 
HPA –   Helath Protection Agency 
HRP –   Horse radish Peroxidase 
huIL-8 –   Human IL-8 
Hz -   Hertz 
IL-8 –   Interleukin 8 
IQR -   Interquartile Range 
M -   Molar 
MCBT –   Multiple Combination Bacteriocidal antibiotic Testing 
MCID –   Minimal Clinically Important Difference  
  xii 
MLST -   Multi-Locus Sequence Typing 
mg -   milligram 
MIC90 –   Miniumum Inhibitory Concentration required to inhibit 
90% of isolates 
mL -   millilitre 
mM –   milli Molar 
MRSA –   Methycillin Resistant Staphylococcus aureus 
MSSA –   Methycillin Sensitive Staphylococcus aureus 
NA –   Not applicable 
Na
+ -   Sodium 
NaCl –   Sodium Chloride 
NE –   Neutrophil elastase 
ng -   nanograms 
Nm –   nano Molar 
nm -   nanometres 
NAA –   Nucleic Acid Extraction 
OF -   oral flora 
OR –   odds ratio 
OR –   Odds ratio 
PBS –   phosphate buffered saline 
PCL –   periciliary Layer 
PCR –   Polymerase Chain reaction 
PMA –   Propidium monoazide 
PRO –   Patient Reported Outcome 
QoL –   Quality of Life 
RCT –   Randomised Controlled Trials 
RFLP –   Restriction Fragment Length Polymorphism 
RPP -   Response Profile Plot 
SaO2 -   Transcutaneous estimated arterial haemoglobin Oxygen 
Saturation  
SCOTIE –   Sputum Changes over Time in Cystic Fibrosis 
SCV –   Small Colony Variant 
SD –   Standard deviation 
SGH –   Southampton General Hospital 
SMG –   Streptococcus milleri group 
SOP -   Standard Operating Procedure  
TMB -   3,3’,5,5’-Tetramethylbenzadine 
T-RF –   Terminal Restriction Fragment 
T-RFLP -   Terminal Restriction Fragment Length Polymorphism 
UK –   United Kingdom 
USA –   United States of America 
VAP –   Ventilator Associated Pneumonia 
VAS -   Visual Analogue Scale 
VFA –   Volatile Fatty Acids 
WHO –   World Health Organisation 
Zn -   Zinc 
 
  
  1 
Chapter 1 -  Introduction 
Cystic Fibrosis (CF) is the most common life threatening recessively inherited 
disease affecting Caucasians. In the United Kingdom (UK) it affects 
approximately 1 in every 2500 live births (Collins 1992), and there are estimated 
to be approximately 8200 registered UK CF patients (Dodge et al. 2006).  CF is 
a multi-system disease affecting the respiratory tract, liver, pancreas, gastro-
intestinal tract, musculo-skeletal system and reproductive organs.   The genetic 
defect causes failure of airway defences, resulting in chronic bacterial infection 
of the lungs (Boucher 2007; Konstan & Berger 1997).  As a consequence the 
majority of deaths are due to respiratory failure or sepsis from repeated lung 
infections (Penketh et al. 1987).  Survival has increased dramatically since the 
first accurate description of the condition by Andersen in 1938 (Anderson 1938).  
Currently the median predicted survival in the UK is 38.8 years (Cystic Fibrosis 
Trust 2009b) with reports predicting a continued increase in age of death over 
the coming years  (Dodge et al. 2006; Elborn, Shale, & Britton 1991).   
There is a pressing need to understand the complex microbiology of the CF 
airway.  Despite improved treatment of pulmonary infections (Knowles & 
Boucher 2002; Ramsey et al. 1999; Retsch-Bogart et al. 2009), pulmonary 
infections still result in a reduction in quantity and impaired quality of life (QoL).  
Thus a better understanding of the interaction between microbes and the 
human lung may then lead on to new or improved treatment strategies, which 
may in turn lead to an improved life expectancy for people born with CF.   
  2 
1.1  CF Pulmonary Exacerbations 
1.1.1 Clinical Significance 
CF Pulmonary Exacerbations (CFPEs) are important healthcare events for 
individual patients, who can suffer from increased dyspnoea, increased sputum 
production, fever, pain, loss of appetite, or absenteeism from school or work.   
Attempts to define CFPEs in more detail are outlined in section 1.1.3 below.  
They also have significant a significant effect on mortality (Liou et al. 2001).  
Corey et al. in 1997 established that a lower FEV1 and a faster rate of decline in 
FEV1 was associated with a greater mortality rate (Corey et al. 1997).  Block et 
al. demonstrated, in a cohort of CF patients infected with multi-resistant 
bacterial organisms, that those with lower lung functions had more frequent 
CFPEs (Block et al. 2006). 
Britto et al. demonstrated a marked negative impact of CFPEs on self-reported 
Quality of Life (QoL) using a number of validated age-specific health related 
QoL tools (Britto et al. 2002).  This negative impact was independent of lung 
function, nutritional status and demographic features.  On 0-100 point scales, 
with higher values representing greater well being, each CFPE was associated 
with a fall of 6 points in the physical well being score, and a 3 point fall in the 
psycho-social score.  Interestingly the negative effects of CFPEs on health 
related QoL were measurable 6 months after the last event.  The researchers 
were unable to comment on the mechanism behind the effect, nor on whether 
different severities of exacerbations, or treatment modalities (e.g. home vs. 
hospital treatment) affected the relationship.  In a later study, the same group 
went on to demonstrate that treatment for CFPE in hospital was associated with 
improvement in health related QoL, whereas treatment at home was associated  
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with deterioration (Yi et al. 2004).  The study had significant flaws, particularly 
that the two groups (inpatient treatment and outpatient treatment) were not well 
matched for age and that the tools used to assess health related QoL differed in 
the two age groups. 
In addition retrospective studies assessed physiological outcome measures in 
well matched episodes of home and hospital treatment for CFPE in children 
(Nazer et al. 2006).  In both groups significant improvements were 
demonstrated in spirometric outcomes, weight gain and transcutaneous arterial 
oxygen saturations (Sa02).  Significant differences were shown in favour of 
hospital treatment, with greater improvements in FEV1 and shorter duration of 
antibiotic therapy.  However, these studies can be criticised for being based on 
retrospective analysis and have not controlled for selection bias.  One such bias 
would be that clinicians would favour hospital therapy for patients who were 
deemed, in some way, to be more ill.  These patients would therefore have to 
gain from any treatment, thus falsely demonstrating greater efficacy for hospital 
vs. home treatment.   
1.1.2 Costs 
CFPEs have a significant health care related cost, although the costs that are 
specific to CFPEs as differentiated from other CF care costs are difficult to 
separate.  In 1999 Lieu et al. ( 1999) calculated that mean costs per CF patient 
aged >18 was $13300 per annum, and that 47% of costs were attributable to 
hospitalisations, which for the purposes of this discussion can assumed to be 
for treatment for CFPEs.  Disease severity also increased costs.  Those with the 
most severe lung function (FEV1 < 40 %) had mean costs of $43300 per 
annum.  Since this study, a number of expensive therapies, including inhaled  
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DNAse (Fuchs et al. 1994), inhaled tobramycin (Ramsey et al. 1999) and oral 
azithromycin have become part of routine therapy.  The full impact of these new 
therapies on costs of care for CFPEs is not known, although recent reviews 
have suggested overall reductions in economic costs are achieved with 
nebulised tobramycin and oral azithromycin (Equi et al. 2002; Saiman et al. 
2003; Wolter et al. 2002). 
1.1.3 Definition 
Despite the clear importance of CFPEs to mortality, QoL, and health costs, as 
well as an outcome measure in a number of pivotal clinical trials, there is no 
standardised definition. Dakin et al. ( 2001) demonstrated that there was 
marked heterogeneity between CF clinicians in Australia in the value they 
placed in a wide variety of clinical and laboratory characteristics in the diagnosis 
of a CFPE.  As an example of the lack of consensus between clinicians, the 
usefulness of only 50% of the variables offered could be agreed upon by 3 out 
of 4 respondents or more.  In many observational clinical trials it has been 
common to use the decision to start antibiotic therapy as a surrogate for CFPEs 
(Mayer-Hamblett et al. 2007).  For a number of reasons however this is sub-
optimal.  First of all, Johnson et al. have shown marked variations between 
different centres in rates of treatment for CFPE (Johnson et al. 2003).  These 
differences are associated with differences in survival rates and FEV1.  Most 
centres would advocate an ‘as required’ treatment strategy for CFPEs.  A few, 
notable the Danish national centre in Copenhagen, practice a more aggressive 
strategy of regular three-monthly courses of intravenous antibiotics, irrespective 
of symptoms (Frederiksen et al. 1996), making comparisons based on hospital 
interventions as a definition of CFPE challenging.  Furthermore the decision to  
  5 
diagnose a CFPE and to start treatment is not always based of clinical 
measures alone.  To a greater or lesser degree pulmonary symptoms are 
frequently present in adult CF patients (Hodson & Geddes 2007).  Although 
there may be a discrete event, such as haemoptysis, which precipitates a 
diagnosis of CFPE, more often there is no such discrete event, and symptoms 
are part of a continuum.  Thus, the point at which an increase in a pre-existing 
symptom reaches a threshold at which a CFPE is diagnosed may be viewed as 
a somewhat arbitrary one.   These problems were recognised in 1994 in a 
Cystic Fibrosis Foundation consensus statement.  Ramsey et al. ( 1994) 
recommended that a definition of a CFPE “should be established as soon as 
possible and universally used in clinical trials”.  They went on to recommend 
that “this definition should include clinical symptoms but not therapeutic 
interventions such as hospitalisation”.  Despite 16 years having passed since 
this call was made, and further calls since (Marshall 2004) there is still no 
accepted universal definition of a CFPE. 
A CFPE has been described as ‘an acute change in pulmonary symptoms 
related to an increase in airway secretions’ (Goss & Burns 2007).  However, 
numerous other definitions have been used, each attempting to provide a more 
robust and specific definition.  In particular, in the 1990s two major 
interventional randomised controlled trials laid out diagnostic criteria for the 
diagnosis of CFPEs (Fuchs et al. 1994; Ramsey et al. 1999).  The definitions 
used in each are laid out in Figure 1-1 below.  
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Figure 1-1 - Diagnostic Criteria for diagnosing CFPEs used by Fuchs et al. ( 1994)  
and Ramsey et al. ( 1999) (from Goss and Burns ( 2007), with permission). 
Despite the central importance of CFPEs as an endpoint to trials and clinical 
outcomes, no set of diagnostic criteria have ever been prospectively validated.  
Rosenfeld et al. analysed components of the above definitions to see which 
clinical characteristics best predicted CFPEs (Rosenfeld et al. 2001).  Using 
multivariate analysis of data from 246 patients enrolled in the placebo control 
arm of the 1999 inhaled tobramycin trial ( 1999) they set out to define a CFPE 
based on clinical parameters rather than decision to treat.  Symptoms rather 
than physical examination or laboratory investigations were found to be more 
predictive of CFPEs.  The associated odds ratios for the studied parameters are 
outlined Table 1-1 below. 
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Table 1-1. Odds ratios for association of clinical characteristics with the 
presence of a pulmonary exacerbation (from Rosenfeld et al. ( 2001), with 
permission). 
Additional work has corroborated these findings.  In the previously mentioned 
survey of Australian CF clinicians (Dakin et al. 2001) the three features that had 
the greatest consensus as either “useful” or “very useful” in diagnosing a CFPE 
were all symptoms rather than clinical signs (‘change in exercise capacity’, 
‘change in activity level’, and ‘change in sputum production’). 
One other study of note has studied the definition of CFPEs, this time using 
data from North America in the Epidemiologic Study of CF (Rabin et al. 2004).  
Retrospectively analysing available data from 11,692 CF patients (3,267 >18 
years old), features most associated with the diagnosis of a CFPE in adults 
were decline in FEV1, new crackles, haemoptysis, and increased cough.  
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Quantifying Subjective Continuous Variables 
One limitation in any attempt to define CF Pulmonary Exacerbations is that 
diagnosing, or defining, a CFPE requires the categorisation of a number of 
continuous variables in to discrete variables.  Indeed the measurement of 
breathlessness is complex has been the subject of much study.  A number of 
alternative tools to quantify dyspnoea have been used, including the Borg Scale 
(Borg 1982), the MRC dyspnoea score (Fletcher et al. 1959), and visual 
analogue scales (VAS) (Gift 1989a).  Cullen and Rodak have undertaken a 
review of these measures, among others, and found the Borg Scale and VASs 
to be most widely applicable with good validity and reliability (Cullen & Rodak 
2002).  Others have demonstrated that there is a close link between VAS 
breathlessness scores and Borg scores (Morris et al. 2007). 
Cough is another major feature of Cystic Fibrosis and related pulmonary 
exacerbations.  It is a notoriously subjective symptom.  In many cases external 
factors such as friends and family may influence the internal experience of a 
cough on quality of life.  Coughing may not trouble the subject directly, but may 
disturb or upset those in close proximity for long periods.  Thus this may be a 
factor that impacts on the subject indirectly.  Other factors such as depression 
and anxiety may also influence, and be influenced by, cough experiences 
(Decalmer et al. 2007).  Smith et al. found a stronger correlation between 
objective sound recording measures of cough and a cough VAS, than between 
objective measures and a six point ‘Cough Score’ (Smith et al. 2006b).  The 
cough VAS also showed a significant response to treatment for CFPE, unlike 
the 6 point ‘Cough Score’.  
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1.1.4 Aetiology 
Despite our extensive and rapidly expanding knowledge of the basic cellular 
defect in the CF airway, little is know about the pathogenesis of pulmonary 
exacerbations (Goss & Burns 2007).  The symptoms that occur with a CFPE 
are probably the result of complex interactions between host defences, airway 
microbial flora, psychological and environmental factors (Hodson & Geddes 
2007).  The airways of most adult CF patients are permanently infected with 
bacteria, most commonly P. aeruginosa (see Figure 1-3 below).  At this point it 
is worth defining the terms ‘colonised’ and ‘infected’.  In general ‘colonised’ 
refers to the (persistent) presence of an organism without evidence that it has 
stimulated an inflammatory or immune response from the host; ‘infected’ refers 
to the situation when the presence of an organism is associated with an 
inflammatory or immune response (Denis et al. 2007). 
A role for viruses? 
It is not currently well understood what triggers the change in the delicate 
balance between host and endobronchial microbial flora.   A number of factors 
have been suggested.  Respiratory viruses have been implicated by a number 
of researchers.  Efthimiou et al. reported that a group of CF adults who were 
deemed to be suffering a deterioration over the preceding one month were 
significantly more likely to have evidence of recent non-Pseudomonas infection 
than a group of adult CF patients deemed to be clinically stable (Efthimiou et al. 
1984)  These other organisms included Mycoplasma pneumonia, Legionalla 
pneumophila, Coxiella burnetii and a number of respiratory viruses.  Such 
findings were based on serological methods of detection that have now been 
replaced by more sensitive and specific methods such as PCR (Jungkind 2001).   
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Wang et al. prospectively followed 49 teenage subjects with CF and 19 
unaffected sibling controls.  Although there were more reported respiratory 
symptoms in the CF group, there was an identical rate of detection of viruses in 
the two groups (Wang et al. 1984).  Importantly however, in the CF group there 
was a highly statistically significant correlation between the annual incidence of 
upper respiratory tract viral infection and every measured marker of disease 
progression.  However the viral detection methods used in the above studies 
were either tissue culture or immuno-fluorescence, both of which have since 
been shown to be relatively insensitive compared to the currently accepted gold 
standard of Nucleic Acid Amplification (NAA) (Punch et al. 2005).  More recent 
studies employing such techniques have detected viruses in nearly half (46%) 
of exacerbations (Wat et al. 2008b), although it should be mentioned that this 
was a population with a mean age of 9, and the definition of ‘exacerbation’ was 
considerably different to other published definitions (see Figure 1-1 above).  
Despite the evidence for a role for respiratory viruses in CFPEs and clinical 
deteriorations, there is little evidence to show that vaccination or passive 
prophylaxis with monoclonal antibodies reduce exacerbation rates or improves 
outcomes (Giebels et al. 2008; Piedra et al. 2003; Wat et al. 2008a).  It should 
be noted that these negative studies of vaccination were retrospective, and only 
contained small numbers of subjects.  In addition there is considerable evidence 
that is suggestive of a significant role for viral infection in the development of 
chronic bacterial lower respiratory tract infections (Hament et al. 2004; Hament 
et al. 2005). 
Viruses may play an indirect role in the development of chronic bacterial lower 
respiratory tract infection.  In a mouse model of chronic pulmonary P.  
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aeruginosa infection, influenza infection enhanced susceptibility of the mouse to 
fatal Streptococcus pneumonia infection (Seki et al. 2004).  In addition several 
studies have shown that there is no increase in the prevalence of viral 
respiratory tract infections in CF subjects compared to controls, but that such 
infections tend to be more severe and of longer duration (Hiatt et al. 1999; 
Ramsey et al. 1989; Van Ewijk et al. 2008; Wang et al. 1984).  The reason for 
the increased severity of infections is not clear.  It has been shown that there is 
no increased expression of IL-8 by in vitro bronchial epithelial cells that are 
deficient in CFTR (Black et al. 1998).  However, there is evidence that 
respiratory viral infection may predispose to chronic P. aeruginosa infection, in 
effect ‘opening the door’ to allow P. aeruginosa to become established (Stark et 
al. 2006; Van Ewijk et al. 2006; Van Ewijk et al. 2007; Van Ewijk et al. 2008). 
A role for new bacterial strains? 
It has been demonstrated that the density of P. aeruginosa increases during a 
CFPE, and decreases during treatment (Regelmann et al. 1985; Regelmann et 
al. 1990; Smith et al. 1999).  Furthermore, in Chronic Obstructive Pulmonary 
Disease (COPD), which is also characterised by chronic stable respiratory 
symptoms punctuated by ‘infective’ exacerbations, it has been shown that new 
strains of existing bacterial species are associated with pulmonary 
exacerbations (Sethi et al. 2002).  Aaron and co-workers undertook prospective 
studies to determine whether new strains of bacteria were responsible for 
CFPEs in adults with CF (Aaron et al. 2004).  They demonstrated that, in 34 of 
36 adults chronically infected with P. aeruginosa, a single clonal species was 
found before, during, and after a CFPE, and that acquisition of a new strain was 
not responsible for the change in symptoms.  They went on to demonstrate the  
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same principle in CF adults chronically infected with Burkholderia cepacia 
complex (Bcc) (Denis et al. 2007). 
Recently, others have used a combination of culture-based and molecular 
techniques to assess microbial changes over time in subjects with CF.  Sibley et 
al. performed T-RFLP in one subject over a period of time including three 
CFPEs (Sibley et al. 2008e).  In addition to P. aeruginosa they identified a T-RF 
band consistent with bacteria from the Streptococcus milleri group (SMG).  
Following this they went to additional lengths to culture bacterial species from 
the same group in the same and additional CF subjects.  They found bacteria 
from the SMG in 39% of samples taken at the time of CFPE, and in 7 of 18 CF 
subjects.  They also reported clinical response to targeted treatment in subjects 
with high levels of SMG (by culture) who had failed to respond to more typical 
anti-pseudomonad treatment.  Put together, the work of Sibley et al. adds to the 
body of evidence that microbial diversity beyond P. aeruginosa may be 
important in the aetiology of CFPE.  The work has not yet been replicated 
beyond Canada, and has not included any clone sequence analysis. 
Biofilm dispersal? 
It has been hypothesised that a the biofilm is the natural state of growth for 
most if not all bacterial infections.  Following from this it has been suggested 
that a CFPE may in fact be a manifestation of the “bacterial blooming” (Reid et 
al. 2006) of a mature biofilm, as part of a seeding process (VanDevanter & Van 
Dalfsen 2005).  Support for this comes from clinical observations of a response 
to intravenous antibiotics (De Boeck & Breysem 1998; Moskowitz et al. 2004), 
but the in vitro biofilm resistance of P. aeruginosa isolates to the same 
antibiotics.  In addition, mature biofilms have been shown to undergo such a  
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blooming process, known as seeding dispersal (Purevdorj-Gage, Costerton, & 
Stoodley 2005), in vitro flow cells (Kirov et al. 2007).  However, others have cast 
doubt on the evidence to support such a hypothesis, with no correlation of P. 
aeruginosa CFU counts to clinical response or airways inflammation (Reid et al. 
2006). 
Non-microbial causes? 
Other, non-microbiological factors have been associated with the incidence of 
CFPEs.  Goss et al. conducted a cohort study of all CF sufferers aged greater 
than 9 years old registered in the American Cystic Fibrosis Foundation 
database (Goss et al. 2004).  They demonstrated that living in a geographical 
area that had higher levels of particulate matter and ozone was associated with 
a significantly increased risk of exacerbation and lower lung function compared 
to those who lived in areas with cleaner air. 
Schechter et al. investigated the role of socioeconomic class on outcomes for 
adult CF sufferers (Schechter & Margolis 1998).  Using Medicaid status as a 
surrogate marker for socio-economic class in a retrospective analysis of the 
CFF database, they demonstrated that Medicaid patients were, among other 
findings, 1.6 times more likely to require treatment for a CFPE.  Further work 
confirmed the initial findings (Schechter et al. 2009).  This additional work 
suggested that factors such as health care utilisation only partially explained the 
discrepancies.  In addition to this work from the USA, others made similar 
findings in UK CF populations, where an independent odds ratio of death of 
2.75 in non-manual compared with manual social classes (Britton 1989).  
However, a smaller cohort study in relatively affluent Southwest England failed 
to demonstrate any such difference (Jarad et al. 2005).  
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Chronic pulmonary infection CF may theoretically result in a high degree of 
oxidative stress.  A number of studies have highlighted a possible role for 
dietary deficiencies in the aetiology of CFPEs, possible mediated through 
deleterious effects oxidative / anti-oxidative balance.  In a retrospective analysis 
of 597 CFPEs in 102 patients, confirmed in prospective analysis of a further 62 
CFPEs, Hakim et al. demonstrated that, for patients with pancreatic 
insufficiency, having lower levels of either Vitamin A or Vitamin E were 
associated with an increased number of CFPEs.  For CF patients who were 
pancreatic sufficient this was true for Vitamin A, but for Vitamin E the results did 
not quite reach statistical significance (Hakim et al. 2007).  It should be noted 
that this effect held true, even for serum levels that are considered within the 
normal range.  The mechanism for this is not clearly elucidated, but there is a 
body of evidence that highlights the role of Vitamin  levels in adequate immunity 
to viral and bacterial pathogens (Beck 2007; Hakim et al. 2007; mit-Romach et 
al. 2008). 
No study has yet demonstrated a significant survival benefit from vitamin 
supplementation.  However, in a small pilot study RCT of 26 children (age range 
7-18) Abdulhamid et al. demonstrated a reduction in the use of oral antibiotics in 
those whose diet was supplemented with zinc (Abdulhamid et al. 2008).  This 
effect was only significant for those with low Zn levels at baseline. 
In another RCT pilot study, Bruzzese et al. investigated a role for the probiotic 
Lactobacillus rhamnosus strain GG (LGG) (Bruzzese et al. 2007).  There is 
evidence that the gastrointestinal tract of people with CF is constantly inflamed.  
LGG may have a role in a number of conditions, including chronic inflammatory 
bowel diseases (Doron, Snydman, & Gorbach 2005), and atopic diseases  
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(Kalliomaki et al. 2003).  In the Bruzzese et al. study, a parallel cross-over 
design with 19 CF subjects in each group using oral rehydration salts or LGG 
supplements for six months before crossing over, significant improvements in 
body mass index (BMI) and FEV1 were demonstrated, and there were 
significant reductions in CFPEs and hospital exacerbations when taking LGG. 
The link between nutritional status and survival in people with CF is well 
established (Elborn 2007).  People with CF have a lower BMI than age matched 
control subjects.  Using the American Cystic Fibrosis Foundation registry data, 
Liou et al. demonstrated that age adjusted weight z scores was negatively 
correlated with survival in a large well validated 5 year survival model (Liou et 
al. 2001).  In order to maintain good lung health and reduce the incidence of 
CFPEs it is necessary to strive to attain a normal BMI. 
Although it is uncontroversial to state that CF pulmonary disease is frequently 
polymicrobial (Vlamakis & Kolter 2005), there is a disproportionate body of work 
focused on understanding P. aeruginosa alone, compared to the body of work 
related to inter-species interactions.  There are only limited publications that 
have attempted to address the mechanisms underlying species-species 
interactions directly relevant to CF (Duan et al. 2003; Hogan, Vik, & Kolter 2004; 
Mashburn et al. 2005; Sibley et al. 2008f).  These studies have mainly focused 
on interactions between two species in vivo.  Bearing in mind that previous work 
from, among others, Rogers et al. ( 2004) demonstrated a mean of at least 13 
different species in adult CF sputum samples in vivo, there is potential for a 
level of interspecies complexity that has hitherto been entirely unsuspected and 
unstudied.  There are a number of limitations to the species-species interactions 
studied in vitro above.  Evidence for interactions comes from in vitro rather than  
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in vivo work.  Thus there can be little certainty that the interactions described 
actually occur in vivo in the CF lung.  A number of possible reasons exist that 
would limit the likelihood that the demonstrated interactions occur in vivo.  
Firstly P. aeruginosa is well known to exist primarily in biofilm form in chronic 
pulmonary infections in CF (Singh et al. 2000).  Secondly it is thought that when 
P. aeruginosa grows in biofilms in the CF lung that it creates a micro-anaerobic 
environment (Worlitzsch et al. 2002).  The interspecies interactions studied 
have been undertaken under aerobic conditions and work suggests that 
growing conditions can profoundly affect the phenotype of the bacteria (Hill et 
al. 2005).  Finally, such simple two species interaction models fail to take in to 
account the additional complexity, both in communication and in competition for 
resources, that will be found when the multi-species nature of chronic CF 
pulmonary disease in taken in to account. It is well recognised that availability of 
bacterial micronutrients such as iron may have important implications on 
bacterial persistence and virulence (Harrison & Buckling 2009; Harrison et al. 
2008; Hoffman et al. 2010) . 
Despite the potential criticisms of these studies, they currently provide an 
insight into a world of potential inter-species interactions that has previously 
been unsuspected in CF microbiology.  The interaction between P. aeruginosa 
and Staphylococcus aureus has long been suspected due to the inverse 
relationship seen in the colonisation rates of CF patients over time where P. 
aeruginosa  rates increase with age while Staphylococcus aureus  rates fall 
(see Figure 1-3 below).  In addition, the work of Duan et al. has shown that the 
presence of the oft overlooked ‘Oral Flora’ in respiratory secretions can have 
significant implications for the virulence of P. aeruginosa in animal models  
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(Duan et al. 2003).  There is as yet no work to assess the clinical relevance of 
these findings. 
Other fields of microbial investigation beyond CF have progressed further.  
There is growing evidence for the role of bacterial intra- and inter-species 
signalling systems when, previously, unicellular bacteria were considered to be 
too primitive to be capable of such complex processes (Czaran & Hoekstra 
2009; Prosser et al. 2007; Vlamakis & Kolter 2005).  Such work may in turn 
inform the complex polymicrobial infections that are so characteristic of cystic 
fibrosis pulmonary disease. 
1.1.5 Pulmonary Inflammation in Cystic Fibrosis 
In addition to the overwhelming evidence for ineffective host immune response 
in CF, there are also laboratory and clinical data to suggest that mutant CTFR 
may be associated with a defective inflammatory modulation process 
(Buchanan et al. 2009), as outlined in Section 1.2.2 below.  It is thought that 
cells deficient in effective CFTR have an exaggerated host inflammatory 
response, and that this in turn may lead on to an exaggerated inflammatory 
response in vivo to otherwise innocuous stimuli, microbial or otherwise.  It has 
been hypothesised that the exaggerated inflammatory response may lead to 
excessive pulmonary destruction that is classical of CF.  However, by the time 
most CF patients reach adulthood, chronic microbial pulmonary infection has 
occurred, with associated lung damage such as bronchiectasis, and resultant 
inflammation.    
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1.2  Airway defence and CFTR gene  
1.2.1 Role of CFTR in airway defence against bacteria 
The innate host defence to inhaled microbes is a multi-layered response that 
includes both chemical inactivation and mechanical clearance of invading 
pathogens.  The chronic respiratory infections that lead to death in up to 90% of 
CF patients suggest that CF lung disease reflects a failure of defence against 
bacterial pathogens.  One of the key mechanical mechanisms that aids host 
defence is the mucociliary apparatus (Wanner, Salathe, & O'Riordan 1996).  
The mucociliary apparatus has three main roles (Goldman et al. 1997; Travis et 
al. 1999).  First it serves as a mechanical barrier that traps particles in the thin 
layer of surface liquid that covers the respiratory epithelium, then clearing them 
from the tracheo-bronchial tree by ciliary action (known as the mucociliary 
escalator), by a process of mucociliary clearance (MCC).  Secondly the thin 
layer of liquid in which the cilia are bathed, known as airway surface liquid 
(ASL), acts as a chemical screen, neutralising pathogens through a number of 
secreted antimicrobial substances (Cole, Dewan, & Ganz 1999; Grubb, Jones, 
& Boucher 2004).  Third mucociliary ASL acts as a biological and physical 
barrier to microorganisms, allowing interaction between host inflammatory cells 
and peptides, thus preventing adhesion or invasion of the respiratory epithelium 
(Matsui et al. 1998a). 
Normal airway defences and mucociliary clearance are therefore dependent on 
ASL in a number of ways.  ASL comprises two main compartments, the 
periciliary liquid layer (PCL), in which the cilia are bathed and allowed to beat 
freely, and the mucus layer which sits on top of the cilia and PCL (Garcia-
Caballero et al. 2009; Wanner, Salathe, & O'Riordan 1996).  The mucus layer is  
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moved caudally by the co-ordinated beating of the cilia.  Only if the PCL is at 
the correct height and of the correct consistency to allow the cilia to beat, can 
mucociliary clearance occur.  
Cystic Fibrosis was first postulated as a disease caused by mutation of a single 
gene by Lowe et al.  ( 1949) based on the autosomal recessive pattern of 
disease inheritance.  It took until 1989 before the gene was located and 
identified (Kerem et al. 1989; Riordan et al. 1989).  The gene was named the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. The 
CFTR gene is located on the long arm of chromosome 7 and covers an area of 
approximately 250,000 base pairs.  The protein that the CFTR gene codes for 
consists of 1480 amino acids.  This CFTR protein has been localised to the 
apical surface of epithelial cells (Rich et al. 1990) and spans the epithelial 
surface.  Within the apical epithelial membrane, CFTR is found in close 
proximity to a number of other ion transport proteins, membrane receptors and 
the cytoskeleton (Short et al. 1998)  (Ismailov et al. 1996).  The role of the 
CFTR protein is primarily as a channel to transport chloride ion (Cl
-) from within 
airway epithelial in to ASL.  Additionally it facilitates transport of sodium (Na
+) 
from ASL back in to the cell, via actions on the separate but co-located 
Epithelial Na
+ Channel (ENaC) (Myerburg et al. 2006).  The presence of Cl
- and 
Na
+ in ASL osmotically draws water with it (Matsui et al. 1998b).  CFTR tonically 
regulates ENaC Na
+ absorption in order to maintain a steady PCL height of 7 
nm (Boucher 2004; Tarran et al. 2001).  Thus a key role of CFTR is the 
maintenance of a normal ASL composition and height (Boucher 2007; Matsui et 
al. 1998b; Matsui et al. 2006; Tarran et al. 2001)  In CF airways, failure of Na
+ 
absorption and failure of Cl
- secretion results in depletion in the volume of the  
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PCL (Matsui et al. 1998b).  Depletion of the PCL leads to inadequate function of 
the cilia and failure of adequate mucociliary clearance (Matsui et al. 2005). 
People with CF demonstrate a marked immunodeficiency to a number of 
airborne pathogens.  CFTR may also play a role in innate cellular airway 
defence.  A number of researchers, including Di et al., have demonstrated that 
alveolar macrophages that are deficient in CFTR are unable to adequately 
acidify intracellular lysozymes (Di et al. 2006; Haggie & Verkman 2007).  
Consequently ingested bacteria are inadequately killed in CFTR deficient 
macrophages, allowing bacteria to persist, potentially contributing to additional 
infection and inflammation burden.  This effect on phagocytic cells is uncertain.  
Moraes et al. demonstrated that, although the neutrophils are the most 
numerically abundant phagocytic cell of the innate immune system, 
abnormalities in CF ASL had no effect on neutrophil antimicrobial function 
(Moraes et al. 2006).  More recently, others have challenged these conclusions 
showing that there may be functional and signalling changes in neutrophils in 
CF.  In addition it has been shown that CFTR is expressed in large quantities on 
the surface of neutrophils (Painter et al. 2006). 
1.2.2 Role of CFTR deficiency in inappropriate immune 
response 
It is still unresolved whether infection precedes inflammation or vice versa in the 
new born CF airway (Armstrong et al. 1997; Armstrong et al. 1995; Armstrong 
et al. 2005).  A number of in vitro studies have highlighted the possibility that a 
defect in CFTR itself may result in a dysregulated and overactive immune 
response without exogenous stimulation  (Bonfield, Konstan, & Berger 1999; 
Hybiske et al. 2007; Tirouvanziam et al. 2000; Tirouvanziam, Khazaal, & Peault  
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2002).  Post mortem studies on 8 CF neonates who died of non-respiratory 
illnesses showed macro- and microscopically normal lungs (Zuelzer & Newton 
1949).  However, these studies were undertaken 6 decades ago in limited 
numbers of patients without access to more advanced techniques.  A more 
recent study of one set of lungs from a 24 week foetus with CF, which was 
terminated for unrelated reasons, showed macroscopically and microscopically 
normal lungs, but evidence of excessive inflammation as measured by a 
number of key inflammatory mediators (Verhaeghe et al. 2007).  More recent 
studies in ante mortem subjects have attempted to determine whether there is 
more inflammation in very young children with CF but who have never had 
respiratory symptoms or requiring antibiotics.  Armstrong et al. ( 1997;  1995) 
performed Broncho-Alveolar Lavage (BAL a sensitive technique for sampling 
the distal airways (British Thoracic Society. 2001; Mehta 1999) and alveolar 
spaces with less contamination from large airway mucus and micro-aspiration) 
on 45 infants with newly diagnosed CF.  Importantly, 32 of the cases were 
identified by screening and 29 were free from any symptoms of respiratory 
infection.  A group of 9 infants with no other illness or symptom other than 
stridor who were undergoing investigation by bronchoscopy provided control 
samples.  When comparing the ‘uninfected’ CF group with the control group 
there was no difference in the mean level of Interleukin-8 (IL-8), a key 
inflammatory mediator.  There was a very significant difference between the 
‘infected’ group and both the control group and the ‘uninfected’ group.  However 
other investigators have had different findings.  Khan et al. showed that a 
variety of inflammatory markers, including IL-8 were raised in BAL samples from 
infants with CF who had culture negative samples (Khan et al. 1995).  It should  
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be noted that no culture independent microbiological techniques were used in 
any of these studies. 
In an attempt to circumvent the practical difficulties in interpreting the results of 
human in vivo work, a great deal of work has been performed on animal models 
and in cell culture models.  Bonfield et al. in 1999 (Bonfield, Konstan, & Berger 
1999)  showed that mutant CFTR cell lines failed to produce any detectable 
levels of the anti-inflammatory interleukin IL-10, but excessive amounts of the 
pro-inflammatory cytokines IL-6 and IL-8, when compared to cell lines from 
healthy controls.  Many others have also found in vitro evidence of excessive 
hyper-inflammatory innate immune response in CFTR deficient cell lines 
(Aldallal et al. 2002; Hybiske et al. 2007; Ribeiro et al. 2005)  .  However 
considerable controversy exists with regard to the validity of this data for two 
main reasons.  The first is methodological and technical concerns regarding the 
nature of the in vitro work and the failure to replicate key findings (Aldallal et al. 
2002).  The second is the failure to convincingly demonstrate that inflammation 
precedes infection in vivo (Armstrong et al. 1997; Armstrong et al. 1995). 
Much of the current understanding of healthy airway defence against microbial 
pathogens comes from research in to the defect caused by CF (Kreda et al. 
2005). 
There are essentially two competing theories to the link the genetic defect and 
the clinical picture.  These can be divided in to the ‘high salt’ hypothesis and the 
‘low volume’ hypothesis.  The ‘high salt’ hypothesis states that abnormally high 
ionic concentrations in airway surface liquid affects the ability of ASL to 
inactivate inhaled matter, leading to failure to eradicate and eliminate inhaled 
microbes.  Support for this hypothesis comes from findings that chemical  
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abnormalities in CF ASL result in inactivation of host antimicrobial peptides, 
known as defensins (Smith et al. 1996).  This then allows bacteria to persist 
unchallenged in the ASL during the attempted mechanical clearance from the 
lung by the mucociliary escalator, leading to infection inflammation and lung 
damage (Cole, Dewan, & Ganz 1999; Goldman et al. 1997; Tesse et al. 2007).   
The ‘low volume’ hypothesis argues that the mechanism by which functional 
CFTR protein deficiency leads to the clinical phenotype is via dehydration and 
loss of height in the periciliary layer of the ASL (Knowles & Boucher 2002; Mall 
et al. 2004; Matsui et al. 2005; Matsui et al. 1998b; Matsui et al. 2006). 
In addition immune defence mechanisms have been implicated as defective in 
CF.  Moskwa et al. demonstrated that respiratory epithelium generated 
hypothiocyanite in sufficient quantities to mediate bacterial killing.  CF 
respiratory epithelium, however, was unable to generate sufficient quantities of 
hypothiocyanite, and thus was unable to adequately kill bacteria (Moskwa et al. 
2007). 
Recently, additional evidence has come to light, linking the CFTR mutation to 
increased pulmonary inflammation and hyper-susceptibility to P. aeruginosa 
infection, through ceramide levels.  Teichgraber et al. showed that inadequate 
acidification of intracellular organelles results in build up of ceramide rafts and 
subsequent inflammation (Teichgraber et al. 2008).  Most interestingly, there 
already exists an acid sphingomyelinase inhibitor with the potential to prevent 
this build up, in the form of amitriptyline (Becker et al. 2009).  
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1.2.3 CFTR as Bacterial Binding Site 
Despite the abundant evidence of impaired local host defence, this does not 
offer an explanation as to why, among all the microbes, the CF airway is so 
prone to infection by P. aeruginosa. Indeed, so associated is the culture of P. 
aeruginosa with respiratory secretions in CF that its discovery is a key part of a 
published algorithm for the diagnosis of CF (De Boeck et al. 2006).  A number 
of key discoveries have been made that may offer some explanation for this, 
and in turn offer better insights to pulmonary immune defence. 
In 1997 Pier et al. (Pier et al. 1996) demonstrated that normal CFTR protein in 
the apical surface of human respiratory epithelium was involved in the 
clearance of P. aeruginosa from the lung by binding to and internalising the 
bacteria.   Cells lacking functional CFTR failed to adequately clear P. 
aeruginosa and thus left the airway at risk of persistent P. aeruginosa infection.  
This provided evidence of a direct link between the primary genetic defect and 
the clinical disease phenotype.  In addition to the role of CFTR as a potential 
receptor for P. aeruginosa, another potential receptor for pathogenic bacteria 
has been identified. 
In addition to CFTR, other apical epithelial molecules may act as receptors for 
pathogenic bacteria.  Imundo et al. (Imundo et al. 1995) showed that P. 
aeruginosa bound to CF epithelial cells.  However this P. aeruginosa could be 
displaced by either free P. aeruginosa or free Staphylococcus aureus (S. 
aureus), both of which are well recognised airway pathogens in CF, but could 
not be displaced by Escherichia coli (E. coli; not recognised as a CF airway 
pathogen).  Through a number of experiments they demonstrated that  
  25 
asialoganglioside 1, a key glycosphingolipid component of eukaryotic cell walls, 
was responsible for the enhanced binding. 
Further evidence for the relationship between P. aeruginosa and CFTR came in 
2007 when MacEachran et al. (MacEachran et al. 2007) demonstrated that one 
strain of P. aeruginosa secretes a protein that inhibits the expression of CFTR 
on the apical surface of human respiratory epithelial cells.  This protein, termed 
CFTR inhibitory factor (Cif), was shown to reduce apical membrane CFTR 
expression and lead to a concomitant reduction in CFTR Cl
- ion secretion.  
Such a mechanism would lead to a greater chance of persistence of P. 
aeruginosa in an airway already deficient in functioning CFTR levels.  In 
addition there may be methods by which P. aeruginosa alters the internal 
epithelial structure to reduce the strength of epithelial tight junctions, thus 
allowing it persist (Kierbel et al. 2007). 
1.2.4 Summary 
It can be seen from the wealth of evidence that CF pulmonary disease is a 
manifestation of both chronic and intrinsic inflammation and chronic persistent 
infection through a considerable number of different but overlapping pathways.  
A role for bacteria in driving pulmonary damage is clear, but the relative 
importance of intrinsic inflammation compared to bacterially derived 
inflammation is not.  In addition, most studies on the role of bacteria in 
inflammation have focused on a role of P. aeruginosa and an extremely limited 
range of other pathogens.  There is, however, increasing evidence for much 
greater bacterial diversity in the CF airway (Bittar et al. 2008; Rogers et al. 
2004), findings that has not been reflected in the in vitro studies reported above.  
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1.3  Microbiology Techniques 
The ability to identify infectious agents involved in the pathogenesis of disease 
revolutionised human health (Newsom 2003).  Since the days of Louis Pasteur 
and Robert Lister, the use of selective media plates to facilitate the growth of 
particular pre-determined bacteria or types of bacteria, whilst inhibiting or 
restricting the growth of others has been the mainstay of microbial identification 
and the investigation of infectious diseases.  However, there are a number of 
potential drawbacks to these techniques.  Firstly, by their very nature, they are 
selective.  This means that there are some bacteria that are actively excluded 
from the possibility of identification.  This may be a valid step in some 
circumstances, but only if the presence of the excluded bacteria has been 
shown to be of no clinical consequence.  In order to demonstrate this, it is 
necessary to first identify these excluded bacteria before their exact role (or lack 
of it) can be determined.  Thus a detailed understanding of the role of these 
excluded organisms cannot be achieved in this way. 
It is therefore clear that culture for the detection and identification of bacteria 
has its limitations.  There are a number of alternatives to culture based methods 
for detection and identification of bacterial species.  The majority of these utilise 
the nucleic acid content of bacterial cells, and these techniques will now be 
discussed in more detail.   There is an alternative to culture that does not rely 
on nucleic acid analysis.  Gas-liquid chromatography utilises the volatile fatty 
acids released by certain bacteria, particularly anaerobes (Foweraker et al. 
2005).  Each species has a particular profile of volatile fatty acids which allows 
for a degree of differentiation between species.  These techniques are not 
dependent on prior culture of the bacteria and thus avoid some of the limitations  
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noted above.  However the technique has not gained widespread acceptance, 
perhaps due to its limited specificity, particularly in comparison to other 
alternatives to bacterial culture (Smith et al. 2003). 
1.3.1 Culture-based techniques 
Identification of bacteria has long relied on the classical technique of growing a 
bacterium under optimal conditions in isolation and in planktonic form.  Physical 
and biochemical characteristics are observed, and typical patterns recognised 
that allow for identification. Such techniques are, however, prone to errors 
(McMenamin et al. 2000; van Belkum et al. 2000), and are no guarantee of 
exact and specific identification of species.  Further more, the results of 
standard antibiotic sensitivity testing has also been shown to be unreliable in CF 
(Foweraker et al. 2005), and unhelpful in predicting clinical response to 
antimicrobial therapy (Smith et al. 2003). 
Culture based techniques are still the only widely accepted and used method for 
routine bacterial detection and identification in clinical practise, but this is 
despite evidence for their lack utility, and because of the lack of a validated 
better alternative, rather than because of their proven worth.  They form an 
integral part of the routine care of patients with CF.  Guidelines from both the 
UK (Cystic Fibrosis Trust 2001) and USA (Yankaskas et al. 2004) recommend 
sputum culture every three months, for the detection of P. aeruginosa, 
Burkholderia cepacia complex, S. aureus and methycillin resistant S. aureus 
(MRSA).   Because of the perceived importance of bacteria to CF lung disease, 
a greater number of selective media plates are routinely used, compared to 
other conditions associated with the presence of bacteria in the lower airways 
(Burns et al. 1998; Carson et al. 1988; Henry et al. 1997; Wong et al. 1984).    
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Guidelines include recommendations on sensitivity testing of P. aeruginosa to a 
panel of locally approved antibiotics.  However, some researchers have cast 
doubt on the utility of routine sputum culture and sensitivity testing in the 
management of adults with CF.  Foweraker et al. set out to test the reliability of 
routine culture and sensitivity testing of P. aeruginosa by clinical microbiology 
laboratories in the UK (Foweraker et al. 2005).  Firstly they prepared four 
different suspensions of the same P. aeruginosa morphotype from 101 CF 
sputum samples taken during a pulmonary exacerbation.  Susceptibility to 12 
different agents was tested against each, using the disc diffusion method.  
Furthermore, the reproducibility of sensitivity testing was tested by preparing a 
standard sputum sample containing four morphotypes from one P. aeruginosa 
genotype, before culture and sensitivity testing by 8 scientists at one laboratory, 
and scientists at seven other accredited laboratories.   Results showed a lack of 
correlation in culture and sensitivity results, either within a single P. aeruginosa 
colony, or between identical isolates tested a different laboratories.. Many of the 
antibiograms from different morphotypes of the same P. aeruginosa genotype 
were completely different from one another.  In addition antibiograms, from a 
standardised sample, produced by different scientists in the same laboratory 
and by scientists in different laboratories gave markedly different results.  The 
same group went on to assess combination testing against multiple resistant P. 
aeruginosa isolates, using Multiple Combination Bactericidal Testing 
(Foweraker et al. 2009).  The results again showed poor internal reliability, and 
poor correlation with clinical outcome measures. 
If P. aeruginosa is the organism responsible for CFPEs, and sputum culture is a 
reliable and useful test, then it should follow that results of P. aeruginosa  
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sensitivity testing should impact on clinical outcomes.  Smith et al.  (Smith et al. 
2003) set out to retrospectively test this hypothesis by analysing results from 
the placebo arm of a large randomised controlled trial of nebulised tobramycin 
in CF (Ramsey et al. 1999).  During the trial period all patients received the 
same two intravenous antibiotics for any CFPEs (ceftazidime and tobramycin).  
Fifty six subjects in the placebo arm had a pulmonary exacerbation.  Change in 
lung function during treatment was used as a surrogate outcome marker for 
clinical improvement.  All subjects had sputum samples cultured and P. 
aeruginosa was tested for susceptibility to the same antibiotics.  If susceptibility 
testing was a useful test it would be expected that patients who harboured 
organisms resistant to the treatment antibiotics would not show a clinical 
response, while those who did respond would be those with susceptible 
organisms.  The results however were at odds with the hypothesis.  Whether 
the most prevalent P. aeruginosa strain or the most resistant P. aeruginosa was 
studied, subjects who showed a clinical deterioration (hypothesised to be those 
with resistant organisms) had sensitive organisms, whist those with resistant 
organisms (who would have been expected to show a clinical deterioration) 
showed adequate clinical response. 
Such findings of a lack of clinical utility of antibiotic sensitivity testing are in 
keeping with the clinical experience of many adult CF physicians (personal 
communications).  One theory to explain the lack of utility, despite an 
improvement during treatment for a CFPE is that standard susceptibility testing 
tests individual antibiotics in vitro, whereas in vivo antibiotics are given together 
and may therefore be acting synergistically.  Aaron et al. set out to test the 
hypothesis that CFPEs would be better treated if antibiotics were chosen on the  
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basis of in vitro  synergy testing against P. aeruginosa (Aaron et al. 2005).  Two 
hundred and fifty one CF subjects, all infected with multiresistant gram negative 
bacteria, gave three monthly sputum samples for conventional culture and 
sensitivity testing and also for combination antibiotic susceptibility tests using 
Multiple Combination Bactericidal antibiotic Testing (MCBT).  Subjects who 
developed a pulmonary exacerbation were randomised to receive a 14 day 
course of two antibiotics, chosen either on the basis of conventional sensitivity 
testing, or on the basis of MCBT.  The primary outcome measure was time to 
next CFPE.  After 132 CFPEs and 4.5 years, despite a logical hypothesis and a 
well executed RCT, no statistically significant difference in time to next CFPE 
was found between the two groups.  The authors concluded that MCBT is no 
better than conventional sensitivity testing for the guiding antibiotic choice for 
CFPEs.  One possible explanation for this may come from recent work by 
Foweraker et al. who showed that the reproducibility, reliability and clinical 
correlation of MCBT were poor (Foweraker et al. 2009). 
A further major limitation of culture, beyond the consciously selective nature of 
the technique, is the long standing acceptance that the growth requirements of 
very many bacterial species cannot be adequately replicated in the laboratory.   
In 1959 the first English language report appeared confirming previous 
discrepancies between the detection of bacteria by culture and other 
techniques.  Jannasch et al. ( 1959) demonstrated that far more bacteria were 
detectable by direct microscopy than could be detected by culture.   In some 
samples as many as 9,700 times more bacteria were detected by direct 
microscopy than by culture plate methods.  It should be noted that this report 
had been preceded by a report in Russian by AS Razumov in 1932 (Razumov  
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1932).  Both reports studied samples from aquatic environments.   However this 
extent of this discrepancy does not hold for all environments.  It has been noted 
that the proportion of bacteria detectable by culture was as low as 0.1-1.0% in 
oligotrophic aquatic habitats [i.e. those with low nutrient content], but as high as 
80-90% in eutrophic habitats [ i.e. those with high nutrient content]  (Staley & 
Konopka 1985).  Although these early studies were from environmental 
microbiology, there were also early studies in clinical settings (Gibbons et al. 
1963; Socransky et al. 1963) with similar findings.  In spite of these findings, the 
methods of detecting and identifying bacteria by culture has remained the 
mainstay of clinical microbiology, despite the research and development of new 
culture independent molecular technologies to aid and augment culture based 
techniques (Nature Editorial 2006). 
One possible mitigation for the ‘great plate count anomaly’ (Staley & Konopka 
1985) as it has been termed, is that the loss of diversity detected by the 
different techniques was equally proportionate, i.e. that an equal amount of 
diversity was lost across the whole phylogenetic range, rather than some 
phylogenetic parts losing diversity disproportionately to other parts.  Dunbar et 
al.  ( 1999) showed that this was not the case, and that the degree of diversity 
loss during cultivation was different between different habitats.   
1.3.2 Techniques for Molecular analysis of microbial diversity 
It is, as yet, not possible to culture all bacteria species.  In some environments 
such as soil it has been suggested that as many as 99 % of bacterial species 
observed under a microscope cannot be cultured by common laboratory 
techniques (Borneman & Triplett 1997; Pace 1997; Torsvik, Goksoyr, & Daae 
1990).   The microbiological significance of the uncultured 99 % has been  
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debated (Kirk et al. 2004).  It has been suggested that the 1 % that can be 
cultured may represent the entire community and that the other 99 % are in a 
physiological state that does not allow for their culture, and thus  of little of no 
significance.  Others have shown that if more extensive attempts to culture the 
bacteria are made, more closely mimicking the natural environment, more but 
by no means all species are identified (Kaeberlein, Lewis, & Epstein 2002).  It 
has been argued that no environment has ever been exhaustively sampled to 
the point that ever species present has been identified (Bell et al. 2005; Curtis 
et al. 2006; Curtis, Sloan, & Scannell 2002; Nusslein & Tiedje 1999; Prosser et 
al. 2007).  In addition, other Kingdoms have been shown to display high levels 
of diversity (Singh et al. 2006). 
There are a number of different methods for analysing bacterial diversity.  Some 
of these will be outlined below. 
1.3.2.1  Limitations of molecular based techniques 
Molecular based techniques have been introduced to overcome some of the 
limitations of more traditional techniques.  They are, however, not without 
limitations of their own.  Firstly, most methods depend on the release of nucleic 
acid material from within bacterial cells by breaching the integrity of the cell wall 
in some way.  However, for any given sample containing a variety of species, 
the efficiency of cell lysis will vary.  If some cells, for example those with 
stronger cell walls, are incompletely lysed, compared to others with thinner 
walls that are more completely lysed, this will lead to different yields of nucleic 
acid product and inaccurate estimates of bacterial community composition 
(Wintzingerode F von, Gobel, & Stackebrandt 1997).  
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1.3.2.2  Non-PCR molecular techniques 
1.3.2.2.1  Guanine plus Cytosine 
Differences in the Guanine plus Cytosine (G+C) content of DNA can be used to 
study the differences between bacterial communities (Nusslein & Tiedje 1999).  
This is based on the knowledge that bacteria differ in their G+C content, and 
that taxonomically related groups of bacteria only differ by 3 % to 5 % (Tiedje et 
al. 1999).  Although this method can only provide a coarse resolution of the 
bacterial community, it avoids a number of the pitfalls of PCR.  Furthermore it 
includes all DNA present, is quantitative and can detect rare species not 
previously suspected (Clegg, Ritz, & Griffiths 2000).  There do not appear to 
have been reports of G+C being used to assess bacterial diversity in clinically 
relevant situations. 
1.3.2.2.2  Nucleic acid re-association and hybridisation 
Deoxyribonucleic acid (DNA) re-association is a measure of genetic complexity 
of any given bacterial community, and has been used to estimate bacterial 
diversity (Torsvik, Goksoyr, & Daae 1990).  Total DNA from a sample is 
extracted and then purified.  This DNA is then denatured and then allowed to re-
anneal.  The rate at which it re-anneals is a measure of the genetic diversity of 
the sample: the more diverse the species in the sample the longer it will take of 
a one strand to be re-united with a complimentary strand.  Although this 
technique avoids PCR-related biases, it offers little in the way of sensitivity and 
offers no information on species identification. 
Nucleic acid hybridisation using specific probes is an important qualitative and 
quantitative technique for estimating bacterial diversity (Clegg, Ritz, & Griffiths 
2000). Importantly these hybridisations can be done on DNA or RNA and can  
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also be done in situ on intact cells (Fluorescent In Situ Hybridisation - FISH) 
allowing three dimensional spatial distribution of organisms within samples to be 
ascertained.  Formerly these hybridisations were done using oligonucleotide 
probes labelled with radioactive isotopes, but are now more commonly 
performed using fluorescent probes (Schramm et al. 1996).  Another refinement 
is the use of Peptide Nucleic Acid (PNA-FISH) (Nielsen et al. 1991).  PNA has a 
number of advantages over DNA probes for use in FISH.  Firstly PNA is 
electrically uncharged, and thus the PNA/RNA hybrid is more stable than a 
DNA/RNA hybrid.  Also PNA is more hydrophobic than DNA, thus favouring 
entry through a lipid-based cell wall.  One drawback of FISH is that it is 
relatively insensitive.  It requires bacteria to be present in relatively high 
quantities in order for the fluorescent probes to be detected.  The probes can be 
designed to be species-specific or more general as is required, but specific 
probes can only be designed for species that have been previously detected 
and sequenced, thus limiting its utility in detection of new or unsuspected 
species (Kirk et al. 2004). 
1.3.2.2.3  DNA microarrays 
DNA microarrays consist of an arrayed series of microscopic dots of DNA 
oligonucleotides, called features, each containing pico-molar quantities of  
different  specific DNA sequences.  These features are arranged in a two 
dimensional grid on a glass or silicone slide, called a chip.  Hybridisation of the 
DNA fragments to fluorescently labelled probes is detected by sophisticated and 
sensitive instruments and software.  The make-up of the features can be many 
different targets including gene products of respiratory epithelium (Wright et al. 
2006), specific bacterial genes and gene products (Hentzer et al. 2003b) and  
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bacteria.  One limitation of the technique is that it is highly dependent on the 
quality of the chip, and, as the chips are costly, quality assurance and 
reproducibility are challenging to demonstrate. 
DNA microarray can also be employed to assess bacterial diversity (Greene & 
Voordouw 2003).  However, one clear limitation of this method for analysis of 
bacterial community composition is that the bacteria detected will be pre-
determined by the features that are chosen for that particular microarray.  Given 
the vast diversity of bacteria, no chip, no matter how large, can ever come close 
to detection of all possible bacteria.  However, if the possible diversity is limited, 
or presumed to be limited, then a DNA microarray chip could be employed 
(Roth et al. 2004). 
1.3.3 PCR techniques 
The polymerase chain reaction (PCR) is an enzyme-driven, primer-mediated, 
temperature dependent process which allows for the replication of a specific, 
pre-determined sequence of DNA (Millar, Xu, & Moore 2007).  PCR has been a 
major step forward in utilising and understanding the genetic information stored 
in nucleic acids of living creatures (White, Madej, & Persing 1992), allowing 
amplification and analysis of miniscule quantities of nucleic acid.  Following 
acquisition, purification and amplification by PCR of nucleic acid from a given 
sample, a number of different techniques have been used to detect bacteria.  
1.3.3.1  Specific PCR 
Specific PCR is the simplest PCR technique, and is designed to detect specific 
target microbes (Coenye et al. 2005; McMenamin et al. 2000).  It is the most 
widely PCR available technique in UK clinical diagnostic microbiology  
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laboratories (Millar, Xu, & Moore 2007).  In order for specific PCR to be useful 
two there are two pre-requisites.  Firstly, the genome of the bacterial species in 
question must have been sequenced.  Secondly, the presence of the species in 
question must be suspected.  It would not be practical for specific PCR to be 
deployed for all known species in order to analyse an entire bacterial 
community.  Furthermore, new species, genera and even families are still being 
described, thus making this approach inherently selective as well as intrinsically 
impractical. 
1.3.3.2 The bacterial genome 
A number of PCR techniques use specific characteristics of the bacterial 
genome that warrant further discussion.  All living cells contain mitochondria.  
Importantly, however, bacterial mitochondria differ from eukaryotic 
mitochondria.  Bacterial mitochondria are composed of two subunits, termed the 
30S subunit and the 50S subunit.  Within the 30S subunit is a strand of 
ribosomal RNA (rRNA) that is termed the 16S rRNA strand.  This 16S rRNA 
strand is specific to bacteria.  Within the bacterial genome is a section of DNA 
that codes for this 16S rRNA.  It is a sequence that is approximately 950 base 
pairs in length and is common to all bacteria.  However, there are differences in 
its code between species allowing for differentiation of most species (Liu et al. 
1997). 
1.3.3.3  Bacterial Clone Libraries 
After isolation of total community DNA from a given community of bacteria in a 
sample, this DNA is used as a template for PCR amplification of 16S rRNA 
genes with universal or genus specific primers (Liu et al. 1997).   This is usually 
followed by construction of a clone library for genes encoding rRNA and the  
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rapid screening of the library based on sequence differences.  Harris et al. have 
applied such techniques to clinical samples, and have demonstrated the ability 
to detect more bacteria in samples from sites of infection than standard culture 
techniques  (Harris & Hartley 2003).  However it was not clear what anatomical 
sites these samples came from.  Van Belkum et al. have applied bacterial clone 
techniques to sputum samples from a limited number of CF patients (van 
Belkum et al. 2000).  Using both general primers for gram negative and gram 
positive bacterial, as well as specific primers for species typically associated 
with CF pulmonary disease.  They demonstrated a wide discrepancy between 
species identified by culture and those identified by PCR techniques.  More 
recently Bittar et al. applied a more automated bacterial cone technique to a 
larger number of CF sputum samples (Bittar et al. 2008).  They analysed 25 
sputum samples from CF patients, and identified 13 different species by culture.  
They went on to generate and analyse 736 bacterial clones from the same 
samples.  In this way they were able to identify 53 different species (mean 7.3 
per specimen).   
However, this technique remains a time and labour intensive process not well 
suited to relatively high throughput situations. 
1.3.3.4  Denaturing gradient gel electrophoresis 
Denaturing Gradient Gel Electrophoresis (DGGE) is a variant of another PCR-
based technique, temperature gradient gel electrophoresis (TGGE).  As with 
other techniques they require the prior purification and amplification of DNA.  
DGGE/TGGE utilise the physical properties of DNA.  At room temperature, DNA 
is a stable negatively charged tightly wound double helix molecule.  However, 
when the temperature is raised the strands start to become unwound from each  
  38 
other.  This process is termed denaturing.  The degree to which the double helix 
is either partially or completely unwound depends on the temperature, and for 
any given sequence, the denaturing temperature will be different.  Further more, 
because the molecule is negatively charged, it will move towards the positive 
electrode when placed in an electric field.  In DGGE/TGGE, bacterial DNA is 
placed on an electrophoretic gel under appropriate denaturing conditions.  The 
resultant pattern of bands is representative of the diversity of bacterial species 
in a given community (Pang et al. 2005; Tominaga 2006). 
1.3.3.5  Ribosomal intergenic spacer analysis (RISA) 
RISA provide ribosomal based fingerprinting of the bacterial community.  RISA 
makes use of the intergenic spacer region between the 16S and 23S ribosomal 
subunit regions of the bacterial genome.  This region is amplified by PCR, 
denatured and separated on a polyacrylamide gel under denaturing conditions.  
RISA has been applied to environmental (Fisher & Triplett 1999) and clinical 
situations (Scanlan et al. 2008), but not to respiratory samples.   The technique 
is highly reproducible but time consuming.  An automated variation (ARISA) 
offers faster turn around times and greater sensitivity (Fisher & Triplett 1999). 
1.3.3.6 Multi-Locus Sequence Typing 
Multi-locus sequence typing (MLST) is another PCR based technique which 
compares strains of the same bacterial species.  It does this by amplifying and 
then sequencing sections of the bacterial genome encoding for well-preserved 
‘house-keeping’ genes.  Multiple house-keeping genes are amplified and 
sequenced to increase discriminatory power (Maiden et al. 1998).  It was first 
used to discriminate different strains on Neisseria meningitis, but has since 
been applied to P. aeruginosa  and B. cepacia strains in CF (Kidd et al. 2011;  
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Waine et al. 2007).  It has revealed interesting adaptations of P. aeruginosa 
strains to the CF airways compared to environmental strains. 
It is a powerful tool for strain typing within a species for epidemiological and 
infection control purposes.  However, it is not well suited to analysis of complex 
multi-species bacterial community structure. 
1.3.3.7  Restriction fragment length polymorphism techniques 
Restriction fragment length polymorphism (RFLP) and terminal restriction length 
polymorphism (T-RFLP) are related PCR techniques.  Common to both, PCR-
amplified rDNA is digested by a restriction enzyme.  In RFLP all the generated 
fragments are detected using agarose or non-denaturing polyacrylamide gel 
(Liu et al. 1997).  RFLP is useful for screening clones or for detecting changes 
in bacterial communities.  However, as any one species may generate as many 
as four to six restriction fragments, RFLP produces banding patterns that are 
too complex to be useful as a measure of diversity or for specific phylogenetic 
groups (Kirk et al. 2004).  T-RFLP attempts to address the short comings of 
RFLP in bacterial community analysis.  T-RFLP follows the same principle as 
RFLP except that the PCR primer is labelled with a fluorescent dye.  When the 
products of PCR are digested using a restriction endonuclease, only the 
terminal fragments that are labelled with the fluorescent dye are detected (Liu et 
al. 1997).  This considerably simplifies the banding patterns, making bacterial 
community analysis possible in even complex bacterial communities.  In 
addition, each species only contributes one band to the result, so that the 
number of bands represents the minimum number of bands in the community. .  
See Figure 1-2 for an example of a T-RFLP gel, and post-T-RFLP processing to 
allow relative abundance calculations.  
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Each band on the polyacylamide gel represents a terminal restriction fragment 
of a certain length.   It is possible for two or more species to share the same 
terminal fragment length, and therefore the presence of a band does not always 
identify a particular species.  However, for T-RFLP the presence of a band can 
be said to represent at least one species, although the same is not true for 
RFLP.  
Figure 1-2 T-RFLP: example of polyacrylamide gel showing control ladder (top 
row - A), and four sample results (B-E).  Lower images show conversion of band 
height, width and intensity into relative abundance.  See text for more details. 
In addition to T-RFLP, a technique performed on bacterial DNA, it is possible to 
add an additional step to the process.  By performing a reverse transcription 
step prior to T-RFLP, it is possible to convert bacterial rRNA (manufactured by 
actively metabolising bacterial cells) to DNA.  This added modification is called 
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RT-T-RFLP, and allows some assessment of the relative metabolic activity of 
the bacterial cells present (Rogers et al. 2005). 
It has been demonstrated that the choice of restriction enzyme can influence 
results (Dunbar, Ticknor, & Kuske 2000).  This is to be expected as different 
restriction enzymes will have different terminal cut points for any given 16S 
DNA fragment.  For a complex community, more or less species may share a T-
RF length, thus altering the apparent bacterial community structure.  However, 
for temporal or spatial comparisons of a particular given bacterial community it 
remains a powerful tool (Dunbar, Ticknor, & Kuske 2000; Fourcans et al. 2007; 
Meier, Wehrli, & van, Jr. 2007; Pringault et al. 2007; Thies, Konig, & Konig 
2007).  Indeed Tiedje et al. reported five times greater success at detecting and 
tracking specific ribotypes using T-RFLP than using DGGE (Tiedje et al. 1999). 
As a technique, T-RFLP has its caveats.  Possibly the main potential bias in T-
RFLP results concerns operon copy number heterogeneity (Klappenbach et al. 
2001).  Different bacterial species have different numbers of copies of the rRNA 
gene in their genome.  The number of copies can range from one to 15.  This 
could presents difficulties when interpreting the results based on quantification 
of the products of PCR that has targeted this gene in multiple different species 
(Crosby & Criddle 2003).  However, as a technique, T-RFLP has been 
demonstrated to be valid for the analysis of temporal and spatial fluctuations in 
bacterial communities (Hartmann & Widmer 2008). 
Since the inception of this study, a new advance and modification to the 
technique of T-RFLP has become available.  Propidium monoazide (PMA) 
photo-cross linking was first described by Nocker et al. ( 2007). It utilizes the 
ability of PMA to bind to both extracellular nucleic acids and to permeate any  
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non-viable bacterial cell membranes to also bind to the nucleic acid present 
there.  Following binding, PMA cross-links when exposed to light.  The bound 
nucleic acid, cross-linked with PMA, is then easily removed from the solution. In 
this way, only nucleic acid from remaining viable cells remains.  The PMA step 
within T-RFLP obviates the need for RT-T-RFLP to demonstrate the presence 
of viable and metabolically active.  The technique has subsequently been 
successfully used on CF sputum in samples from this study (Rogers et al. 
2008). 
1.3.4 Taxonomic Ambiguity of Bacteria 
One problem when considering the question of bacterial diversity in any 
environment is that there is no unified definition of what constitutes a species 
(Hey 2001).  Traditional definitions of a species are based on higher organisms 
such as plants and animals and do not readily apply to prokaryotes (Godfray & 
Lawton 2001).  Bacteria display a high degree of genetic plasticity that defies 
easy definitions of what constitutes a species.  Whilst accepting that there is a 
degree of disagreement, most taxonomists would accept a percent identity 
score of > 97% for classification to genus, and > 99% for classification to 
species level, when using the 16S rRNA gene for identification (Petti 2007). 
1.4  Microbiology of Pulmonary Disease in CF 
There has been a longstanding belief that the range of pathogens found in CF 
lungs is limited (Govan & Nelson 1992; Lyczak, Cannon, & Pier 2002), and 
include bacteria such as S. aureus, Haemophilus influenzae (H. influenzae ), P. 
aeruginosa and Burkholderia cepacia complex (Bcc). See Figure 1-3 below.  
Indeed, when only selective culture based techniques are used, species  
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detected are unsurprisingly, limited.  Until recently such information has formed 
the basis of an understanding CF pulmonary microbiology. 
   
Figure 1-3 Respiratory Infections in CF. From 2005 CFF Patient Registry Report 
to Center Directors [with permission]. 
Historically these pathogens have been identified by culture-based techniques.  
From these culture-based surveillance data, a number of important messages 
can be determined.  First of all, it can be seen that the rise of P. aeruginosa 
occurs after the peak incidence of S. aureus.  Secondly, the rise in P. 
aeruginosa coincides with a fall in the incidence of isolation of S. aureus.  
Finally there is a degree of co-infection, with percentages adding up to greater 
than 100%.  The traditionally accepted CF bacterial pathogens would thus be 
(in approximate order of acquisition): S. aureus, H. influenzae, P. aeruginosa, 
Stenotrophomonas maltophilia (S. maltophilia), Bcc. 
This traditional view that the pathogens isolated from the CF sputum are limited 
in their diversity (Lyczak, Cannon, & Pier 2002) has been questioned through 
findings from both conventional and molecular biological methodologies (Bittar  
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et al. 2008; Rogers et al. 2003; Tunney et al. 2008).  These methodologies have 
shown a marked range of phylogenetically diverse bacteria have been isolated.  
Although these discoveries have been of interest at the level of the individual 
CF patient, they have not as yet been shown to carry any wider morbidity or 
mortality implications.   Furthermore, the techniques used have limited 
availability outside of the research laboratory.   
Given the advances made in CF care based on the previously wide acceptance 
of a limited number of pathogens as important in CF pulmonary disease, a 
number of these will be discussed in more detail. 
1.4.1 Recognised pathogens 
1.4.1.1 Staphylococcus aureus 
S. aureus was the first organism recognised as a pathogen of the CF airways.  
In the pre-antibiotic era few children survived beyond infancy and 
staphylococcal infection was the major cause of mortality (Anderson 1938).  
This lead to widespread use of anti-staphylococcal antibiotic prophylaxis. This in 
turn coincided with steady improvements in survival with CF.  However, later 
retrospective studies suggested that such anti-staphylococcal treatments were 
associated with increased colonisation with H. influenzae and P. aeruginosa, 
and worse outcomes (Bauernfeind et al. 1987).  Others have noted an 
association between S. aureus colonisation in adults and improved survival 
probability due to the beneficial effect of not being colonised with P. aeruginosa 
(Liou et al. 2001).  
More recently controversy has surrounded the role of methicillin resistant 
Staphylococcus aureus  (MRSA) in adults with CF.  In both adult and paediatric  
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populations investigators have found a relationship between the isolation of 
MRSA from respiratory CF specimens and a worse clinical markers (Miall et al. 
2001; Ren et al. 2007).  However it has been suggested that such findings do 
not relate to increased pathogenicity of MRSA over and above MSSA, rather 
that those patients with MRSA are from a more unwell cohort, with 
consequently more exposure to healthcare institutions and thus at more at risk 
of contracting MRSA.  More recently Dasenbrook et al. (Dasenbrook et al. 
2008) attempted to control for such confounders by retrospectively analysing a 
very large cohort enrolled on to the (American) Cystic Fibrosis Foundation 
(CFF) patient registry.  Subjects who became persistently MRSA positive in 
their sputum had a significantly faster rate in decline of FEV1, when controlling 
for other variables.   This, however, does not prove causation, and it remains an 
unlikely possibility that MRSA is a marker for greater exposure to healthcare 
services.   
1.4.1.2  Haemophilus influenzae 
H. influenzae is commonly found as a commensal in the upper airways of 
healthy individuals (Moller et al. 1998).  It is also frequently isolated from 
respiratory secretions in CF (see Figure 1-3 above), with a peak prevalence of 
around 35% in early childhood, declining to around 5% in later life (Gilligan 
1991).  However these reported figures may not be representative of the true 
prevalence for a number of reasons.  Firstly culture of the relatively fastidious H. 
influenzae can be difficult in the presence of other more vigorous organisms 
(Govan & Nelson 1992).  Despite early reports that H. influenzae does not 
persist between exacerbations of chronic respiratory tract illnesses (Govan & 
Nelson 1992), it is now recognised that the organism may be present in the  
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lower respiratory tract, evading host immune defences and antibiotics (Starner 
et al. 2006).  In addition Moller et al. demonstrated that in explanted lungs from 
CF patients, H. influenzae was isolated in 10 of 16 CF patients, and was 
distributed throughout all divisions of the bronchial tree (Moller et al. 1998). 
Additional factors that might contribute to an underestimation of the prevalence 
of H. influenzae by culture, as standard culture only employs aerobic conditions, 
and isolation of H. influenzae has been shown to be greatly improved by 
anaerobic culture (Gilligan 1991).  Finally, H. influenzae has recently been 
shown to be able to exist and grow in biofilm phenotype in CF patients, a form 
which is inherently slower growing and more resistant to antimicrobial agents 
than the planktonic form (Starner et al. 2006; Starner et al. 2008).  
The contribution of H. influenzae to the lung damage that is characteristic of CF 
lung disease has yet to be clearly delineated. When isolated in the context of a 
pulmonary exacerbation, it has been reported to be associated with higher 
levels of systemic inflammatory markers such as C-reactive protein (Govan & 
Nelson 1992). 
1.4.1.3  Pseudomonas aeruginosa  
P. aeruginosa is a gram negative, rod shaped bacterium that is a common 
environmental organism.  In humans it is an opportunistic pathogen and in the 
respiratory tract it only causes disease if the host immune defence system is 
impaired in some way, for example in pre-existing chronic lung disease or in 
ventilator associated pneumonia (Sadikot et al. 2005). 
Historically the improved survival of infants and children with CF that occurred 
with the advent of anti-staphylococcal therapy was followed by the emergence  
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of P. aeruginosa as the most important bacterial airway pathogen (Gilligan 
1991).  The prevalence of P. aeruginosa in cultured respiratory CF samples 
peaks at approximately 80% at around the age of 30 (see Figure 1-3 above).  
Understanding the interaction between P. aeruginosa and human airway 
epithelium defences has been a major focus for CF researchers for over four 
decades (Doggett, Harrison, & Wallis 1964; Hoffman et al. 2010).  It is 
particularly adept at provoking an intense immune and evading host defences 
(Campodonico et al. 2008; Sabroe & Whyte 2007) 
The success of P. aeruginosa is likely to at least in part due to its ability to form 
biofilms. Biofilms are defined as ‘a structured community of bacterial cells 
enclosed in a self-produced polymeric matrix and adherent to an inert or living 
surface’ (Costerton, Stewart, & Greenberg 1999).  Although the discovery of the 
biofilm mode of growth for bacteria did not occur until the 1970s some 
researchers have since hypothesised that the free swimming planktonic state 
exists primarily as a mechanism for migration of bacteria from one place to 
another and that biofilms are the de facto state (Watnick & Kolter 2000).  
Biofilms are a profoundly different mode of existence to the planktonic form.  
They are intrinsically slower growing, and are many orders of magnitude more 
resistant to antibiotics (Hill et al. 2005).  For P. aeruginosa biofilms there is at 
least a six-fold up- or down-regulation of at least 800 genes when compared to 
planktonic growth, which is over 50% of the entire bacterial genome (Sauer et 
al. 2002).  P. aeruginosa biofilms in CF were first identified by Singh et al. 
through the identification of quorum sensing (QS) molecules (Singh et al. 2000).  
Quorum Sensing is a mechanism of communication between individual bacteria 
that allows them to monitor the number of individuals in the vicinity, thus  
  48 
allowing them to convert to biofilm growth at the optimum time (Bassler 2002).  
Other organisms have also been shown to be capable of forming biofilms, 
including in CF airways, such as H. influenzae (Starner et al. 2006), S. aureus 
(Leid et al. 2002) and some fungal species (Hogan 2006; Loussert et al. 2009).  
Molecules that block the QS ability of bacteria have been suggested as possible 
future non-antibiotic therapeutic options for CF (Hentzer et al. 2003b; Hentzer et 
al. 2003a; Wu et al. 2004). 
In a child or adult with CF the first positive culture of Pseudomonas aeruginosa 
is of considerable clinical significance.  The age of onset of chronic P. 
aeruginosa  infection is a predictor of survival (Frederiksen, Hoiby, & Koch 
1998), and delaying the onset of chronic infection by aggressive antibiotic 
treatment prompted by detection of early isolates has been shown to improve 
lung function (Frederiksen, Hoiby, & Koch 1998; Littlewood et al. 1985).  
Antibiotic treatment with the aim of P. aeruginosa eradication with prolonged 
antibiotic therapy is thought to be successful in its aims (Taccetti et al. 2005; 
Valerius, Koch, & Hoiby 1991).  It has been suggested that antibiotic strategies 
such as these can achieve eradication of P. aeruginosa from the lower 
respiratory tract in most subjects for a considerable period of time (Munck et al. 
2001).  However, in work by Taccetti et al. (Boussaud et al. 2008), the definition 
of eradication was based on detection of P. aeruginosa  by culture from throat 
swabs or sputum samples, and serum P. aeruginosa  antibody titres.  Both tests 
are considered insensitive marker of the presence of P. aeruginosa  (da Silva 
Filho et al. 2007; Farrell & Govan 2006).  Other data suggesting that eradication 
may indeed be possible comes from the analysis of the strains identified in 
respiratory samples at first isolation, and then at second isolation.  Munck et al.  
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demonstrated that, in 14 of 19 cases, P. aeruginosa  strains identified after an 
‘eradication’ were different strains to those identified at first isolation (Munck et 
al. 2001).  This still implies that, in 5/19 (26%) ‘eradication’ may not have been 
achieved. 
Treatment for CFPEs is targeted at P. aeruginosa although it is not clear that it 
is the main cause of CFPEs (See CF Pulmonary Exacerbations on page 9 for 
more details). 
1.4.1.4 Burkholderia cepacia complex 
Burkholderia cepacia complex (Bcc) is a term that refers to a group of bacterial 
species.  The Bcc is an important part of the rhizosphere as well as the wider 
environment.  Its specific properties have been utilised in bio-remediation, and 
plant-growth promotion (Mahenthiralingam, Baldwin, & Dowson 2008).  In 
particular, Bcc is also noted as an onion pathogen (Govan & Vandamme 1998).  
Initially the species in Bcc were considered as one species, in part due to the 
fact that biochemical testing was unable to tell them apart (Mahenthiralingam, 
Baldwin, & Vandamme 2002).  The advent of molecular diagnostic allowed 
differentiation in to distinct species (also called genomovars).  To date 17 
genomovars (I – XVII) have been described (Cystic Fibrosis Trust 2010; 
Papaleo et al. 2010; Vanlaere et al. 2008; Vanlaere et al. 2009).  The most 
clinically important is genomovar III (B. cenocepacia), which is the most 
frequently associated with a rapid clinical decline, as well as poor outcomes 
after lung transplantation (Boussaud et al. 2008; De Soyza et al. 2010; Hopkins 
et al. 2009).  ‘Cepacia syndrome’, a devastating pulmonary infection in CF 
patients characterized by fevers, pulmonary infiltrates, rapid pulmonary decline 
and a high mortality rate, was first reported in 1984, from an outbreak in a CF  
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centre in Canada (Isles et al. 1984).  Person-to-person transmission was 
demonstrated in 1990 (Lipuma et al. 1990), which led to the implementation of 
much more stringent infection control and segregation policies in CF units. 
The mechanism by which Bcc, and particularly genomovar III exerts its marked 
detrimental effect, when other bacteria, typically more virulent in other clinical 
settings, fail to make such an impression is, as yet, not clear (Saldias & Valvano 
2009).  A large numbers of putative mechanisms have been investigated, that 
include genetic, transcription, secretory, protein, biofilm, and quorum sensing 
mechanisms..  Some of these include two transcription regulating proteins 
RpoE and RpoN, which are necessary to allow engulfed Bcc to delay 
phagosomal fusion and lysis (Flannagan & Valvano 2008), and for biofilm 
formation (Saldias et al. 2008).  In addition, the biofilm quorum sensing system, 
cepRI, appears to be important to Bcc virulence, with Bcc  CepRI knockout 
mutants showing reduced motility (Lewenza, Visser, & Sokol 2002), less stable 
biofilms (Tomlin et al. 2005), and reduced virulence in a rat lung model (Sokol et 
al. 2003). 
The role of human anti-microbial peptides has previously been discussed in 
Section 1.2 above.  Bcc  possesses zinc metalloproteases which may give it the 
ability to cleave human anti-microbial peptides (Kooi & Sokol 2009). 
Overall, Bcc is a virulent, transmissible, and difficult to treat infection with 
severe ramifications for CF patients. 
1.4.2 CF as a Polymicrobial Pulmonary Disease 
For people with CF lung disease it has long been recognised that more than 
one bacterial species may be identified, either from the same sample, or from  
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different samples from the same patient at different times.  Even by the 
relatively insensitive and inaccurate methods of laboratory culture, it can be 
seen from the CFF registry data (See Figure 1-3 above) that the total vales for 
any one age group add up to more than 100%, indicating a significant degree of 
co-infection.  As long ago as 1974 N. Hoiby reported co-infections in ‘most 
patients’ (Hoiby 1974). More recently Burns et al. reported finding a mean of 2.9 
species per specimen by culture (Burns et al. 1998).  Culture independent 
molecular methods are better suited to unbiased attempts to unravel the true 
diversity of bacteria in any environment (Kirk et al. 2004), not least in the CF 
lung (Bittar et al. 2008; Rogers et al. 2004).  Using universal bacterial primers, 
Rogers et al. employed T-RFLP to analyse sputum samples from adults with CF 
(see 1.3.3 above.  They found a mean of 13.3 (SD+7.9) species per sample 
(Rogers et al. 2004), and went to demonstrate, using RT-T-RFLP that most of 
species detected were metabolically active (Rogers et al. 2005).  Although such 
techniques are not able to assign a species name with absolute certainty, 
Rogers et al., and others, have used bacterial clone library analysis to confirm 
such diversity (Bittar et al. 2008; Harris et al. 2007).  In work by Harris et al. the 
median age was 9.1 for the females and 8.5 for the males, and the lung disease 
severity was not reported.  A large degree of diversity was, however, detected 
compared to both disease and healthy controls.   
1.4.2.1  The Role of Anaerobic Bacteria 
Recently, unequivocal evidence demonstrating that anaerobic bacteria are 
present in the lower airways of CF lungs has come to light.  Tunney et al. used 
anaerobic culture of sputum and BAL fluid to demonstrated that 64% of samples 
from CF adults had high concentrations of species from the anaerobic genera  
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Prevotella, Veillonella, Propionibacterium and Actinomyces (Tunney et al. 
2008).  Anaerobes were also isolated in the majority of samples from healthy 
control volunteers, but at much lower concentrations and from different genera.  
The identification of P. aeruginosa from the same sample significantly increased 
the likelihood of also identifying anaerobes.  This finding has since been 
challenged by Worlitzsch et al., who, although finding obligate anaerobes by 
culture in 41 or 45 CF subjects, did not find an association with colonisation with 
P. aeruginosa  (Worlitzsch et al. 2009). 
As previously discussed, anaerobic culture is not routinely part of the panel of 
bacterial identification deployed in routine CF care (Cystic Fibrosis Trust 2002; 
Henry et al. 1997; Wong et al. 1984).  The recent work by Tunney et al. is not 
the first evidence of anaerobes in the CF lung.  In 1984 Thomassen et al. 
demonstrated that samples obtained from both the distal and proximal CF 
airway, obtained at thoracotomy, contained anaerobes in at least 20% of cases 
(Thomassen et al. 1984).  Jewes et al. also demonstrated high concentrations 
of anaerobic bacteria in 24% of samples from 21 CF patients (Jewes & Spencer 
1990).  However, although efforts were made to distinguish between the 
presence of anaerobes in the lower respiratory tract and contamination by 
oropharyngeal anaerobes during passage through the oropharynx, there still 
remained concerns regarding the scientific validity of analysing expectorated 
samples for the presence of anaerobes; hence the importance of the anaerobes 
found in BALF by Tunney et al., and by Harris et al.. 
The work on anaerobic bacteria in CF sputum mentioned so far has relied on 
culture for detection and identification.  Rogers et al.  (Rogers et al. 2004)used 
T-RFLP to analyse CF sputum (see PCR techniques 1.3.3 ci-dessus).  Although  
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T-RFLP does not allow identification with complete certainty, some small 
bacterial clone libraries were generated to strongly indicate that a significant 
proportion of anaerobes were present, including species such as Bacteroides, 
Veillonella, Porphyromonas, and Prevotella.  It an attempt to demonstrate that 
such species were not due to oropharyngeal contamination mouth wash 
samples were also studied and compared to expectorated samples (Rogers et 
al. 2006).  This added further weight to the evidence that the anaerobes were 
from the lower respiratory tract.  More recently, Bittar et al. have undertaken 
much more extensive bacterial clone library analysis, generating 720 clones 
from 25 sputum samples, demonstrating 53 different species of which 16 (30%) 
were anaerobes (Bittar et al. 2008). 
If there really are so many anaerobes in CF sputum where are the anaerobic 
environments in which they are finding an ecological foothold? Secondly, if P. 
aeruginosa is an aerobic species (Hoffman et al. 2006), but appears to be 
numerically dominant, how does it manage to inhabit a different ecological niche 
to the anaerobes?  To help answer these questions a number of important 
pieces of work have been published, and in many areas, controversy remains.  
Firstly the biofilms which form the majority of bacterial growth in CF lower 
respiratory tract appear to be anaerobic environments.  Worlitzch et al. 
demonstrated that, in vitro, a steep hypoxic gradient exists in thick CF sputum, 
in to which motile P. aeruginosa  is able to penetrate before adapting to a 
biofilm mode of growth (Worlitzsch et al. 2002).   Furthermore, Yoon et al. have 
demonstrated that P. aeruginosa  is in fact capable of metabolising as a 
facultative anaerobe (Yoon et al. 2002).  Although some ( (Alvarez-Ortega & 
Harwood 2007)) have disputed these conclusions, concluding that P.  
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aeruginosa  is in fact only metabolising in a micro-aerobic environment rather 
than an anaerobic one, the balance of evidence currently appears to favour P. 
aeruginosa  as an anaerobic pathogen in the CF lung. 
The clinical significance of the CF lung as a harbour for anaerobic bacteria is 
not yet clear.  Tunney et al., in their important work on anaerobes in CF sputum, 
tested antibiotic susceptibility patterns to the bacteria, both aerobic and 
anaerobic, that they detected (Tunney et al. 2008).  Meropenem was the only 
antibiotic with Minimum Inhibitory Concentrations for 90% of isolates that fell 
within ‘susceptible’ for all species.  All other antibiotics, including metronidazole 
which is typically considered to be effective against anaerobic infections (British 
Medical Association. & Royal Pharmaceutical Society of Great Britain. 2009), 
showed high levels of resistance.   
1.4.2.2 Significance of bacterial diversity 
What is the significance of this diversity?  It is clear that a number of different 
bacterial species co-exist in close proximity to each other on the epithelial 
surface of the human lower respiratory tract in people with CF.  However it also 
appears likely that such co-infection does not occur simultaneously, but 
changes over time, as both intra-pulmonary conditions shift, and as 
environmental exposure to potential community members continues.  This 
principle of succession can be seen in Figure 1-3 on page 43 above.  The 
potential for significant interactions between bacterial species, either directly 
through inter-species signalling, or indirectly through competition for limited 
resources, is great.  Some work has been performed using in vitro culture of two 
or more species.  For example P. aeruginosa has been implicated in the 
pathogenesis of Bcc, through up-regulation of Bcc virulence factors in the  
  55 
presence of P. aeruginosa.  Both species use N-acylhomoserine lactone (AHL) 
quorum sensing signalling molecules and have been shown to co-exist in mixed 
biofilms in the CF lung (Riedel et al. 2001).  The study demonstrated that, in 
vitro, AHL from P. aeruginosa could be detected and influences Bcc but that 
AHL from Bcc had no effect on P. aeruginosa.  Others have demonstrated 
similar communication between these two species, but additionally that the 
communication may in fact be bi-directional, if only for certain strains (Lewenza, 
Visser, & Sokol 2002). 
When considering the importance of species diversity it is important to take 
account of the work done in different fields.  Ecological study has been a 
scientific discipline long before such concepts were applied to bacteria.  In order 
for any bacterial community to become established in a previously sterile 
environment, there must be some influx, or immigration, of bacteria.  In the 
lungs, the normal host defence system is thought to prevent the establishment 
of a chronic bacterial community, and certainly prevents chronic inflammation 
and lung damage (See Section 1.1 above).  For a chronic bacterial community 
to have become established some of the immigrant bacteria most become 
persistent.  However, not all immigrant bacterial species will form part of the 
chronic bacterial community.  For some species, conditions will not favour their 
persistence, and their presence in the environment in question will only be 
transient.  Which species become established will be determined partly by 
deterministic factors such as the nature of the conditions, availability of 
substrate for the bacteria and the host response, and partly by stochastic 
factors (van der Gast, Ager, & Lilley 2008).  Once a chronic bacterial community 
is established, the process of immigration will not stop.  For new immigrant  
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species the presence of the established bacterial community will result in the 
environment being very different to that encountered by the first immigrants.  
Many of these later immigrants will be transient, but some may become 
established if they can find an ecological niche.  When studying results of 
sampling of a community, it is valuable to be able to differentiate between 
transient species and resident species.  Such analysis has been pioneered in 
other habitats by Magurran and Henderson (Magurran & Henderson 2003). 
In ecological studies at a single time point it not possible to differentiate 
between species that are resident, i.e. permanent members of the community, 
from non-resident, i.e. transient species.  These terms are ecologically 
synonymous with ‘core’ species and ‘satellite’ species.  However, in data sets 
that are longitudinal it is possible to determine which species are core and 
which are satellite.  Such an ability could have important implications in 
determining which species are the most relevant to the interaction between a 
community and its environment i.e. the human lungs, and are therefore more 
likely to play a role in chronic lung damage..   
1.4.2.3  P. aeruginosa and S. aureus Interactions 
There is a historical and temporal association between S. aureus and P. 
aeruginosa in the succession of CF pulmonary species (see section 1.4.1.1 
above).  Beyond this, Hoffman et al. demonstrated that there is communication 
between the two species in vitro ( 2006).  Co-culture of the two species results 
in products of P. aeruginosa inhibiting respiration of S. aureus.  Such inhibition 
leads to growth of a small colony variant (SCV) of S. aureus, which in turn has 
been shown to be intrinsically more resistant to key antibiotics used in clinical 
CF care such as tobramycin (Hoffman et al. 2006).  Such findings could have  
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important clinical consequences, as antibiotics, particularly aminoglycoside 
antibiotics, are an extremely important treatment in CF pulmonary disease 
(Cystic Fibrosis Trust 2009a; Ramsey et al. 1999). 
1.4.2.4  P. aeruginosa and Fungal Interactions 
P. aeruginosa has been shown to have the potential to interact with organisms 
from different Kingdoms.  It has been demonstrated that fungi from genera such 
as Candida and Aspergillus can be cultured from lower respiratory tract 
samples in patients with CF pulmonary disease (Burns et al. 1998).  It is also 
common to find co-infection with P. aeruginosa.   Both fungal species and 
bacterial species communicate with each other using small diffusible molecules, 
e.g. quorum sensing molecules.  McAlester et al. demonstrated that 
communication between Candida albicans and P. aeruginosa is bi-directional 
(McAlester, O'Gara, & Morrissey 2008). A quorum sensing molecule (called 3-
oxo-C12HSL) produced by some strains of P. aeruginosa affected the 
morphology of Candida albicans in a dose dependent fashion; and a molecule 
from Candida albicans (called Farnesol) limited the swarming ability of P. 
aeruginosa.  Others have suggested that pyocyanin, a major inflammatory 
metabolite of P. aeruginosa, is able to inhibit growth of Candida and Aspergillus 
species (Kerr et al. 1999). 
1.4.2.5  Bacterial Competition for Nutrients 
Another area of potentially significant interaction between species is that of 
nutrient availability.  In this area most work has focused on the role of iron as a 
nutrient for P. aeruginosa.  Free extracellular iron in the lung can cause damage 
either directly, through oxidative free radicals, or indirectly by providing a vital 
food source for otherwise non-replicating bacteria (Moreau-Marquis et al. 2008).   
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Iron content of the CF airway is thought to be raised, possibly directly due to the 
defect in CFTR protein, and may provide an additional stimulus for P. 
aeruginosa to convert to its biofilm mode of growth, adding to aminoglycoside 
resistance.  In addition, S. aureus may serve as a source of iron, providing P. 
aeruginosa with an additional stimulus to achieve chronic pulmonary infection in 
CF (Mashburn et al. 2005). 
Since the discovery of iron as a key nutrient for P. aeruginosa growth, iron 
chelating has been explored for a potential therapeutic role in CF.  Musk et al. 
explored the utility of 20 potential iron chelators for activity against P. 
aeruginosa biofilms in vitro (Musk, Jr. & Hergenrother 2008).  After screening, 
potentially therapeutic compounds were tested for suitability to be delivered to 
the lungs by nebulisation.  Two compounds (ferric picolinate and ferric 
acetohydroximate) passed both tests, and thus show potential for further in vivo 
investigational studies. 
1.4.2.6  In Vivo Studies of Bacterial Interactions 
Much of the work investigating the possibility of inter-species interactions in CF 
has been in vitro work.  This in vitro work, although demonstrating that 
interspecies interactions are possible, does little to shed light on the tripartite 
relationship between different micro-organisms and host in the context of CF 
pulmonary disease. These short falls have been, in part, a necessity due to the 
difficulty of studying bacteria in situ within the CF lung.  One group of 
investigators has attempted to circumvent some of these short comings by 
studying complex bacterial interactions in high throughput animal models.  
Although there are short falls in this approach, and results may not be directly 
applicable to humans, it does encompass some of the intrinsic complexity of  
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polymicrobial infections.  Duan et al. used a rat agar bead model of CF 
pulmonary disease to investigate the interaction between oropharyngeal 
bacteria (oral flora – ‘OF’) and P. aeruginosa (Duan et al. 2003).  Oral flora, in 
and of itself is part of the commensal microbial flora intrinsic to all humans.  Oral 
flora include species from genera such as Staphylococci, Streptococci, 
Veillonella, Porphyrmonas, and Prevotella (Aas et al. 2005).  Such species 
include both aerobes and obligate anaerobes.  The study by Duan et al. study 
demonstrated marked P. aeruginosa virulence, when compared to OF when 
infecting the rat lung.  However, when P. aeruginosa and OF co-infection 
occurred, P. aeruginosa numbers remained unchanged, but virulence increased 
very markedly.  Molecular gene expression analysis demonstrated a number of 
key P. aeruginosa virulence genes that were up-regulated.  Such works 
demonstrates the potential importance of bacterial that are frequently 
overlooked in clinical practice.   
The same group has gone on to use an alternative animal, the drosophila (fruit 
fly) model, to allow higher throughput and faster results.  Using this drosophila 
model, Sibley et al. investigated the nature of potential interactions between OF 
and P. aeruginosa (Sibley et al. 2008f).  Using mortality of flies after a fixed time 
period as a surrogate marker of virulence, they were able to demonstrate that 
OF – P. aeruginosa interactions could be divided in to three broad groups, 
based on alterations in virulence: I) virulent alone, with increased virulence 
when co-infected; II) avirulent, even when co-infected with P. aeruginosa; and 
III) synergistic virulence, where killing of flies by OF occurred without P. 
aeruginosa, but was markedly enhanced by co-infection.   
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The bacterial interactions above specifically relate to species that may be some 
significance to CF.  There has been work done that has investigated 
interactions between other species that may, or may not, be of significance to 
the polymicrobial situation in CF.  Lysenko et al. used a mouse model to 
investigate the interaction, at the mucosal surface, between H. influenzae and 
S. pneumoniae (Lysenko et al. 2005).  Both species were able to establish 
chronic colonisation at the mucosal surface when inoculated individually.  
However, when inoculated together, the result was chronic infection with H. 
influenzae and rapid clearance of the S. pneumoniae, associated with rapid 
influx of neutrophils.  This finding provides an interesting insight in to the 
potential for species-species and host-species interactions, and how there may 
be unsuspected consequences when more than one species colonises a 
mammalian epithelial surface.  This may have important implications for the 
direction of future therapeutic research in CF and beyond.   
1.4.2.7  Summary 
These studies demonstrate the potential for inter-species communication, but 
so far have only touched the surface of the potential complexity that may play a 
role in CF pulmonary disease.  As previously discussed there may be 10 or 
more bacterial species in the lungs of one patient.  There may also be a number 
of different ecological niches within any given lung, particularly in the more 
advanced stages of the lung disease.  This may mean that the bacterial 
diversity estimates obtained so far are conservative.  However it seems likely 
that many of these species will be living in close proximity, close enough to 
interact, and that these interactions may have clinical relevance.  
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1.5  Inflammation in Clinical CF Pulmonary Disease 
The presence of bacteria such as P. aeruginosa are thought to stimulate the 
production of pro-inflammatory cytokines such as Interleukin-8 (IL-8) (Dean et 
al. 1993), and that endobronchial levels of such cytokines are raised in children 
and adults with CF.  Furthermore, treatment for CFPE with antibiotics results in 
significant falls in endobronchial levels of the pro-inflammatory cytokine 
neutrophil elastase, as well as IL-8 (Ordonez et al. 2003).  Others have 
demonstrated similar falls in sputum cytokine levels, correlating with falls in 
bacterial sputum density and serum markers of inflammation (Colombo et al. 
2005).  In addition, it has been demonstrated that sputum inflammatory 
mediators correlate to validated markers of disease severity such as FEV1 
(Mayer-Hamblett et al. 2007). 
Eosinophil Cationic Protein (ECP) has been shown to be present in high levels 
in both serum and sputum of patients with CF (Koller et al. 1996; Koller et al. 
1997).  Serum ECP levels correlated with sputum levels and in addition 
correlated to markers of pulmonary gas exchange (Virchow, Jr., Holscher, & 
Virchow, Sr. 1992).  However, unlike levels of neutrophil elastase, levels of ECP 
were not reduced during treatment with antibiotics.  In other chronic pulmonary 
diseases, such as COPD and asthma, ECP levels have been shown to be 
raised both in the chronic phase, and more so during exacerbations (Fujimoto et 
al. 1997; Gibson et al. 1998).  In many situations, however, ECP appears to be 
related to allergy more than infection (Aldridge et al. 2002).  Thus the role of 
ECP in CF pulmonary disease remains to be elucidated.  
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1.6  Summary 
Despite major advances in our understanding of lung host defence, as well as 
many new treatments for CF, the great majority of people with CF continue to 
suffer with morbidity and mortality due to pulmonary infections.  New insights in 
to the complexity of the symptoms and microbiology mean that efforts are 
required to further assess the in vivo mechanisms underlying CF pulmonary 
disease and exacerbations. 
1.7  Hypothesis 
For the purposes of this study it was hypothesised that, in the pathogenesis of 
CF pulmonary exacerbations, new bacterial species would be detected in, and 
otherwise disrupt, the stable bacterial community. 
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Chapter 2 -  Materials and Methods 
2.1  Clinical Trial 
In order to assess changes in CF sputum before, during and after a CFPE, it 
was necessary to follow a cohort of volunteers, prospectively, over a period of 
time that included both CFPEs and periods of stability.  In this way sputum 
samples and clinical data could be obtained, before either the symptoms of a 
CFPE began or treatment started. 
The study was a cohort design that aimed to monitor longitudinal changes in 
symptoms, sputum bacteria and sputum inflammatory mediators.  All volunteers 
received some or all of their CF care at the Department of Adult Cystic Fibrosis, 
Southampton University Hospitals Trust.  The study was called ‘Sputum 
Changes Over Time in Infective Exacerbations Of CF’, or SCOTIE for short.  
Ethics committee approval for the study was obtained from the Southampton 
and South West Hants Local Research Ethics committee (06/Q1704/26).  
Written informed consent was obtained from all patients enrolled in the study.  
Dr. Mary Carroll, director of Southampton University Hospital NHS Trust adult 
CF service, supervised the study. 
2.1.1 Study Duration 
Each participant participated for 12 months.  CFPEs are difficult to predict, but 
by attempting to recruit a cohort of volunteers who had exacerbated frequently 
in the previous 12 months, the chances of obtaining data from as many CFPEs 
as possible was maximised.  
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2.1.2 Sampling Frequency 
It was necessary to achieve a balance between obtaining as many samples as 
possible so as to most accurately capture the dynamic changes during a CFPE, 
and the personal inconvenience to the participants, as well as the additional 
work and financial costs involved in such a strategy.  It was decided that during 
periods of stability (in this instance defined as not taking additional antimicrobial 
therapy for a CFPE) samples would be collected on alternate days during the 
usual working week, i.e. on Mondays, Wednesdays and Fridays.  Most 
participants provided samples during their normal morning routine of CF 
treatment on these days.  However, some participants preferred to provide 
samples during the evenings with courier collection the following morning.  
These participants thus provided samples on Sundays, Tuesdays and 
Thursdays. 
During CFPEs it was thought that the rate of any changes occurring in the CF 
lung would be greater.  Thus, during a CFPE sampling frequency increased to 
daily.  Daily sampling continued from the day antibiotic therapy started until the 
day it ceased.  See Figure 2-1. 
 
 
Treatment for CFPE  Recovery/stab
ility 
Stable/Pre-CFPE 
Legend: each arrow represents a sampling event 
 
Figure 2-1 Sampling Frequency 
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2.1.3 Inclusion and Exclusion Criteria 
The demands on participants’ time due to the nature of the study design meant 
that a large number of the CF patients under the care of the Southampton Adult 
CF Unit would not be suitable.  In order to obtain sputum samples from 
participants who were at home, it was necessary that each participant was able 
to spontaneously expectorate sputum most days.  Furthermore, in order to 
study the mechanisms underlying CFPEs, participants would need to be likely 
to exacerbate during the course of the 12 months.  CFPEs are difficult to 
predict.  However recent work has been done to identify risk factors for CFPEs.  
Block et al (Block et al. 2006) studied CFPEs in 249 patients with multi-resistant 
organisms in their sputum.  Fifty percent experienced a CFPE in the first year.  
Risk factors identified for developing a CFPE included younger age, female sex, 
lower FEV1, previous CFPE and the use of inhaled corticosteroids.  Although 
the SCOTIE study was not primarily looking at multi-resistant organisms, the 
identification of risk factors allowed selection CF patients who would be most 
likely to exacerbate. 
For the practicalities of transporting samples back to SGH it was also necessary 
that all participants lived within a distance of SGH that would allow the courier to 
return the samples within the allotted time.  Furthermore, the transportation 
costs per sample increased considerably for collections further from the SGH 
hub.  This meant that those CF patients living on the Isle of Wight or on the 
island of Jersey would not be suitable, as well as those living at greater 
distances from SGH on the mainland.   
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2.1.3.1  Inclusion and Exclusion Criteria 
The following inclusion and exclusion criteria  were selected.  It was  felt that 
these would provide a robust definition of CF, whilst making the practicalities of 
the study design realistic.   
Inclusion 
1.  Aged 18 or over. 
2.  Confirmed diagnosis of Cystic Fibrosis. 
3.  CF genotype: either two copies of defective gene at position 508, or one 
copy at position 508 and one of the other 33 commonest recognised 
genetic defects.  
4.  Frequent exacerbators (ideally 3 or more exacerbations requiring 
antibiotic treatment in the last 12 months).     
5.  Clinically stable (no changes in antibiotic treatment in the last two 
weeks).   
6.  Geographically close to Southampton General Hospital (and excluding 
the Isle of Wight).   
7.  Some or all of their CF care received from the Adult CF Unit at 
Southampton General Hospital. 
Exclusion Criteria 
1.  Currently having an Infective Exacerbation.   
2.  Previously received lung transplantation.    
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3.  Unreliable hospital attendees (having missed 2 or more outpatient 
appointments without giving notice in the last 12 months).   
2.1.4 Clinical Monitoring Form 
It was necessary to prospectively collect data on the wellbeing of participants 
during the study.  This fulfilled a number of objectives.   
a)  It allowed ‘time to treatment’ from the start of CFPE symptoms.  
This was also used to identify the time during which changes to 
the microbial community would be most likely to be found. 
b)  It allowed monitoring of ‘time to recovery’ during treatment for a 
CFPE.   
c)  It also allowed a grading of the severity for each CFPE. 
d)  It is part of the nature of PF pulmonary disease that symptoms 
and lung function fluctuate from day to day.  Prospective 
monitoring of health status also allowed identification of 
fluctuations in health status that did not trigger treatment to be 
started for a CFPE.  If these were shown to be of a similar 
magnitude to fluctuations that did trigger treatment, but recovered 
without treatment, then that may shed light on aetiology, and the 
role of treatments. 
With each sputum sample that they provided, participants also provided data on 
their wellbeing.  This data was captured by means of a specially designed 
sheet, termed Clinical Monitoring Form (CMF).  See Appendix Section 9.1, page 
274, for an example page.  The CMF included four visual analogue scales, 
forced expiratory volume in the first second (FEV1), forced  expiratory volume in  
  68 
the six seconds (FEV6), oral temperature, a question about the presence of 
upper respiratory tract symptoms, and a section to track changes in antibiotic 
usage. 
2.1.4.1  Visual Analogue Scales 
A Visual Analogue Scale (VAS) is an instrument which attempts to measure a 
characteristic or symptom that constitutes a continuum of values and which 
cannot be easily measured (Grant et al. 1999).  From a subject’s perspective, 
this spectrum is continuous and cannot be easily categorised into discrete 
steps, as may be used in other scoring systems.  As such, a VAS is a form of 
Patient Reported Outcome (PRO).  PROs are increased recognised as an 
important tool in clinical CF research (Goss & Quittner 2007).   
Each VAS used in this study constituted a horizontal black line 100mm in 
length, anchored at either end by a pair of descriptors representing opposite 
ends of the spectrum for that symptom.  ‘Best’ was always at the left hand end 
and ‘worst’ at the right hand end for each VAS.  The subject was required to 
indicate, by marking on the line, how they felt for that symptom at that time.  
The score was generated by measuring the distance, in millimetres, from the 
left hand end of the VAS to the mark made by the subject on the line.   Thus a 
number was generated between ‘0’ (=’Best’) and ‘100’ (‘Worst’) for that 
symptom for that day (Gift 1989a; Kelsall et al. 2008; Wewers & Lowe 1990). 
The four symptoms assessed on the Symptom Sheets for this study were: 
a)  Breathlessness 
b)  Cough 
c)  Sputum  
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d)  General Wellbeing 
These four symptoms were thought to best correlate with CFPEs, based on 
work by Rosenfeld et al..  (Rosenfeld et al. 2001).   
2.1.4.2  VAS Repeatability Testing 
 In order to demonstrate whether subjects were reliably able to record their 
symptoms via the Visual Analogue Scales used as part of the CMF, 
measurement of the internal validity of the VAS was undertaken.  Four subjects 
were asked to assist with this.  Each of these four subjects was asked to 
complete the VAS parts of the CMF, before returning this to the investigator.  
Immediately after returning the CMF to the investigator, they were asked to 
repeat the exercise with a new CMF, before also returning this to the 
investigator.  This exercise was repeated a total of four times, giving five 
completed CMF/VASs, for each of the four subjects.   
2.1.4.3 Spirometry  
FEV1 is the most widely used pulmonary function testing parameter of lung 
status used in CF (Gibson, Burns, & Ramsey 2003).  This is for a number of 
reasons, including the wide availability of standardised spirometric equipment, 
accepted standards for performance, published validated reference values, 
inter- and intra-operator reproducibility and proven correlation to long term 
outcomes (Miller et al. 2005a; Miller et al. 2005b; Ramsey et al. 1999).  FEV1 is 
also frequently used to attempt to objectively define the need for antibiotic 
therapy in clinical trials (Fuchs et al. 1994).  Using serial measurements from 
the same person, a decline in lung function has been used as one of a number 
of indicators that the subject is experiencing a CFPE (Izbicki et al. 2000).  
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In this study, subjects measured their own spirometry each time they provided a 
sputum sample using a Koko Peak Pro [Ferraris Cardiorespiratory, Louisville, 
CO, USA].  This has been previously used in clinical studies in asthma (Wilson 
et al. 2006).  Subjects were asked to record their FEV1 and FEV6 on their 
Clinical Monitoring Form.  FEV6 was selected above FVC as FEV6 has been 
reported to be more acceptable to breathless subjects (Akpinar-Elci, Fedan, & 
Enright 2006) and has been shown to be equivalent to FVC (Jensen, Crapo, & 
Enright 2006; Jing et al. 2009).  In this year long, longitudinal study, it was 
decided that a measure of spirometric obstruction that did not require a 
complete vital capacity manoeuvre would improve subject acceptability, 
adherence to the study protocol, and thus the quality of the data. 
2.1.4.4  Oral Temperature 
Acute infective episodes in any condition are commonly associated with a rise 
in body temperature.  In some clinical trials in CF where CFPE have been an 
outcome measure, temperature >38
oC has been one of the diagnostic criteria 
(Elkins et al. 2006).  Furthermore, in one prospective study to identify risk 
factors for diagnosis of a CFPE fever was associated with an Odds Ratio of 5.9 
(Rosenfeld et al. 2001). 
In this study the oral temperature of each subject was assessed on each 
occasion that a sputum sample was provided.   Temperature was measured 
using  3M™Tempa￿DOT™ single use disposable thermometers [3M 
Healthcare, St. Paul, USA].  These thermometers were chosen for a number of 
reasons.  Firstly they can be used sublingually in a way that is familiar to 
subjects (Macqueen 2001).  They also allow for easy self-recording of 
temperature that could be awkward with other methods such as tympanic 
membrane thermometers.  Thus no special technique is required.  Secondly  
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they are single use and disposable, thus eliminating the chance of cross 
infection or misreading from previous attempts.  Finally, the use of 
Tempa￿DOT™ for measurement of oral temperature has been shown to be 
sensitive and specific compared to the historical standard of temperature using 
a mercury thermometer (Morley, Murray, & Whybrew 1998).  The axillary route 
for measurement was rejected due to evidence of greater inaccuracy compared 
to oral measurements (Falzon et al. 2003).  Compared to oral measurements, 
the axillary route has the added disadvantage of taking longer (3 minutes vs. 1 
minute) (Macqueen 2001).  The ‘gold standard’ rectal route was not considered 
for practical reasons.  Infra-red aural thermometers were rejected due to 
concerns over the practicalities, and evidence of greater inaccuracy (Devrim et 
al. 2007).   
2.1.4.5  Changes to Antibiotic Therapy 
Any bacterial community is likely to be influenced in some way by antimicrobial 
therapy.  CF patients with severe lung disease tend to be on a number of long 
term antibiotic therapies, such as inhaled colomycin, inhaled tobramycin, oral 
azithromycin or oral flucloxacillin.  In order to study the effects of long term 
treatments and short term treatments on microbial communities and diversity it 
was necessary to be fully aware of all the antimicrobial therapy that each 
participant was taking at the time each sputum sample was provided.  It was 
decide that the easiest way to do this was to take a complete medication history 
at the start of the study, and then ask participants to record any changes to their 
antibiotic treatment. This was achieved using the check box system seen on the 
CMF seen in Appendix 9.1.  
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2.1.5  Sputum Sample Collection Methods 
As with most biological samples, it is generally accepted that the sooner a 
sample can be processed the more reliable and accurate the result.  This is 
reflected in the Health Protection Agency Standard Operating Procedures 
(S.O.P.) (HSE Advisory Committee on Dangerous Pathogens 2005), which 
recommends that specimens should be transported and processed as soon as 
possible, but may be refrigerated for 2-3 hours “without appreciable loss of 
pathogens”.  However, given the longitudinal community-based sampling 
approach taken for the SCOTIE study it was not possible to meet these 
standards.  The S.O.P. allows for culture of samples that are delayed by up to 
48 hours, but advises that they should be refrigerated during the period of 
delay.  Great care was taken with the design of the SCOTIE study to ensure 
that all samples were processed within 48 hours and were adequately 
refrigerated during the delay between production and processing.  Adequate 




C inclusive.   
2.1.5.1   From Expectoration to Collection by Courier 
Subjects expectorated sputum as part of their normal daily routine of treatment 
and physiotherapy.  They were provided with 60 ml sterile screw-top containers 
[Barlow Scientific, Stone, U.K.] for their samples.  Sputum samples were then 
refrigerated at 2-6
o
C.  Domestic fridges were offered to all subjects for this 
purpose.  The courier then arranged to collect each sample from subjects at a 
time that allowed the courier to ensure delivery of samples to the laboratory for 
processing within 36 hours.  Although samples could be processed up to 48 
hours after production according to the S.O.P. (HSE Advisory Committee on 
Dangerous Pathogens 2005), this 12 hour window allowed for handling time on 
receipt of samples in the laboratory, as well as providing a balance between the  
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practicalities of collecting and delivering large numbers of samples over a long 
period of time, and the aspirational scientific ideals. 
It was not always possible for subjects to be present when the courier could 
collect their samples.  Although this was generally discouraged, arrangements 
were made to allow for this.  Subjects were provided with an insulated ‘cool bag’ 
and some freezer blocks [sourced locally].  Sputum samples could be placed 
with the pre-frozen [-18
 o
C] freezer blocks in the cool bag in a place accessible 
to the courier.  This place had to be in a shady spot, and not in public view. 
2.1.5.2   From Collection to Delivery and Processing 
Transportation of biological samples by anyone other than the subject is closely 
regulated by the U.K. Health and Safety Executive report of 2005 (HSE 
Advisory Committee on Dangerous Pathogens 2005).  All transportation of 
samples during the conduct of this research complied with those regulations.  
On collecting the sample from the subject, the courier transported the sample in 
an insulated specimen transportation bag [Versapak W-PYB1, Versapak, Erith, 
Kent, U.K.] that complied with UN3363 and PI650.  Frozen cool blocks were 
provided to maintain the ambient temperature between 2-6
o
C. 
One further transportation stage was required.  All samples were delivered to 
the HPA microbiology laboratory at SGH.  Following culture, the remaining raw 
samples were frozen at –80oC prior to transportation at Kings College London 
for molecular analysis.  Safeguards to the cold chain were used to ensure that 
frozen samples did not thaw during this stage of the transportation process.  
Samples were sent in large batches, in insulated transportation bags 
(conforming to PI650), and dry ice pellets were used to completely surround the  
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samples.  A professional courier was used for all transportation of samples 
(OTR Couriers, 18 Hunters Crescent, Totton, Southampton, SO40 7FA). 
2.1.5.3  Auditing of Specimen Delivery 
In order to ensure that these standards were adhered to, a number of methods 
were employed to ensure standards. 
2.1.5.3.1  Time to Laboratory 
Each sputum sample was accompanied with a hand written log of the time and 
date of sample production (completed by the subject), the time and date of 
collection by the courier, and the time and date of delivery to the laboratory 
(both completed by the courier).  If necessary, the time of delivery to the 
laboratory could be corroborated by cross checking with the laboratory 
computer records.   
2.1.5.3.2  Temperature Chain  
In order to monitor the ambient temperature of samples during the collection 
and delivery process, a small temperature recording device was used 
[ThermoData™ Logger; Electronic Temperature Instruments, Worthing, West 
Sussex, U.K.].  This recorded, but did not display, temperature recordings every 
2 minutes from activation by the user for up to 72 hours.  Data was 
subsequently uploaded to a personal computer for analysis using the 
ThermoData™ Logger software v 2.0.3. 
2.1.5.4 Effects of refrigeration time on measures of microbial 
diversity 
An integral part of the protocol for longitudinal sputum collection (see section 
2.1.5 above) was collection and transportation of sputum samples from subjects  
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in the community to the base hospital.  This was done in a timely fashion, and 
samples were kept chilled at all times in keeping with established protocols. 
Inherent to this process were short delays between expectoration and initial 
processing.  The protocol outlined above allowed for delays of up to 36 hours 
between sample production to sample delivery and 48 hours from sample 
production and sample processing.  However, prior to the undertaking of this 
study, the effects of short delays such as these on bacteria in the samples was 
not known.  In order to ascertain the effects on the ability to detect bacteria, as 
well as their relative abundances, a small additional study was undertaken. 
Freshly expectorated samples were collected and immediately separated from 
any adherent saliva.  Sputum was then washed three times with 0.9% PBS 
before being placed on a sterile empty Petri dish.  The sample was then 
physically homogenised using a sterile scalpel and forceps, before being 
separated into 6 separate aliquots.  One aliquot was immediately frozen at -
80
oC (called sample T0).  Three samples were stored at +4oC for 18 hours prior 
to freezing at -80
oC; one sample was stored at +4
oC for 36 hours prior to 
freezing at -80
oC; and finally one sample was stored +4
oC for 72 hours prior to 
freezing at -80
oC.  Four degrees centigrade was chosen as representative of 
the usual refrigeration temperature.  The times of 18 hours, 36 hours and 72 
hours were chosen as representative of, respectively, the median time to 
delivery of samples, the maximum acceptable time of delivery of samples, and 
an outlying value, most likely to show variation from T zero.  
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2.2  Sputum Microbiology 
The methods used for collection and delivery of samples to the Health 
Protection Agency laboratory at Southampton General Hospital are detailed in  
Sputum Sample Collection Methods 2.1.5 above.   
2.2.1 Laboratory Culture Techniques 
All sputum samples were cultured in the clinical microbiology laboratory under 
the auspices of the Health Protection Agency at Southampton General Hospital.  
HPA standard operating procedures (Health Protection Agency 2004) for 
handling and processing clinical respiratory samples were followed throughout.  
This work was done by Biomedical Scientists working within the framework of 
the research team.  Thus samples were processed in an identical manner to 
those samples received from CF patients as part of their standard clinical care. 
2.2.1.1 Sputum Culture 
Samples were first assessed for suitability for processing based on appearance.  
Samples that appeared entirely composed of saliva without mucopurulent 
sputum were rejected as inadequate.  Samples were then physically 
homogenised using a sterile loop, before a small representative aliquot was 
placed on each of seven different culture plates.   All culture plates were 
obtained from E & O Laboratories [E & O Laboratories Ltd., Burnhouse, 
Bonnybridge, Scotland. FK4 2HH]. 
The standard culture plates, specific incubation conditions and intended 
selected bacteria are detailed in Table 2-1 Media used for the culture of sputum 
samples below.    
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Microbial species identification was then undertaken, according to the chemical 
and physical properties of the isolates (Brenner et al. 2005; Health Protection 
Agency 2004). 
In addition to microbial identification, the abundance of the isolate on the culture 
plate was determined in a semi-quantitative manner, in to three categories: 
‘Scanty growth (+)’; ‘Moderate growth (++)’; and ‘Heavy growth (+++)’.  
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Table 2-1 Media used for the culture of sputum samples (COPD samples 1-2; CF 
samples 1-7) 
2.3  Molecular Microbial Analysis 
Sputum samples were collected, processed and transferred to Kings College 
London as described in  Sputum Sample Collection Methods 2.1.5 above.  All 
Name  Incubation Conditions 
Example bacteria 
cultured 
1. Blood Agar  5% Carbon Dioxide; 35
oC; 
Optochin disc  
Streptococcus 
pneumoniae 
2. Chocolate Agar  5% Carbon Dioxide; 35
oC; 
bacitracin disc  
Haemophilus influenzae 
3. Cepacia Plate  Aerobically; 35
 oC  Burkholderia cepacia 
4. CNA  Aerobically; 35
 oC  Staphlococci  and 
streptococci 
5. PYO  Aerobically; 35
 oC  Pseudomonas species 
6. Sabouraud agar  Aerobically; 35
 oC  Fungi 




 oC  Enterobacteriaceae  
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T-RFLP work was carried out at Kings College London (see Acknowledgements 
on page x) 
It should be noted that there were scientific advances that occurred during the 
course of the study that were incorporated in to the methods to improve the 
performance of the techniques.  One such technique was the use of Propidium 
Monoazide (PMA) extracellular nucleic acid photo-crosslinking, the principles of 
which are discussed in more detail in Section 1.   
2.3.1 Nucleic Acid Extraction 
Prior to nucleic acid extraction, sputum samples were washed in a 5 × volume 
of phosphate buffered saline (PBS) to remove saliva. The sputum bolus was 
disrupted by the addition of 0.2% w/v solution of dithiothreitol (DTT) with 
incubation at room temperature for 15 min. Bacterial cells were pelleted by 
centrifugation at 5000 × g for 5 min. The pellet was re-suspended in 10 ml of 
200 mM (pH 8.0) PBS and re-pelleted by centrifugation at 5000 × g for 5 min. 
This was repeated 3 times. Equal volumes (500 µl) of sputum or bacterial 
suspensions, PBS and Guanidinium thiocyanate-EDTA-Sarkosyl (GES) were 
added to 1.5 ml screw-cap tubes (Sarstedt, Leicester, UK) that contained one 3 
mm tungsten carbide bead and 0.2 g of 0.2 mm acid-washed glass
 beads 
(Sigma-Aldrich, Gillingham, UK).  Samples were homogenised for 60 s at 30 Hz 
in a Mixer Mill 300 (Qiagen, Crawley, United Kingdom). 
Cell debris was pelleted by centrifugation at 12,000 x g for 3 min at 4
oC. 
Supernatant was transferred to a fresh non-stick RNase-free microfuge tube 
(Ambion, Applied Biosystems, Warrington, UK) that contained pre-aliquoted and 
cooled to 4
 oC polyethylene glycol (to a final concentration of 15%) and NaCl (to 
a final concentration of 0.5 mM). After mixing, nucleic acids were left to  
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precipitate at -20
oC for 5 min, followed by precipitation at 4 
oC  in a chilled 
centrifuge (Wolflabs, York, UK) at 12,000 x g for 20 min. Supernatants were 
removed and the nucleic acid pellets re-suspended in 500µl nuclease-free water 
(Ambion), vortexing for 2 s. To remove protein contaminants an equal volume of 
saturated phenol (pH6.6) (Fisher Scientific, Loughborough) was added, 
samples were vortexed for 10 s and left at room temperature for 1 min. Phases 
were separated by centrifugation at 12,000 x g for 4 min at 4
oC. The upper 
aqueous phase was transferred to a fresh micro-centrifuge tube and 500 µl 
phenol: chloroform: isoamylalcohol (125:24:1, pH 4.3) (Fisher Scientific) was 
added. Samples were vortexed vigorously and phases separated by 
centrifugation at 12,000 x g for 4 min at 4
oC. The supernatants were separated 
into two aliquots for separate RNA (400µl) and DNA (100 µl) precipitation.  
Prior to DNA precipitation, some samples underwent treatment with PMA, as 
detailed below.  Meanwhile other samples, analysed earlier in a separate part of 
the study, did not and went directly on to nucleic acid precipitation.  See Section 
1.3.3.7 above for more details. 
Propidium monoazide cross-linking  
DNA cross-linking using PMA was performed as described previously by 
Rogers et al. (Rogers et al. 2008). PMA was dissolved in 20% dimethyl 
sulfoxide to create a stock
 concentration of 20 mM with this added to 100 µl
 of 
sample to give a final concentration of 50 µM. Following an incubation period of 
30 min in the dark
 with occasional mixing, samples were transferred to 24 well, 
flat-bottomed, cell culture cluster plates (Corning, New York, USA) for exposure 
to light. Samples were exposed for 3 min
 using a 500W halogen light source 
(AC220-240V/50Hz halogen floodlight; RS, Northampton, UK) at a distance of  
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20 cm.
  During this process, cell culture plates were placed on top of ice, with 
occasional shaking to guarantee homogeneous light
 exposure. After photo-
induced cross-linking, cells were transferred to 1.5ml microfuge tubes and 
pelleted
 at 5,000 x g for 5 min prior to DNA isolation. 
DNA precipitation 
DNA was precipitated at -20
oC for 30 min after addition of an equal volume 
isopropanol (Sigma-Aldrich), 0.1 volume of 10 M ammonium acetate and 1 µl 
linear polyacrylamide (GenElute
™-LPA, Sigma-Aldrich, Gillingham, UK). DNA 
was pelleted at 12,000 x g for 5 min and washed twice in 1 ml of 70% ethanol, 
dried at 37
oC for 5 min and re-suspended in 50 µl nuclease-free water.  
RNA precipitation 
Total RNA was precipitated in an equal volume of lithium chloride (final 
concentration 4M) (Sigma) for 30 min at -20
oC, pelleted at 12,000 x g for 2 min 
at 4
oC, washed once in 1 ml 70% ethanol (ice-cold), dried and re-suspended in 
10 µl nuclease-free water (Ambion) by gently mixing with a pipette. Any 
contaminating DNA was removed with the Ambion Turbo-DNA-free™ kit 
according to manufacturer’s instructions for rigorous DNase treatment (37
oC for 
30 min with the addition of 1 U of Turbo-DNase at the beginning and after 30 
min).  
Reverse Transcription 
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied 
Biosystems) was used for the generation of cDNA according to manufacturer’s 
instructions. In a 20 µl reaction, 2 µl of 10 x Reverse Transcriptase buffer, 0.8 µl 
of deoxynucleotide triphosphates (dNTPs) (to a final concentration of 5 mM),  
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primer 926r to a final concentration of 5 µM, 1 µl Multiscribe Reverse 
Transcriptase, 1 µl RNase Inhibitor and 300 ng of RNA were mixed. RNA was 
reverse transcribed in a GeneAmp PCR System 2400 (Perkin-Elmer, 
Beaconsfield, UK) at 25
 oC for 10 min, 37
 oC for 120 min, and 85 
oC for 5 s. 
2.3.2 In silico sequence analysis 
In order to establish candidate species that were detected as bands in the 
sputum samples using the methods outlined above, published bacterial 16S 
rRNA gene sequence data, stored online at Genbank 
(http://www.ncbi.nlm.nih.gov/sites/entrez?keywords=db_Nucleotide), were 
retrieved.  Mapsort (Wisconsin package version 10.3; Accelrys) was used to 
predict the band sizes for T-RFLP analysis.  Mapsort, which locates the position 
of restriction endonuclease recognition motifs in a given sequence, was used to 
determine the length (in bases) from the 5' end of primer 8f-700IR (see below) 
to the first cleavage position of the endonuclease CforI in each of the Bacterial 
16S rRNA gene sequences retrieved from Genbank.  This process was 
performed on all the bacterial entries in the Genbank database that spanned the 
amplified region.  In this way, it was possible to predict the length of T-RF bands 
generated from 853 separate phylotypes. 
2.3.2.1  T-RF Band Length Note 
In T-RFLP results of a number of subjects it was noted that two T-RFs 
dominated.  These were T-RF 155 and T-RF 567.  T-RF 155 is well 
characterised as the expected T-RF for P. aeruginosa.  T-RF 567 is a band that 
is not associated with a identified bacterial species from in silico analysis of T-
RFLP profiles.  However it was noted that band 567 was only detected when 
band 155 was detected.  In addition no species consistent with a predicted T- 
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RF of this length was identified by bacterial clone sequence analysis.    Finally, 
it was also noted that a restriction fragment of length 567 was predicted fro the 
genetic sequence of the 16S gene in P. aeruginosa.  Additional work was done 
to perform T-RFLP on pure cultures of P. aeruginosa.  When this was 
performed, a band was detected at length 567, in addition to one at 155.  This 
was taken as conclusive proof that the band seen in T-RFLP results at band 
length 567 was indeed a second fragment P. aeruginosa.  Thus, when 
analysing results, percentage abundances at 155 were combined with 
percentage abundance at 567 to derive the final percentage abundance for P. 
aeruginosa.  
2.3.3 16S Ribosomal Clone Sequencing 
Clone library construction and sequencing were carried out at The Wellcome 
Trust Sanger Institute (The Wellcome Trust Genome Campus, Cambridge, 
CB10 1SA, UK) as described previously (Ludwig et al. 2004). One hundred and 
ninety two colonies of E. coli, with 16S sequence inserts from original bacteria, 
were randomly selected for sequencing from agar plates for each patient.  
Sequences were aligned using the ‘NAST aligner’ (Ashelford et al. 2006) and 
these alignments were subject to extensive manual curation using the ARB 
package (DeSantis et al. 2006) before further analysis. Sequences were tested 
for chimeras with Mallard (Ashelford et al. 2005) Bellerophon at Greengenes 
(Wang et al. 2007) and Pintail (Schloss & Handelsman 2005) and any sequence 
that appeared to be chimeric were removed. After removal of chimeras and 
other suspect sequences, the remaining sequences (deposited in Genbank 
under accession numbers FM995625-FM997761) were initially given a broad 
classification to the phylum level using the Classifier tool at the RDPII website 
(Zhang et al. 2000). To obtain more detailed taxonomic information, the  
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sequences were divided into phylotypes. Distance matrices were then entered 
into the DOTUR program (Schloss & Handelsman 2005) set to the furthest 
neighbour and 99%-similarity setting. The resulting phylotypes were then 
assigned similarities to nearest neighbours using MegaBLAST (Kelly et al. 
2002). The Shannon diversity index (SDI) for each individual patient sample 
was calculated using DOTUR (Hewson et al. 2006). 
2.4  Sputum Inflammatory Mediators 
2.4.1 Clinical Sampling Methods 
The effect of delays in processing samples on inflammatory mediators is not 
known (Health Protection Agency 2004).  In order to minimise the time from 
sputum production to processing, samples for measurement of inflammatory 
mediators were only obtained when the sample could be frozen at -80
o
C within 
2 hours.  In general, this meant that these samples were expectorated by 
participants whilst on site at Southampton General Hospital.  Thus, samples 
expectorated by participants for microbial analysis whilst at home were 
invariably unsuitable, as transportation time by courier to SGH was greater than 
2 hours.  
Participants expectorated sputum samples for inflammatory mediator analysis 
whenever they attended SGH for other reasons.  Examples of these reasons 
included routine outpatient appointments, visits to the Adult CF Unit for the start 
or end of a course of intravenous antibiotics or visits for annual review.  
Samples  were expectorated into a 60 ml sterile container and then immediately 
frozen at -80
o
C for further processing later.  These samples were stored for 
between 1 week and 18 months before completion of processing.  
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2.4.2 Sputum Processing to Generate a Soluble Phase 
Whole sputum samples were thawed on ice in batches.  Adherent saliva was 
removed from the mucus component of the sample by sterile pipette and a 
sterile metal implement with the assistance of gravity.  Saliva is more watery 
than mucus and samples were thawed on a slight incline to assist in the 
separation of saliva from sputum. 
Up to 750mg of the sputum component was transferred to a 1.5ml Eppendorf 
tube and weighed.  PBS was added in a 1ml:1mg ratio.  Thus no more than 
750mg of sputum could be added due to the size of the tube.  Samples were 
then vortexed thoroughly on a Whirlymixer for 30 seconds, before being mixed 
on an orbital plate mixer for 10 minutes on ice.  They were then vortexed again 
on the Whirlymixer for another 30 seconds.  Each sample was visually 
assessed to ensure adequate homogenisation.  Additional mixing was done if 
necessary.  Once adequate homogenisation had been obtained, samples were 
centrifuged at 20,000g for 20 minutes at 4
 o
C.  The resulting supernatant was 
aspirated using a pipette into 0.5ml Eppendorf tubes.  The first and second 
tubes contained 20µL each.  Additional tubes were filled with 100µL each.  
Finally a tube with any remaining supernatant was filled. 
The first 20µL was used to measure neutrophil elastase (NE) activity on the 
same day.  The additional tubes containing supernatant were frozen at 80
o
C for 
measurement of inflammatory mediators at a later date.  
2.4.3 Inflammatory Mediator Analysis 
2.4.3.1  Neutrophil Elastase  
Neutrophil elastase activity was measured in samples of CF sputum 
supernatant.  Measurements were undertaken on the same day as the  
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supernatant was generated.  Sputum supernatant samples were diluted in 
assay buffer (0.3M TRIS-HCl, containing 1.5M NaCl, pH 8.0).  Samples were 
diluted to 1:1, 1:5 and 1:10, also 1:50 when required.  To generate a standard 
curve, NE standard (human leucocyte elastase; Sigma Poole, UK) was used in 
serial dilutions.  The diluted supernatant samples, and the NE serial dilutions of 
the NE standard were placed in the wells of a 96 well plate and allowed to pre-
incubate for one minute at 37
oC .  To each well was then added 90 µL of 
substrate (see below for method for substrate).  The plate was allowed to 
incubate for a further 10 minutes at 37
oC.  The colour change was read as an 
increase in light absorbance at a wavelength of 410 nm, using a microtitre plate 
reader (Dynex Revelation 4.21, Dynex Technologies, Worthing U.K.).  Results 
from samples were interpolated from the standard curve, and adjusted to 
correct for the dilution factor to generate a result.  Results were reported as mu 
of NE activity/mL (mu/mL). 
Substrate was made as follows: N-methoxysuccinyl-ala-ala-pro-val-p-
nitroanilide was as a concentrated stock solution in dimethylsulphoxide (DMSO) 
at 88.9mM (i.e. 10 mg/190 µL) and stored in 20 µL aliquots at –20
oC.  On the 
day of assay, aliquots were diluted to 0.555 mM in assay buffer, as required. 
2.4.3.2 Interleukin-8 
Human IL-8 (huIL-8) was measured in all generated supernatant using PeliKine 
Compact™ human IL-8 ELISA kit [Sanquin Reagents, Amersterdam, The 
Netherlands].  This is an immunoassay of the ‘sandwich-type’.  In brief, a 
monoclonal anti-human IL8 antibody (huIL-8) is bound onto microtitre wells.  
HuIL-8 present in a standardised volume of supernatant or standard, is 
captured by the anti-HuIL-8antibody.  Non-bound IL-8 is removed by washing.  
Following this, biotinylated sheep anti-huIL-8 antibody is added, which binds to  
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the bound huIL-8 from the supernatant.  Excess biotinylated sheep anti-huIL-8 
is washed away, followed by addition of horseradish peroxidise (HRP) 
streptavidin, which binds on the biotinylated side of the anti-huIL-8 sandwich.  A 
substrate solution is then added that generates a yellow coloured product in 
proportion to the amount of huIL-8 in the supernatant or standard.  The reaction 
is then terminated by a stop solution, and absorbance is then measured in a 
microtitre plate reader.  The wells containing the standard solution allow for the 
creation of a standard curve, and the concentration of IL-8 in the wells 
containing supernatant is determined by interpolation of the absorbance with 
the standard curve. 
Assay Procedure 
PeliKine Compact™ human IL-8 ELISA kit instructions were followed at all 
times.   
Day One: Step One - Preparation of Samples and Reagents 
On the day before the main assay day, the coating buffer was prepared.  This 
consisted of 0.1M Carbonate/bicarbonate solution with ph 9.6.  This was 
prepared by making two solutions, A and B.  Solution A was made from 1,24 g 
Na2CO3.H20 in 100 ml distilled water.  Solution B was made by adding 1.68 g of 
NaHCO3 in 200 ml of distilled water.  Solution B was added to solution A until a 
pH of 9.6 was reached.  The coating antibody (a monoclonal anti-huIL-8 
antibody) solution was diluted 1:100 with the coating buffer.  One hundred 
microlitres of this solution was added to each well of the 96 well plate.  The 
plate was then incubated at room temperature overnight. 
Day Two: Step Two -  Preparation  
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The morning of the assay a number of buffer solutions were prepared.  A stock 
solution of phosphate buffered saline (PBS) (Ca
2+ and Cl
- deplete) was 
prepared.  A polysorbate surfactant washing buffer was prepared by adding 
50µL of TWEEN to 1000ml of PBS.  Blocking buffer was prepared by adding 
500µL of the pre-prepared blocking reagent to 25 mL.  Dilution buffer was 
prepared by diluting the provided 5-fold concentrated dilution buffer with distilled 
water to provide a working strength dilution buffer. 
Step Three – Washing 
The contents of the wells were discarded.  Each well was then filled with wash 
solution before being discarded again.  Complete removal of the wash solution 
was achieved by tapping.  This wash process was repeated until each well had 
been washed five times.  After the final aspiration the wells were dry. 
Step Four – Blocking Procedure 
To each of the wells of the microtitre plates was added 200µL of blocking buffer 
(prepared as described above).  The plate was then covered with an adhesive 
seal and gently agitated, by tapping the edge of the plate a few times, to ensure 
adequate mixing of the contents of the wells.  The plate was then allowed to 
incubate at room temperature for one hour.  After incubation the wells were 
again washed 5 times, following the procedure described in Step Three. 
 Step Five – Preparation of IL-8 Standard 
A natural human IL-8 standard has previously been calibrated against the World 
Health Organisation (WHO) Interim International al Standard (IL-8 89/520; 
National Institute for Biological Standards and Control, Potters Bar, U.K. 1 WHO 
unit = 10 ng IL-8).  Using this standard, serial dilutions of IL-8 were prepared to  
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allow the calculation of a standard curve with which to compare the study 
sample supernatant results with.  The seven serial dilutions of Il-8 contained 
240, 96, 38.4, 15.4, 6.1, 2.5, and 1 pg/mL respectively, with a blank well 
representing 0 ng/mL.  
Step Six – First Incubation  
In duplicate, 100 µL of the prepared samples and standards were transferred to 
the appropriate wells.  The plate was then covered and agitated gentle by hand 
for a few seconds.  The plate was then incubated at room temperature for one 
hour.  After one hour the supernatant was aspirated from the wells and the 
plates was washed repeatedly as outlined in Step Three (above).   
Step Seven – Second Incubation 
Just prior to use, the concentrated biotinylated IL-8 antibody was diluted by 
adding 120 µL to 12mL of working strength dilution buffer.  All except the 
substrate blank wells had 100 µL of the diluted biotinylated antibody solution 
added.  The plate was again covered, and agitated by hand for a few seconds, 
before being left to incubate at room temperature for one hour.  After one hour 
the supernatant was aspirated from the wells and the plates was washed 
repeatedly as outlined in Step Three (above).   
Step Seven – Third Incubation 
Just prior to use, 3 µL of streptavidin-HRP conjugate was added to 30 mL of 
dilution buffer to make working strength streptavidin-HRP conjugate.  The 
substrate blank wells were left empty, but 100 µL of working strength 
streptavidin-HRP conjugate was added to all other wells.  The plate was again 
covered, and agitated by hand for a few seconds, before being left to incubate  
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at room temperature for 30 minutes.  After thirty minutes the supernatant was 
aspirated from the wells and the plates was washed repeatedly as outlined in 
Step Three (above). 
Step Seven – Fourth Incubation 
Approximately ten minutes prior to its use, the substrate buffer was prepared in 
the following way: 15.0 g of sodium acetate ( CH3COONa.3H2O ) was dissolved 
in 800 mL of distilled water.  The pH was adjusted to 5.5 with glacial acetic acid, 
and the final volume was made up to 1 litre with distilled water. To all wells, 
including the substrate blank wells, was added 100 µL of substrate solution.  
The plate was again covered, and then gently agitated by hand for a few 
seconds.  The plate was then incubated at room temperature in the dark for 
thirty minutes. 
Step Eight – Stop Enzymatic Reaction 
Sulphuric acid (1.8 M H2SO4 solution in distilled water) was added in 100 µL 
aliquots to all wells. 
Step Nine – Plate Reading 
Within 30 minutes of the stop reaction, the enzymatic colour change in each of 
the wells of the plate was read by a microtitre plate reader (Dynex Revelation 
4.21, Dynex Technologies, Worthing U.K.).  Sample results were interpolated 
from the generated standard curve.  Results were reported in ng. 
2.4.3.3  Eosinophil Cationic Protein 
Eosinophil Cationic Protein (ECP) was measured in sputum supernatant that 
was generated using the protocol described in detail above.  ECP was  
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measured using a commercially available kit (Medical and Biological 
Laboratories International Corporation, Woburn, USA).  The manufacturer’s 
instructions were followed at all times.  In brief this assay is a sandwich ELISA 
which measures ECP with a minimum detection limit of 0.125 ng/mL and does 
not cross react with other eosinphil derived products such as Eosinophil derived 
neurotoxin (EDN). 
Preparation of Reagents and Samples 
All reagents were brought up to laboratory room temperature (20-25
oC) prior to 
use.  The wash solution was prepared by diluting 100 mL with 900 mL of 
distilled water. Sputum supernatant samples for analysis, that had been stored 
at -80
oC, were thawed and brought up to laboratory room temperature.  They 
were then diluted with the assay diluent (0.09% sodium azide with 1% Goat 
serum preservative) to a final concentration of 1:5, 1:50 or 1:500.  The positive 
control was also sequentially diluted with the diluent, leaving eight aliquots. 
Assay Procedure: 
Step One – Sample Incubation 
Aliquots of 150µL of the prepared samples and standards were added to a 96-
well polyvinyl preparation plate. Then 100 µL of each sample was transferred to 
the antibody coated microwell and mixed well.  Incubation at room temperature 
was allowed for 60 minutes. 
Step Two - Washing 
The contents of the wells were discarded.  Each well was then filled with wash 
solution before being discarded again.  Complete removal of the wash solution  
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was achieved by tapping.  This wash process was repeated until each well had 
been washed four times. 
Step Three – Conjugate incubation 
One hundred microlitres of conjugate reagent (Horseradish peroxidase 
conjugated anti-human ECP polyclonal antibody, 1% Bovine Serum Albumin 
(BSA ) was pipetted into each of the wells and incubated at room temperature 
for 60 minutes.  This was followed by further washing as detailed in Step Two 
(above). 
Step Four – Substrate Incubation 
After washing, 100µL of substrate reagent (3,3’,5,5’-Tetramethylbenzadine 
(TMB) with hydrogen peroxide (H2O2)) was added to each well and incubated at 
room temperature for 10 minutes. 
Step Five – Stopping Reaction 
After 10 minutes, 100 µL of stopping reagent (0.5 mol/L sulphuric acid (H2SO4)) 
was pipetted into each well.  Reading of the plates took place within 30 minutes 
of stopping solution having been added. 
Step Six – Reading  
All plate reading took place using a computer spectrophotometer (Dynex 
Revelation 4.21, Dynex Technologies, Worthing U.K.) at wavelength of 450 nm. 
Step Seven – Calculation of Results 
The wells that contained the standard solution allowed for the creation of a 
standard curve. The concentration of ECP in the wells that contained  
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supernatant was determined by interpolation of the absorbance with the 
standard curve.  The final concentration was determined by multiplying the 
result by the dilution factor (e.g. x5, x 50 or x500 – see Preparation of Reagent 
and Samples above).  Results were reported in ng/mL. 
2.5  Definitions 
Bacterial community stability: a community of bacteria which retain the same 
dominant species, and for which all the species present at >10% remain in the 
same rank abundance position. 
Subjects: shall be used to refer to any particular individual who took part in this 
study.  When referring to a group of participants the lower case ‘subject(s)’ shall 
be used. 
Clinical stability: at 30 days before the start and 30 days after the end of 
systemic antibiotics for changes in pulmonary symptoms. 
‘Species Richness 
In order to describe the species richness of a sample or population, the number 
of species was counted (species richness).  Bacterial species richness 
measures a similar quality of a bacterial community to the Slope of the rank 
abundance curve (see below).  However, unlike Slope, species richness has the 
advantage of giving a valid score for communities consisting of only one 
species. Variations in species richness within subjects (temporal variations) and 
between subjects (spatial variations) are described.  In addition, as not every 
species was found in every sample, a measure of the cumulative species 
richness was used.  Subjects for whom cumulative richness became asymptotic 
quicker than others could be thought of has having a more stable bacterial  
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community that those subjects for who the cumulative species abundance curve 
took longer to reach a plateau. 
Bacterial Community Composition 
In order to describe the similarity between different samples, a number of 
measures were used.  Sorensen’s Index of Similarity was used (Pye et al. 
2007).  The formula for Sorensen’s Index is 2W/(a1 + a2); where ‘a1’ is the total 
number of species detected in sample 1, and ‘a2’ is the total number of species 
detected in sample 2, and W is the number of species that are common to both 
samples.  It is the same measure as the Dice Co-efficient.  It is used for 
comparing detection of species between samples were the presence or 
absence of species are presented in a binary format.  In the form described it 
cannot be used for data that is in a quantitative or semi-quantitative format.  It 
always gives a value in the range 0-1. 
In addition to the Sorensen Index of Similarity, an additional measure of 
similarity that took in to account relative abundance was used. The Bray-Curtis 
Index was used, due to its proven validity and acceptance (Magurran 2003).  In 
addition, its use was familiar to the research team. 
Bacterial Community Structure 
In an effort to measure species evenness in a given sample, additional 
measures of community structure were used. In order to convert the species 
dominance curves to analysable values, a variety of measures were derived.  
Firstly, the slope of plot of the log(n) of the ranked percentage values was used, 
termed the slope of the rank abundance curve (Ager et al. 2009).  The more 
negative the value the steeper the species dominance curve, and the less even 
the species distribution.  A minimum of two values were required to calculate a  
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slope.  For a number of samples there was only one species detected (i.e. value 
= 100%) and thus no slope could be calculated.  Such samples were excluded 
from this analysis. 
In addition to the described measures on individual sputum samples, a number 
of multivariate methods were used in an attempt to determine patterns in large 
data sets.  Principle Component Analysis (PCA) and Multidimensional Scaling 
(MDS) were used.  Results were found to be similar, and thus results of PCA 
are presented, as this was felt to be a more robust technique.  Multivariate 
analysis and graphical output were undertaken using Community Analysis 
Package v.4 (www.pisces-conservation.com).  
Core/Satellite Analysis 
Three subjects had samples analysed from times other than before, during and 
after one single CFPE: Subjects 02, 09 and 14, who had 45, 121 and 59 
samples analysed respectively.  When assessing for core/satellite 
differentiation, the greater the number of samples the more robust the analysis 
(Magurran 2003).  Only the sample size for Subject 09 was sufficiently large to 
adequately differentiate between core and satellite species. 
 
2.6  Statistical Analysis 
All data were checked visually for outlying values that might represent 
erroneous values. This was performed with the naked eye, histograms and box 
and whisker plots. Once identified, such values were rechecked against source 
data wherever possible.  Also using histograms, the data were assessed for 
normality of distribution.  Data that conformed to a normal distribution were  
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analysed with parametric statistical tests, whist those which did not conform to a 
normal distribution were analysed with non-parametric tests.    
The majority of the statistical data analysis was undertaken using SPSS (v. 16 
for Windows; SPSS, Chicago, Illinois, USA) or Microsoft Office Excel for 
Windows 2003.  Graphical display was generated with SPSS, or Microsoft 
Office Excel.  The Principle Component Analysis was performed using 
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2.7  Validation of Study Techniques 
2.7.1 Visual Analogue Scales Repeatability Testing 
Results for repeatability testing for the VASs are presented in Table 2-2 below.  
All four VAS domains performed extremely well, with very high measures of 
repeatability, assessed by both Cronbach’s Alpha, and by Intraclass Correlation 
Coefficient (ICC).   General Wellbeing performed best, with a Cronbach’s Alpha 
of 0.998, and ICC of 0.991 (0.962-0.999).  Although still performing well, cough 
VAS performed the worst, with a Cronbach’s Alpha of 0.989, and an ICC of 
0.944 (0.791-0.996). 
 
Table 2-2 Measures of Repeatability Testing for VASs 
 
2.7.2 Sample Delivery Cold Chain 
As outlined above in 2.1.5.3.2, the ability of the cold chain to deliver samples to 
the laboratory from subjects in the community, often many miles away, was 
audited.  Results are presented in Table 2-1 below.  An acceptable temperature 
was defined as ≥0
oC, and ≤6.0
oC.  These values were chosen by the research 
team, as the UK HPA SOP makes no reference to the optimal temperature to 
store samples prior to processing, except to say that refrigeration is preferable 




  Subjects (& 
Repeats) N  
Cronbach’s 
Alpha (0-1)  Coefficient 
(0-1)  Lower  Upper 
Breathlessness 
VAS  4 (5)  0.998  0.988  0.948  0.999 
Cough VAS  4 (5)  0.989  0.946  0.791  0.996 
Sputum VAS  4 (5)  0.997  0.987  0.944  0.999 
GWB VAS  4 (5)  0.998  0.991  0.962  0.999  
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the cold chain was felt to offer an acceptable service.  The 14 deliveries 
presented here had a mean time from being produced to being unpackaged in 
the laboratory of 831 minutes, or just under 14 hours.  There was a mean time 
to achieve adequate cooling of 91 minutes.  All subjects had a mean 
temperature (once cooling had been achieved) within the target range, with the 
lowest mean being 0.08 in subject 10, and the highest being 5.35 in subject13.  
Only one of the 14 subjects had a median value outside the target range 
(subject 01), along with a value of 89% of the time spent outside the target 
range (after cooling was achieved).  This appears to have been caused by a 
prolonged period of time at 7.0
oC, reflected by the maximum temperature in this 
case being 7.5
oC.  The month that the study was performed in seemed to have 
no bearing on the mean temperature.  
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Subject Number    
   1  2  3  4  5  6  7  8  9  10  11  12  13  14 
Total 
  
Total Time (min)  302  210  1090  1068  322  1428  364  1496  216  372  1316  1090  594  1770  831 
Time to stabilise 
(min)  34  72  42  42  36  496  42  32  18  14  288  70  18  66  91 
Time above 6
oC  270  0  0  0  30  0  0  136  0  0  0  0  134  0  41 
Time below 0
oC  0  0  244  10  0  44  244  22  0  136  4  244  0  0  68 
Total time out of 
range  270  0  244  10  30  44  244  158  0  136  4  244  134  0  108 
Percentage of time 
out of range  89  0  22  1  9  3  67  11  0  37  0  22  23  0  20 
Min temp  1.5  2.5  -3.5  -0.5  1.5  -2  -1.5  -8  0  -3.5  -1.5  -9  4  0.5  -8 
Max Min  7.5  5.5  5.5  5.5  9  4.5  5.5  16  6  5  5.5  6  9  6  9 
Mean Temp  5.34  3.44  1.65  1.71  5.17  1.38  1.91  4.01  3.15  0.08  3.41  1.66  5.35  3.30    
Median Temp  6.5  3.5  2.5  1.5  4.5  1.5  1  3.5  3.5  0.5  3.5  2.5  4.5  3.5    
SD  2.06  0.76  2.24  0.58  1.79  0.94  0.187  2.52  1.9  1.95  1.22  2.24  1.29  0.494    
Month of study  Oct  Oct  Nov  Dec  Oct  Dec  Nov  Jan  Jan  Feb  Feb  Mar  Mar  Oct    
Table 2-3 Results of Specimen Delivery Cold Chain Auditing  
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2.7.3 Duration of Transportation of Sample to Laboratory 
In order to assess whether there was delay from samples being expectorated to 
there arrival and subsequent processing in the laboratory, a random selection of 
clinical monitoring forms were analysed.  After using SPSS to select 2% of 
samples at random, the time of expectoration and the time of delivery to the 
laboratory were documented.  A summary of results are shown in Table 2-4 
below.  Of the 35 samples selected for analysis, four did not have the delivery 
time recorded.  For the other 31 samples, the median time to delivery of samples 
was 9.8 hours, with a mean of 12.6 hours (SD±9.4).  The maximum time to 
delivery was 30.2 hours.  
After arrival of samples in the laboratory samples were processed for bacterial 
culture on selective media plates.  This resulted in a period of time, after delivery 
but before samples were placed in the -80
oC freezer.  This delay was audited 
internally by senior staff within the HPA.  Results are presented below in Table 
2-5 below.  The mean time to freezer from arrival in the laboratory was 42 
minutes, with a maximum time of 105 minutes. 
Overall these data suggest that the delivery and cold chain worked satisfactorily 
to ensure the safe receipt of appropriately chilled samples in good time. 
  
  101 
Table 2-4 Results of time to delivery audit 
 
 
Table 2-5 Results of time to freezer analysis 
 
2.7.4 Reproducibility, and Effects of Delays in Time to Freezer on 
Bacterial Diversity 
As part of the validation process, a small pilot study was undertaken on sputum 
samples to assess the effects of time spent in the refrigerator prior to freezing on 
measures of bacterial diversity.  Expectorated samples were collected and 
immediately homogenised prior to separating in to separate aliquots.  Each 
aliquot was stored at 4
oC for different periods of time. 
The graphs below ( 
Valid  31.0  Number 
Missing  4.0 
Mean (hours)  12.6 
Median (hours)  9.8 
Std. Deviation (hours)  9.4 
Minimum (hours)  1.6 
Maximum (hours)  30.2 
25  3.6 
50  9.8 
Percentiles 
(hours) 
75  22.8 
Valid  12  Number 
Missing Data  0 
Mean (minutes)  42  
Median (minutes)  35  
Std. Deviation (minutes)  30  
Maximum (minutes)  105  
25-75
th Percentiles  26-48   
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Figure 2-2) show that there is little effect of refrigeration time prior to freezing of 
samples up to 36 hours.  At 72 hours, the next time period assessed, there were 
detectable differences in the bacterial community, mainly reflected by the 
dominant species becoming less dominant.  Such results confirmed the validity of 
both the study protocol and the extensive efforts in establishing a reliable and 
efficient cold chain to deliver samples from subjects in the community.  In 
addition it provided validation of the process of T-RFLP, as the whole process, 
from expectoration to PCR and T-RFLP had to be working with problem to 
achieve these highly reproducible results. 
 
Figure 2-2 Effects of Time from expectoration to sample freezing for two subjects 
(A and B). 
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2.7.5 Repeatability of Molecular Techniques 
In addition to demonstrating the effects of increasing time of storage at 4
oC,  
Figure 2-2 above also demonstrates the reproducibility of the whole process of T-
RFLP.  If there were methodological flaws, it would be expected that significant 
differences in the bacterial populations would be seen with each different sample 
processed.  It can be seen that this was not the case.  This suggests that T-
RFLP, as undertaken during this study, is reproducible, as has been previously 
described (Rogers et al. 2004).  In turn, this gives confidence that any changes in 
the bacterial community detected over time during the rest of the study were due 
to other reasons than methodological ones. 
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2.7.6 Discussion 
Others have assessed the effects of temperature and delays on bacteria in 
sputum samples (Pye et al. 2007), but only using culture.  This previous study 
by Pye et al. was aimed at demonstrating whether sputum samples could be 
reliable analysed after being sent by post (at ambient air temperature ~20
oC) to 
the laboratory by the subject.  This paper was published after the work 
presented here was completed, and did not make clear how long the delay from 
sample expectoration to analysis was.  By culture, they found that transportation 
at ambient temperature provided results that were closer to results of immediate 
analysis than were results from samples that had been refrigerated. However, it 
adds weight to the assertion that samples arriving by courier were in the best 
possible condition for analysis.  The results of assessment of possible delays in 
samples reaching the laboratory provided additional reassurance that samples 
were arriving in a timely manner.  The absolute minimal delay possible would 
provide the optimum quality samples, and a mean of 13 ½ hours from being 
produced in the community for samples to reach the laboratory and processed 
is a satisfactory result. 
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Chapter 3 -  Results Overview 
3.1  Overview 
Ethical approval was obtained for the study for the Southampton and Southwest 
Hampshire Ethics Committee (LREC 06/Q1704/26).  Fourteen subjects agreed 
to participate in the longitudinal study after providing written informed consent.  
Subjects commenced in the study between 1
st June 2006 and 5
th October 2006.  
No subjects withdrew, and all continued in the study for at least 12 months.  The 
last subject left the study on 4
th October 2007. 
3.1.1 Subject Demographics 
Subject Baseline Characteristics 
The subjects were selected by review of the notes of patients in the adult CF 
service at SGH, and in discussion with the adult CF clinical team. 
The 14 subjects had a mean age of 30.2 years (SD + 12.0; range 17.9 – 55.7 
years).  They had a mean FEV1 of 1.79 L (SD + 0.71 L; range 3.21 – 0.73 L), 
and a mean FEV1% predicted of 53.3% (SD + 18.9%; range 17.4 – 86.4%).  In 
terms of pulmonary disease severity classification, based on the Cystic Fibrosis 
Foundation disease severity classification (FEV1% predicted: normal lung 
function ≥ 90%; mild pulmonary impairment 70-89%; moderate pulmonary 
impairment 40-69%; severe pulmonary impairment < 40%) no subjects had 
normal lung function, 3/14 had mild impairment, 7/14 had moderate pulmonary 
impairment, and 4 had severely impaired pulmonary function. They had a mean 
body mass index (BMI) of 21.9 kgm
2 (SD + 3.75; range 18.0 – 29.0) which was 
within the accepted normal range for healthy adults.  Twelve of fourteen  
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subjects had CF related pancreatic insufficiency; eight of fourteen had CF 
related diabetes (CFRD). There were six females and eight males; their lung 
function by gender was 58.1%(±18.4%) and 49.6% (±19.7%) respectively; 
difference p=ns.  Further details of baseline characteristics for individual 
subjects can be found in Table 3-1and Table 3-2 below.  
Subject 









2)  Age  P.S.?  CFRD?  Genotype 
1  M  2.51  60.9  1  29.0  30.7  Yes  No  ∆F508/NK 
2  F  1.3  57.0  2  18.2  45.2  No  Yes  ∆F508/∆F508 
3  M  1.23  38.0  3  19.9  46.9  No  Yes  ∆F508/NK 
4  F  1.3  42.0  2  27.1  29.9  Yes  No  ∆F508/T20 
5  F  1.23  39.3  3  18.0  22.8  No  Yes  ∆F508/∆F508 
6  M  1.59  48.7  2  23.9  55.7  No  Yes  ∆F508/T20 
7  F  1.68  51.0  2  20.3  21.1  No  No  ∆F508/T20 
8  M  1.91  60.8  1  19.4  40.4  No  Yes  ∆F508/∆F508 
9  M  0.73  17.4  3  18.4  22.6  No  Yes  ∆F508/∆F508 
10  F  2.86  86.4  0  22.5  17.9  No  No  ∆F508/∆F508 
11  F  2.17  73.0  1  21.0  24.8  No  No  ∆F508/T20 
12  M  1.19  30.0  3  20.4  20.5  No  Yes  ∆F508/∆F508 
13  M  2.1  66.0  1  28.5  20.5  No  No  ∆F508/∆F508 
14  M  3.21  75.0  1  21.1  23.6  No  Yes  ∆F508/∆F508 
Table 3-1 Baseline characteristics for individual subjects.  FEV1 = Forced 
Expiratory Volume in the first second in Litres; FEV1% Predicted = FEV1 as a 
percentage of the predicted value for a person of the same age, height, gender 
and ethnicity; BMI = body mass index; P.S. = Pancreatic sufficient; CFRD = CF 
related Diabetes Mellitus. 
 
    FEV1 (L)  FEV1 (% Predicted)  BMI (kgm2)  Age (years) 
N    14  14  14  14 
Mean  1.79  53.25  21.98  30.17 
Median  1.64  54.01  20.70  24.18 
Std. Deviation  0.71  18.93  3.75  11.97 
Minimum  .73  17.4  18.0  17.9 
Maximum  3.21  86.4  29.0  55.7 
Interquartile Range  1.23-2.26  39.0-67.8  19.2-24.7  21.0-41.6 
Table 3-2 Baseline characteristics for all subjects 
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Values for FEV1, BMI and age did not conform to a normal distribution.  Further 
statistically analysis that involved these variables was performed using non-
parametric techniques.  Values for FEV1 % predicted did conform to a normal  
distribution, and statistical analysis that only involved this, and other normally 
distributed data, were analysed using parametric methods.  Histograms for 
values demonstrating these distributions can be found in the appendix (9.2 
below) 
Subject Baseline Medications 
As would be expected, no two subjects were on the same medications at 
baseline. 
Thirteen of the fourteen subjects were taking a long term antimicrobial therapy, 
with 11 taking a macrolide and 12 taking a nebulised antibiotic.  Two were on 
long term antifungal therapy in the form of oral itraconazole.  
Ten subjects were on mucolytic therapy, either in the form of dornase alpha (a 
DNAse), or inhaled hypertonic saline.  Thirteen of fourteen were on inhaled 
corticosteroids, with only one taking oral corticosteroids.  This subject was also 
on long term itraconazole for Allergic Bronchopulmonary Aspergillosis (ABPA), 
and had been demonstrated to have inadequate endogenous adrenal 
corticosteroid production. 
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  Subject Number   
Long term Medication  01  02  03  04  05  06  07  08  09  10  11  12  13  14  Total 
Macrolide    Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes      11 
Colomycin nebulised    Yes  Yes    Yes  Yes  Yes  Yes  Yes    Yes      Yes  9 
Tobramycin nebulised                        Yes      1 
Tobramycin/Colomycin 
nebulised (alt. months)                     Yes      Yes    2 
Antimicrobial 
Therapy 
Itraconazole          Yes                Yes    2 
DNAse  Yes    Yes  Yes  Yes  Yes  Yes    Yes  Yes  Yes    Yes    10 
Mucolytic 
Hypertonic saline                  Yes            1 
Oral corticosteroids                          Yes    1 
Corticosteroids 
Inhaled corticosteroids  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes    Yes  Yes  13 
Diabetic treatment    Yes  Yes          Yes  Yes          Yes  5 
Table 3-3 Long term medications taken by subjects during study 
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3.2  Pulmonary Exacerbations 
The 14 subjects had 42 physician defined pulmonary exacerbations 
necessitating treatment with antibiotics.  The range was 0-5, with a median of 3.   
See Figure 3-1  below . 
For these 42 pulmonary exacerbations, subjects required 30 courses of 
intravenous antibiotics for CFPEs and 21 courses of oral antibiotics (see Figure 
3-2 below. 
There were also two courses of elective intravenous antibiotics administered to 
two different patients.  In addition one subject had a course of oral antibiotics for 
an unrelated skin infection.  See Figure 3-1 and Figure 3-2 below.  
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Figure 3-2 Type of Treatment for CF Pulmonary Exacerbations by Subject  
  111 
Table 3-4 Pulmonary Exacerbations and antibiotics per subject 
3.3  Results of Bacterial Culture 
In total 2061 sputum samples were received in to the Health Protection Agency 
laboratory at Southampton General Hospital.  The results of selective bacterial 
culture (as outlined in Section 2.2.1 above) are summarised in Figure 3-3. 
Figure 3-3 Summary of organisms detected by selective culture (all subjects). 
Subject 
No. 
No. of CFPEs 
per Subject 
No. of Abx 
Courses for 
CFPEs 
No. of Non-Elective 
IV Courses 
No. of Oral 
Courses 






1  3  6  2  4  0  0 
2  3  3  3  0  0  0 
3  0  0  0  0  0  0 
4  3  3  0  3  0  0 
5  5  9  5  4  0  0 
6  2  2  1  1  0  1 
7  4  4  2  2  0  0 
8  0  0  0  0  0  0 
9  5  6  5  1  1  0 
10  2  2  1  1  1  0 
11  3  3  1  2  0  0 
12  4  5  2  3  0  0 
13  4  4  4  0  0  0 
14  4  4  4  0  0  0 
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It can be seen that, unsurprisingly, Pseudomonas species make up the most 
frequently detected species.  ‘Pseudomonas species’ includes non-mucoid P. 
aeruginosa (n=301), mucoid P. aeruginosa (n=377), Pseudomonas species that 
were not typed (947) and Pseudomonas fluorescens (n=1).  Pseudomonas 
species that were not typed are clinically assumed to be P. aeruginosa. 
Previous clinical surveillance work suggests that over 99% of these isolates are 
indeed P. aeruginosa (Mr. A. Tuck, HPA, Southampton General Hospital: 
personal communication). Oral flora include species such as group D β-
haemolytic streptococci, α-haemolytic streptococci (non-pneumococcal), S. 
sanguinis and mitis, and coagulase negative (non-S. aureus) Staphylococci.  
Although anaerobic bacteria are a major component of normal oral flora 
(Kolenbrander 2000), the species identified under the heading ‘Oral flora’ do not 
include anaerobic species as culture was not performed in anaerobic 
conditions. 
The third commonest bacterial group to be detected in this cohort of 14 was 
isolates of group F streptococci.  This group is of interest, as it includes S. 
constellatus and related species that make up the Streptococci milleri group, 
which has previously been implicated as a possible cause of CFPEs by Sibley 
et al. (Sibley et al. 2008g).  
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Figure 3-4 Relationship between CFPEs, antibiotics and detection of Gp F 
streptococci by culture, for Subject 09. 
In Figure 3-4 above, is presented the data for the only subject (09) who cultured 
group F streptococci.  It can be seen that there is no apparent relationship 
between the detection of these bacteria and either the occurrence of CFPEs, or 
with treatment with IV antibiotics.  This data would not support a role for these 
bacteria alone to be a major cause of CFPEs, in contrast to the data from Sibley 
et al..  However it is noted that, although group F strep. species were detected, 
specific culture media optimised for the detection of bacteria from this group 
were not used in this study (Sibley et al. 2010). 
 





























































  114 
Chapter 4 -  Results: Clinical Monitoring 
In total 2059 completed or partially completed Clinical Monitoring Forms (CMF) 
were received from the 14 subjects (mean 147 per subject SD±35.9). There 
were two outlying subjects: the minimum number of forms received for any 
subject was 52 (subject 04), the maximum was 209 (subject 09). The other 12 
subjects produced between 121 and 174 CMFs during the study period.  The 
variation in the number of forms received per subject depending on a number of 
factors, including frequency of sputum expectoration, frequency of 
exacerbation, holidays, and length of time in the study. For example subject 04 
was unable to expectorate spontaneously as frequently as other study subjects, 
at an average of only one sample per week.  In contrast, subject 09 could 
produce copious quantities of sputum per day, had 7 courses of antibiotics (with 
the associated daily sampling, compared to thrice weekly when not having a 
CFPE), had no holidays and agreed to remain in the study longer than 12 
months. 
4.1  Analysis of Individual Components of Clinical Monitoring  
All variables measured using the Clinical Monitoring forms differed between 
subjects.  The distribution of values for Visual Analogue Scales (VASs) and 
spirometric variables did not conform to a normal distribution, and thus data is 
presented as ‘median’ values and Interquartile range (IQR).  In order to 
demonstrate the range and distribution of values for individuals, box and 
whisker plots were plotted for each VAS and spirometric category.  The ‘box’ in 
each box and whisker plot represents the IQR, the horizontal line inside each 
box represents the median, the ‘whiskers’ represent ±1.5x IQR.  Outlying values  
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between ±1.5 to 3x IQR are represented by ‘￿’, while extreme values greater 
than ±3x IQR are represented by ‘*’.   
Table 4-1 below shows the distribution of values for each of the VASs.  In 
general they performed similarly, with similar ranges, medians and IQRs.  The 
General Wellbeing (GWB) VAS had the highest values for all measures.  
 
Table 4-1 Distribution of Values for components of Clinical Monitoring Form 
(subjects combined).  All differences p=NS, by unpaired T Test. Br. = 
breathlessness; VAS = Visual Analogue Scale. 
Different subjects showed variable patterns of correlation between their 
individual and summed VASs and lung function.  Individual summaries are 
presented later.  In order to provide an overview of the value of the Sum of VAS 
score that is presented along with FEV1 and FEV6 data in Response Profile 
Plots (RPP), a summary of the correlations is presented below in Table 4-2 
below.  Individual values are discussed in more detail in the following sections. 
  Br VAS  Cough VAS  Sputum VAS  GWB VAS 
Mean (SD)  23.5 (16.8)  25.0 (17.7)  24.9(17.5)  27.2 (17.5) 
Median  20  22  20  24 
Min/Max  0/83  0/89  0/82  0/94 
IQR  12-31  11-33  12-35  14-37  
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Table 4-2 Summary of Correlations between Sum of VAS scores and lung 
function, by subject.  Rho represents Spearman's Rank Correlation Coefficient; 
** = statistically significant at p≤0.05 level. 
 
Correlation between: 
Subject  Sum of VAS & FEV1  Sum of VAS & FEV6 
rho  -.397**  -.448** 
p value  <.001  <.001  1 
N.  130  130 
rho  -.486**  -.418** 
p value  <.001  <.001  2 
N.  146  145 
rho  -.298**  -.210* 
p value  <.001  .015  3 
N.  135  135 
rho  .204  .053 
p value  .151  .714  4 
N.  51  51 
rho  -.484**  -.545** 
p value  <.001  <.001  5 
N.  139  139 
rho  -.392**  -.390** 
p value  <.001  <.001  6 
N.  117  117 
rho  -.522**  -.482** 
p value  <.001  <.001  7 
N.  159  159 
rho  -.106  .084 
p value  .184  .293  8 
N.  158  158 
rho  .500  .500 
p value  .667  .667  9 
N.  3  3 
rho  .186*  -.260** 
p value  .020  .001  10 
N.  157  156 
rho  -.315**  -.170* 
p value  <.001  .032  11 
N.  159  159 
rho  -.084  -.129 
p value  .376  .172  12 
N.  113  113 
rho  -.565**  -.329** 
p value  <.001  <.001  13 
N.  153  153 
rho  -.437**  -.460** 
p value  <.001  <.001  14 
N.  171  171  
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Figure 4-1 Visual Analogue Box and Whisker plots 
 
4.1.1 Breathlessness VAS 
Breathlessness VAS scores showed wide inter-and intra-subject variability.  See 
Figure 4-1 above.  Subject 04 showed the greatest intra-subject variability for 
Breathlessness VAS, with an IQR of 30, and a range of 81.  In contrast subject 
13 had an IQR of 3, and a range of 20, representing the lowest variability.  
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4.1.2  Cough VAS 
Cough VAS scores showed wide inter-and intra-subject variability.  See Figure 
4-1 above.  Subject 04 again showed the greatest intra-subject variability for 
Cough VAS, with an IQR of 38.75, and a range of 86.  In contrast Subject 13 
had an IQR of 3, and a range of 35, representing the lowest variability. 
4.1.3 Sputum VAS 
Sputum VAS scores showed wide inter-and intra-subject variability.  See Figure 
4-1above Subject 04 showed the greatest intra-subject variability for sputum 
symptom scores, with an IQR of 45, and a range of 82.  In contract subject 13 
had the lowest IQR (2) and a range of 28.  Subject 08 also had low variability, 
with an IQR of 5, and a range of 26. 
4.1.4  General Wellbeing VAS 
GWB VAS scores showed wide inter-and intra-subject variability.  See Figure 
4-1 above.  Subject 04 showed the greatest intra-subject variability for GWB 
symptoms, with an IQR of 29.75, and a range of 81.  In contrast subject 13 had 
an IQR of 1, and a range of 22, representing the lowest variability.  
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4.1.5 Spirometric Values 
Figure 4-2 Forced expiratory volume in one second; box and whisker plot by 
subject. 
Spirometric values at baseline showed a bi-modal distribution which persisted 
through the study (see Appendix Figure Figure 9-2).  Group one (subjects 2, 3, 
4, 5, 9, and 12) had more severe lung function with FEV1 values clustered 
around 1L.  Group two (subjects 1, 6, 7, 8, 10, 11, 13, and 14), had less severe 
lung function, with FEV1 values clustered more widely around 2L.  Subject 12 
showed the least variability with an IQR of 0.06 L, and a range of 0.28 L.  
Subject 01 showed the greatest variability in FEV1 with an IQR of 0.3 L, and a 
range of 1.51 L.  See Figure 4-2 above.  A similar pattern was seen for FEV6 
(forced expiratory volume in 6 seconds).  A box and whisker plot of the values 
for FEV6 is presented in the Appendix.  See Figure 9-4 below. 
FEV1 and FEV6 values were not analysed for correlation as they are not 
independent variables, as FEV1 is an integral independent component of FEV6. 
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4.1.6  Correlations between components of Clinical Monitoring 
Form 
In order to asses the validity of the domains chosen for the symptom 
components of the Clinical monitoring Form, it was necessary to correlate the 
individual domains with each other.  In Figure 4-3 below, it can be seen that 
there are strong linear correlations between all combinations of symptoms (R
2 
range 0.55 – 0.858).  Overall the strongest correlation is between ‘Cough’ and 
‘Sputum’; the weakest correlation is between ‘Sputum’ and ‘Breathlessness’.  
For ‘General Wellbeing’, the strongest correlation is with ‘Breathlessness’.  
Finally it is worth noting that there is a marked clustering of values above and 
away from the regression line in the two scatter plots, GWB vs. Cough, and 
GWB vs. Sputum. On inspection of the raw data it was noted that the vast 
majority of these cases were from Subject 08.  
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Figure 4-3 Scatter plot correlations for four symptom domains. 
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4.2  Individual Subjects’ Response Profile Plots 
A summary Response Profile Plots (RPP) for each subject was plotted, with 
each point presenting the sum of the four VAS scores for that day.  Each of the 
four VAS scores was plotted for each subject as RPPs, and these individual 
plots can be found in the Appendix (Section 9.4 below).  Spirometric values for 
each subject for the whole study period are presented.  As are described below, 
there are a number of episodes recorded where symptoms worsened 
considerably, and then improved without treatment for a CFPE.  This may or 
may not have been associated with a decline in lung function.  Such episodes 
will be henceforth described as pseudo-exacerbations if they last for at least 7 
days. 
4.2.1  Subject 01 
Subject 01 had three CFPE in the study period.  Symptoms scores rose 
gradually over the first 95 days of the study period, and peaked during 
treatment with IV antibiotics during the first CFPE.  A gradual downward decline 
in lung function was also observed in this period that improved at the start of 
treatment, but decline again immediately afterwards.  Symptoms worsened 
again shortly after the end of the first CFPE treatment period, but declined again 
at the start of the second CFPE treatment period.  Between the second and 
third period symptoms worsened, and there appears to have been a pseudo-
exacerbation, without decline in lung function, around days 180-200.  After this 
pseudo-exacerbation, symptoms improved again before deteriorating again and 
treatment for a CFPE was started.  Symptoms improved with treatment, but a 
further pseudo-exacerbation occurred at around days 290-315.  
  123 
Table 4-3 shows the correlation between individual components of the CMF for 
subject 01.  It can be seen that there is reasonable correlation between the 
different VAS scores, with rho ranging from 0.552 and 0.809.  The sum of VAS 
scores correlated even better with the other individual components VASs, and 
also had the best correlation with FEV1 of all the VAS measures, although not 
the quite the best correlation with FEV6.  Interestingly, subject 01 also had 
moderate correlations between recorded daily temperatures and all of the other 
components of the CMF.  These were in a biologically plausible direction, with 
increased temperature correlating with increased symptoms and decreased 
lung function.  This correlation was not a universal finding among other 
subjects. 
 
Figure 4-4 Subject 01: Response Profile Plot for Sum of VASs  
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Figure 4-5 Subject 01: Response Profile Plot for FEV1 and FEV6 
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Table 4-3 Subject 01: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05. Temp. = temperature. 
4.2.2  Subject 02 
Subject 02 had three courses of antibiotics for CFPEs during the study period.  
The first coincided with the start of the study.  Attempts had been made to 
recruit subjects who were not having a CFPE.  This subject was indeed 
recruited when CFPE-free, but by the time the booking visit had been arranged 
a clinical decision had been made to commence treatment for a CFPE. 
Symptoms fell from a high level during treatment for the first CFPE, only to peak 
again at around 80 days, and again fall with treatment.  This was associated 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .608**  .669**  .552**  .802**  -.378**  -.464**  .467** 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  <.001  Breath 
VAS 
N.  134  134  134  134  134  130  130  131 
rho  .608**  1.000  .809**  .619**  .861**  -.329**  -.341**  .293** 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .001  Cough 
VAS 
N.  134  134  134  134  134  130  130  131 
rho  .669**  .809**  1.000  .607**  .879**  -.361**  -.372**  .318** 
p value  <.001  <.001  .  <.001  <.001  <.001  <.001  <.001  Sputu
m VAS 
N.  134  134  134  134  134  130  130  131 
rho  .552**  .619**  .607**  1.000  .844**  -.331**  -.390**  .354** 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  <.001  GWB 
VAS 
N.  134  134  134  134  134  130  130  131 
rho  .802**  .861**  .879**  .844**  1.000  -.397**  -.448**  .415** 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  <.001  Sum of 
VASs 
N.  134  134  134  134  134  130  130  131 
rho  -.378**  -.329**  -.361**  -.331**  -.397**  1.000  .791**  -.273** 
p value  <.001  <.001  <.001  <.001  <.001  .  <.001  .002  FEV1 
N.  130  130  130  130  130  132  132  129 
rho  -.464**  -.341**  -.372**  -.390**  -.448**  .791**  1.000  -.292** 
p value  <.001  <.001  <.001  <.001  <.001  <.001  .  .001  FEV6 
N.  130  130  130  130  130  132  132  129 
rho  .467**  .293**  .318**  .354**  .415**  -.273**  -.292**  1.000 
p value  <.001  .001  <.001  <.001  <.001  .002  .001  .  Temp. 
N.  131  131  131  131  131  129  129  133  
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250, prior to treatment for the third CFPE.  Again this was associated with 
marked decline in lung function.  Lung function improved with treatment for both 
the second and third CFPEs.  Symptoms remained generally low for most of the 
remainder of the study period, although two peaks of potential pseudo-
exacerbation are noted, one at around days 135 and the other at around day 
355. Support for these being classified as pseudo-exacerbations comes from a 
relative decline in lung function at around the same time. 
Table 4-4 shows the correlations between the individual components of the 
CMF for subject 02.  VASs scores show strong correlate win each other, 
particularly Breathlessness VAS with Cough VAS.  The sum of VAS score, 
however, correlates even more strongly with correlations to three of the four 
individual VAS scores having a rho of ≥0.9.  Sum of VAS also correlated 
moderately well with spirometry, with a rho value to FEV1 of -0.486, a value 
marginally higher than for any of the individual VAS scores. 
 
 
Figure 4-6 Subject 02: Response Profile Plot for Sum of VASs    
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Figure 4-7 Subject 02: Response Profile Plot for FEV1 and FEV6  
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Table 4-4 Subject 02: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05 
4.2.3  Subject 03 
Subject 03 had no CFPEs treated in the study period.  However, there is clearly 
a large worsening in the symptoms between days 210 – 265, consistent with a 
pseudo-exacerbation.  This is not associated with decline in lung function, and 
improves spontaneously. 
Figure Table 4-5 below shows the correlations between the various components 













VASs  FEV1  FEV6  Temp 
rho  1.000  .852**  .362**  .819**  .918**  -.458**  -.389**  .210* 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  .011  Breath 
VAS 
N.  148  148  148  148  148  146  145  147 
rho  .852**  1.000  .406**  .795**  .900**  -.412**  -.337**  .204* 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .013  Cough 
VAS 
N.  148  148  148  148  148  146  145  147 
rho  .362**  .406**  1.000  .424**  .573**  -.254**  -.234**  .035 
p value  <.001  <.001  .  <.001  <.001  .002  .005  .672  Sputu
m VAS 
N.  148  148  148  148  148  146  145  147 
rho  .819**  .795**  .424**  1.000  .925**  -.484**  -.433**  .237** 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  .004  GWB 
VAS 
N.  148  148  148  148  148  146  145  147 
rho  .918**  .900**  .573**  .925**  1.000  -.486**  -.418**  .217** 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  .008  Sum of 
VASs 
N.  148  148  148  148  148  146  145  147 
rho  -.458**  -.412**  -.254**  -.484**  -.486**  1.000  .936**  -.109 
p value  <.001  <.001  .002  <.001  <.001  .  <.001  .187  FEV1 
N.  146  146  146  146  146  149  148  148 
rho  -.389**  -.337**  -.234**  -.433**  -.418**  .936**  1.000  -.100 
p value  <.001  <.001  .005  <.001  <.001  <.001  .  .226  FEV6 
N.  145  145  145  145  145  148  148  147 
rho  .210*  .204*  .035  .237**  .217**  -.109  -.100  1.000 
p value  .011  .013  .672  .004  .008  .187  .226  .  Temp. 
N.  147  147  147  147  147  148  147  150  
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Figure 4-8 Subject 03: Response Profile Plot for Sum of VASs 
 
Figure 4-9 Subject 03: Response Profile Plot for FEV1 (solid line) 
and FEV6 (dashed line)  
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Table 4-5 Subject 03: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05 
4.2.4  Subject 04 
As has been noted previously, Subject 04 was not as productive of sputum (and 
therefore CMFs) as had been hoped.  However, useful data was obtained none 
the less.  There were three treated CFPEs, all of which were associated with 
worsening of symptoms.   The first two can be seen to improve with treatment, 
although briefly for the first.  The third CFPE coincided with the end of the study 
period, and data for the post-CFPE period was not obtained.   There was little in 
the way of change in lung function associated with either the diagnosis of a 
CFPE, or in response to treatment.  The data was too patchy to be sure of the 












VASs  FEV1  FEV6  Temp 
rho  1.000  .843**  .594**  .779**  .884**  -.245**  -.215*  .212* 
p value  .  <.001  <.001  <.001  <.001  .004  .012  .014  Breath 
VAS 
N.  135  135  135  135  135  135  135  135 
rho  .843**  1.000  .713**  .786**  .947**  -.295**  -.193*  .197* 
p value  <.001  .  <.001  <.001  <.001  .001  .025  .022  Cough 
VAS 
N.  135  135  135  135  135  135  135  135 
rho  .594**  .713**  1.000  .643**  .805**  -.260**  -.125  .218* 
p value  <.001  <.001  .  <.001  <.001  .002  .147  .011  Sputu
m VAS 
N.  135  135  135  135  135  135  135  135 
rho  .779**  .786**  .643**  1.000  .874**  -.273**  -.202*  .302** 
p value  <.001  <.001  <.001  .  <.001  .001  .019  <.001  GWB 
VAS 
N.  135  135  135  135  135  135  135  135 
rho  .884**  .947**  .805**  .874**  1.000  -.298**  -.210*  .248** 
p value  <.001  <.001  <.001  <.001  .  <.001  .015  .004  Sum of 
VASs 
N.  135  135  135  135  135  135  135  135 
rho  -.245**  -.295**  -.260**  -.273**  -.298**  1.000  .519**  -.171* 
p value  .004  .001  .002  .001  <.001  .  <.001  .047  FEV1 
N.  135  135  135  135  135  135  135  135 
rho  -.215*  -.193*  -.125  -.202*  -.210*  .519**  1.000  .098 
p value  .012  .025  .147  .019  .015  <.001  .  .256  FEV6 
N.  135  135  135  135  135  135  135  135 
rho  .212*  .197*  .218*  .302**  .248**  -.171*  .098  1.000 
p value  .014  .022  .011  <.001  .004  .047  .256  .  Temp. 
N.  135  135  135  135  135  135  135  135  
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between the various components of the CMF for subject 04.  This confirms the 
impression from visual inspection of the RPPs, that there is little or no 
correlation between Sum of VAS scores, or any individual VAS scores, and 
spirometry.  There are a number of expected strong correlations between 
individual VASs, but no correlation between any of these and any objective 
measure.  
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Figure 4-10 Subject 04: Response Profile Plot for Sum of VASs 
 
Figure 4-11 Subject 04: Response Profile Plot for FEV1 (solid line) 
and FEV6 (dashed line)  
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4.2.5 Subject 05 
Subject 05 had five treated CFPEs during the study period, with exacerbations 
1, 4, and 5 being treated either with IV antibiotics alone or oral and then IV 
antibiotics.  CFPEs 1, 4 and 5 were also the episodes that were associated with 
the largest deteriorations in symptoms at initiation of treatment, and response to 
therapy.  Of note, for all three of the IV treated CFPEs, the symptom scores 
became worse following the initiation of treatment before an improvement back 
to baseline.  In addition, all three IV treated CFPEs were associated with 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .681**  .533**  .714**  .802**  .190  .027  -.182 
p value  .  <.001  <.001  <.001  <.001  .181  .850  .197  Breath 
VAS 
N.  52  52  52  52  52  51  51  52 
rho  .681**  1.000  .804**  .757**  .916**  .274  .082  -.006 
p value  <.001  .  <.001  <.001  <.001  .052  .566  .967  Cough 
VAS 
N.  52  52  52  52  52  51  51  52 
rho  .533**  .804**  1.000  .797**  .890**  .117  .073  .191 
p value  <.001  <.001  .  <.001  <.001  .413  .610  .176  Sputum 
VAS 
N.  52  52  52  52  52  51  51  52 
rho  .714**  .757**  .797**  1.000  .917**  .106  -.014  -.037 
p value  <.001  <.001  <.001  .  <.001  .461  .924  .793  GWB 
VAS 
N.  52  52  52  52  52  51  51  52 
rho  .802**  .916**  .890**  .917**  1.000  .204  .053  -.014 
p value  <.001  <.001  <.001  <.001  .  .151  .714  .922  Sum of 
VASs 
N.  52  52  52  52  52  51  51  52 
rho  .190  .274  .117  .106  .204  1.000  .623**  -.183 
p value  .181  .052  .413  .461  .151  .  <.001  .198  FEV1 
N.  51  51  51  51  51  51  51  51 
rho  .027  .082  .073  -.014  .053  .623**  1.000  -.090 
p value  .850  .566  .610  .924  .714  <.001  .  .532  FEV6 
N.  51  51  51  51  51  51  51  51 
rho  -.182  -.006  .191  -.037  -.014  -.183  -.090  1.000 
p value  .197  .967  .176  .793  .922  .198  .532  .  Temp. 
N.  52  52  52  52  52  51  51  52 
Table 4-6 Subject 04: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05.  
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if only partially recovered.  The first CFPE, which was associated with the worst 
symptoms and the lowest lung function, lasted 42 days and required 3 
consecutive different antibiotic combinations. 
Correlations between the individual components of the CMF for subject 05 are 
presented in Table 4-7 below.  This confirms the visual inspection of the RPPs, 
with strong negative correlations between the Sum of VAS and both FEV1 and 
FEV6 (rho -0.484 and -0.545 respectively).  Unlike some other subjects, 
however, there was no correlation between temperature and symptoms or lung 
function.  




Figure 4-12 Subject 05: Response Profile Plot for Sum of VASs 
 
Figure 4-13 Subject 05: Response Profile Plot for FEV1 and FEV6  
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4.2.6 Subject 06 
Subject 06 had two treated CFPEs, both treated with oral antibiotics.  There 
appears to have been a large deterioration in symptoms between days 75 – 100 
which is only associated with a small gradual decline in lung function.  However, 
the first treated CFPE occurs at day 210, the second at day 255.  The first 
course of treatment is associated with a short lived improvement in symptoms, 
whilst the second course of treatment is associated with a longer lasting 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .757**  .725**  .651**  .848**  -.499**  -.539**  .098 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  .234  Breath 
VAS 
N.  153  153  153  152  152  140  140  150 
rho  .757**  1.000  .840**  .706**  .908**  -.431**  -.494**  .106 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .198  Cough 
VAS 
N.  153  153  153  152  152  140  140  150 
rho  .725**  .840**  1.000  .694**  .892**  -.418**  -.491**  .030 
p value  <.001  <.001  .  <.001  <.001  <.001  <.001  .718  Sputum 
VAS 
N.  153  153  153  152  152  140  140  150 
rho  .651**  .706**  .694**  1.000  .890**  -.442**  -.461**  .179* 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  .029  GWB 
VAS 
N.  152  152  152  152  152  139  139  149 
rho  .848**  .908**  .892**  .890**  1.000  -.484**  -.545**  .136 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  .098  Sum of 
VASs 
N.  152  152  152  152  152  139  139  149 
rho  -.499**  -.431**  -.418**  -.442**  -.484**  1.000  .816**  .037 
p value  <.001  <.001  <.001  <.001  <.001  .  <.001  .667  FEV1 
N.  140  140  140  139  139  140  140  137 
rho  -.539**  -.494**  -.491**  -.461**  -.545**  .816**  1.000  -.004 
p value  <.001  <.001  <.001  <.001  <.001  <.001  .  .964  FEV6 
N.  140  140  140  139  139  140  140  137 
rho  .098  .106  .030  .179*  .136  .037  -.004  1.000 
p value  .234  .198  .718  .029  .098  .667  .964  .  Temp. 
N.  150  150  150  149  149  137  137  150 
Table 4-7 Subject 05: correlation between components of Clinical Monitoring Form, 
by Spearman's rank correlation.  ** = correlations significantly different at p<0.05.  
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that improves without treatment and is not associated with a measurable 
decline in lung function.  This is consistent with a pseudo-exacerbation. 
Correlations between the components of the CMF for subject 06 are presented 
in Table 4-8 below.  This shows very strong correlations between the individual 
VAS scores, and moderate correlations with lung function.  However, although 
Sum of VAS does correlate relatively well with FEV1 and FEV6 (rho -0.392 and 
-0.390 respectively), both Breathlessness VAS and General Wellbeing VASs 
correlate more strongly (rho up to -0.478). 
It can be noted that there is a long delay from a considerable increase in 
symptoms consistent with a CFPE, and instigation of treatment (oral antibiotics).  
Discussion with the clinical team revealed that this CFPE was diagnosed and 
treated at a routine out patients’ appointment visit.  This subject only reported 
the increase in symptoms of direct questioning by the clinician.  It was not self-
recognised as a CFPE. 
 
Figure 4-14 Subject 06: Response Profile Plot for Sum of VASs  




Figure 4-15 Subject 06: Response Profile Plot for FEV1 and FEV6  
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4.2.7  Subject 07 
Subject 07 had four treated CFPEs.  The first two were treated with IV 
antibiotics and the second two with oral antibiotics.  Judged by changes in 
symptoms and lung function, the second exacerbation was a major health 
event, with a rise from around 80 to a peak of 280 for the sum of the VAS 
scores, and a fall in FEV1 from around 1.8L to a nadir of less than 1.4L..  












VASs  FEV1  FEV6  Temp 
rho  1.000  .904**  .735**  .820**  .927**  -.410**  -.387**  -.048 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  .602  Breath 
VAS 
N.  121  121  121  121  121  117  117  121 
rho  .904**  1.000  .831**  .817**  .947**  -.367**  -.371**  -.104 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .258  Cough 
VAS 
N.  121  121  121  121  121  117  117  121 
rho  .735**  .831**  1.000  .741**  .854**  -.208*  -.298**  -.049 
p value  <.001  <.001  .  <.001  <.001  .025  .001  .591  Sputum 
VAS 
N.  121  121  121  121  121  117  117  121 
rho  .820**  .817**  .741**  1.000  .874**  -.415**  -.478**  -.085 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  .356  GWB 
VAS 
N.  121  121  121  121  121  117  117  121 
rho  .927**  .947**  .854**  .874**  1.000  -.392**  -.390**  -.069 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  .451  Sum of 
VASs 
N.  121  121  121  121  121  117  117  121 
rho  -.410**  -.367**  -.208*  -.415**  -.392**  1.000  .578**  .049 
p value  <.001  <.001  .025  <.001  <.001  .  <.001  .599  FEV1 
N.  117  117  117  117  117  117  117  117 
rho  -.387**  -.371**  -.298**  -.478**  -.390**  .578**  1.000  .131 
p value  <.001  <.001  .001  <.001  <.001  <.001  .  .160  FEV6 
N.  117  117  117  117  117  117  117  117 
rho  -.048  -.104  -.049  -.085  -.069  .049  .131  1.000 
p value  .602  .258  .591  .356  .451  .599  .160  .  Temp. 
N.  121  121  121  121  121  117  117  121 
Table 4-8 Subject 06: correlation between components of Clinical Monitoring Form, 
by Spearman's rank correlation.  ** = correlations significantly different at p<0.05.  
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improving within a few days compared to 30 or more days for a recovery in 
FEV1. 
Symptom scores responded to all the course of antibiotics, to a greater or lesser 
degree.  There was only one episode which could be described as a pseudo-
exacerbation: around 14 days after the end of the second CFPE there was a 
large deterioration in symptom scores, greater in magnitude than all but the 
second CFPE.  This resolved within 10 days of starting. There was no change 
in lung function with this pseudo-exacerbation. 
Table 4-9 shows the correlations between the various components of the CMF.  
Compared to some other subjects 09’s VAS scores do not correlate as strongly 
with each other (rho 0.478 to 0.844).  However, particularly noteworthy is the 
very strong negative correlation between Breathlessness VAS and FEV1 (rho -
0.720).  It is also worth noting that there are some weak positive correlations 
between temperature and Cough and Sputum VAS scores (rho 0.217 and 0.232 
respectively), which seem biologically plausible.  However there is also a 
statistically significant weak (rho 0.184) positive correlation between 
temperature and FEV1 (but not FEV6) which is less biologically plausible.   
  





Figure 4-16 Subject 07: Response Profile Plot for Sum of VASs 
 
Figure 4-17 Subject 07: Response Profile Plot for FEV1 and FEV6  
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Table 4-9 Subject 07: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05. 
4.2.8 Subject 08 
Subject 08 had no treated CFPEs during the study period, which extended to 
450 days.  He received one course of oral antibiotics for an unrelated presumed 
staphylococcal skin infection.  The Sum of Symptoms and FEV1 RPPs were 
very consistent (compared to other subjects) through the study period.  A more 
in depth look at individual VAS plots shoed an upward trend for Breathlessness 
and General Wellbeing, but downward trend for cough and sputum.  These 
divergent trends appeared to cancel each other out in the Sum of VAS plot.  
There appeared to be a general trend of increasing FEV6 values though out the 













VASs  FEV1  FEV6  Temp. 
rho  1.000  .478**  .333**  .553**  .680**  -.720**  -.641**  -.119 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  .137  Breath 
VAS 
N.  159  159  159  159  159  159  159  159 
rho  .478**  1.000  .844**  .674**  .889**  -.335**  -.298**  .217** 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .006  Cough 
VAS 
N.  159  159  159  159  159  159  159  159 
rho  .333**  .844**  1.000  .611**  .829**  -.244**  -.218**  .232** 
p value  <.001  <.001  .  <.001  <.001  .002  .006  .003  Sputum 
VAS 
N.  159  159  159  159  159  159  159  159 
rho  .553**  .674**  .611**  1.000  .856**  -.487**  -.493**  .167* 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  .035  GWB 
VAS 
N.  159  159  159  159  159  159  159  159 
rho  .680**  .889**  .829**  .856**  1.000  -.522**  -.482**  .146 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  .067  Sum of 
VASs 
N.  159  159  159  159  159  159  159  159 
rho  -.720**  -.335**  -.244**  -.487**  -.522**  1.000  .930**  .184* 
p value  <.001  <.001  .002  <.001  <.001  .  <.001  .020  FEV1 
N.  159  159  159  159  159  159  159  159 
rho  -.641**  -.298**  -.218**  -.493**  -.482**  .930**  1.000  .181* 
p value  <.001  <.001  .006  <.001  <.001  <.001  .  .022  FEV6 
N.  159  159  159  159  159  159  159  159 
rho  -.119  .217**  .232**  .167*  .146  .184*  .181*  1.000 
p value  .137  .006  .003  .035  .067  .020  .022  .  Temp. 
N.  159  159  159  159  159  159  159  159  
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The visual inspection of the individual RPPs for subject 08 suggest different 
factors at play, as noted above.  These perceptions are strengthened by the 
results of the correlations between the components of the CMF, presented in 
Table 4-10.  From this it can be seen that there is a biologically plausible 
negative correlation between Cough and Sputum VAS scores with FEV1 (rho -
0.434 -0.489 respectively) and biologically implausible positive correlations 
between Breathlessness and General Wellbeing scores with FEV1 (rho 0.24 
and 0.214 respectively).  It is worth noting, that for this subject, FEV6 correlated 
more strongly with all other measures than FEV1.  
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Figure 4-18 Subject 08: Response Profile Plot for Sum of VASs 
 
Figure 4-19 Subject 08: Response Profile Plot for FEV1 and FEV6.  
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4.2.9 Subject 09 
Subject 09 had some difficulties with completing the Clinical Monitoring Form.  
For the first 220 days of the study he scored almost zero across all four VAS 
domains, yet had a number of IV antibiotic courses for CFPEs, and had the 
lowest FEV1% predicted.  The principle researcher was not keen to apply 
undue influence on the way subjects complete their subjective symptom 
scoring.  However, it became apparent that the data being recorded was in no 












VASs  FEV1  FEV6  Temp. 
rho  1.000  -.689**  -.563**  .826**  .659**  .240**  .506**  -.040 
p value  .  <.001  <.001  <.001  <.001  .002  <.001  .623  Breath 
VAS 
N.  159  159  159  159  159  158  158  156 
rho  -.689**  1.000  .823**  -.689**  -.097  -.434**  -.634**  .083 
p value  <.001  .  <.001  <.001  .224  <.001  <.001  .303  Cough 
VAS 
N.  159  159  159  159  159  158  158  156 
rho  -.563**  .823**  1.000  -.534**  .057  -.489**  -.628**  .096 
p value  <.001  <.001  .  <.001  .478  <.001  <.001  .234  Sputum 
VAS 
N.  159  159  159  159  159  158  158  156 
rho  .826**  -.689**  -.534**  1.000  .651**  .214**  .523**  -.056 
p value  <.001  <.001  <.001  .  <.001  .007  <.001  .491  GWB 
VAS 
N.  159  159  159  159  159  158  158  156 
rho  .659**  -.097  .057  .651**  1.000  -.106  .084  .076 
p value  <.001  .224  .478  <.001  .  .184  .293  .348  Sum of 
VASs 
N.  159  159  159  159  159  158  158  156 
rho  .240**  -.434**  -.489**  .214**  -.106  1.000  .648**  .004 
p value  .002  <.001  <.001  .007  .184  .  <.001  .961  FEV1 
N.  158  158  158  158  158  160  159  157 
rho  .506**  -.634**  -.628**  .523**  .084  .648**  1.000  -.113 
p value  <.001  <.001  <.001  <.001  .293  <.001  .  .159  FEV6 
N.  158  158  158  158  158  159  160  157 
rho  -.040  .083  .096  -.056  .076  .004  -.113  1.000 
p value  .623  .303  .234  .491  .348  .961  .159  .  Temp. 
N.  156  156  156  156  156  157  157  158 
Table 4-10 Subject 08: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different 
at p<0.05.  
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understanding of the process of completing VASs.  During this discussion it 
became clear that he was completing the VAS for how he felt at the moment of 
filling it in (i.e. while sitting), as opposed to how he felt during that day so far.  
Such a misunderstanding may have be made more likely by his previous record 
of poor educational attainment and low levels of adherence with appointments 
and the CF service.  The misunderstanding was corrected.  VAS data prior to 
the corrective discussion was regrettably discarded. 
In addition to the above difficulties with the VAS process, Subject 09 also had 
difficulties with the home spirometer.  This was problem developed during the 
course of the study and was not apparent at the start.  With his FEV1% 
predicted being less than 20% at the start of the study, completion of FEV1 and 
FEV6 caused severely disabling dyspnoea and curtailed his ability and 
willingness to go through this each morning.  Thus by the end of the study he 
was no longer recording his spirometry. 
With regard to the recorded data presented below in Table 4-11, he had 5 
separate treated CFPEs.  All of these were treated at least in part with IV 
antibiotics.  In addition, he received one course of IV antibiotics that were 
arranged electively.  For his symptoms, there was a clear improvement in 
symptoms during and after the CFPE treatment that started on day 256.  
Although there is no clear pattern of an increase leading up to this treated 
CFPE, there may have been an insufficient period of time with captured data to 
allow visualisation of any deterioration that preceded the start of treatment.  
Following the end of treatment at day 279, symptoms began to deteriorate 
culminating in another treated CFPE on day 336.  Symptoms improved 
considerably with treatment for this CFPE at day 336, and continued to improve  
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after the end of IV antibiotics at day 357.  Symptoms then worsened again at 
around day 380 before starting to improve around day 390.  It was around this 
time that elective IV antibiotics were started, the decision having been made at 
or shortly after the end of the previous course of IV antibiotics.  During and after 
the elective course of IV antibiotics, symptoms improved to their lowest level. 
Other than the deterioration and subsequent improvement in symptoms that 
coincided with the elective course of antibiotics there were no apparent 
episodes of pseudo-exacerbations in the study period.  Unfortunately there was 
no overlap between the available data for symptoms and that available for lung 
function. 
  




Figure 4-20 Subject 09: Response Profile Plot for Sum of VASs. 
 
Figure 4-21 Subject 09: Response Profile Plot for FEV1 and FEV6  
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4.2.10  Subject 10 
Subject 10 had two courses of antibiotics for CFPEs, the first orally and the 
second intravenously.  In addition one course was given intravenously as an 
elective treatment.  For Sum of Symptoms, there was a marked worsening in 
symptoms at around the time of the start of the course of elective IV antibiotics 
that was not associated with any perceptible deterioration in spirometry.  This 
deterioration in symptoms was not improved by the elective course of 
antibiotics.  In addition, there were two further courses of antibiotics for CFPEs: 
there was a further worsening in symptom scores at the time of the first, and a 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .884**  .777**  .736**  .907**  .500  .500  -.148 
p value  .  <.001  <.001  <.001  <.001  .667  .667  .222  Breath 
VAS 
N.  83  83  83  83  83  3  3  70 
rho  .884**  1.000  .839**  .778**  .945**  .500  .500  -.111 
p value  <.001  .  <.001  <.001  <.001  .667  .667  .359  Cough 
VAS 
N.  83  83  83  83  83  3  3  70 
rho  .777**  .839**  1.000  .761**  .924**  1.000**  1.000**  -.093 
p value  <.001  <.001  .  <.001  <.001  .  .  .442  Sputum 
VAS 
N.  83  83  83  83  83  3  3  70 
rho  .736**  .778**  .761**  1.000  .876**  .500  .500  -.218 
p value  <.001  <.001  <.001  .  <.001  .667  .667  .070  GWB 
VAS 
N.  83  83  83  83  83  3  3  70 
rho  .907**  .945**  .924**  .876**  1.000  .500  .500  -.176 
p value  <.001  <.001  <.001  <.001  .  .667  .667  .144  Sum of 
VASs 
N.  83  83  83  83  83  3  3  70 
rho  .500  .500  1.000**  .500  .500  1.000  .536**  .086 
p value  .667  .667  .  .667  .667  .  <.001  .563  FEV1 
N.  3  3  3  3  3  47  47  47 
rho  .500  .500  1.000**  .500  .500  .536**  1.000  -.043 
p value  .667  .667  .  .667  .667  <.001  .  .774  FEV6 
N.  3  3  3  3  3  47  48  48 
rho  -.148  -.111  -.093  -.218  -.176  .086  -.043  1.000 
p value  .222  .359  .442  .070  .144  .563  .774  .  Temp. 
N.  70  70  70  70  70  47  48  177 
Table 4-11 Subject 09: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05.  
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correlation between values from the CMF and antibiotic treatment, either 
elective or for CFPEs. 
This lack of correlation between CMF values and objective markers such 
CFPEs lung function and temperature is born out by the correlations between 
the values presented in Table 4-12 below.  There only the weakest of significant 
positive correlations of VAS scores with FEV1, which is biologically implausible, 
and a marginally stronger (negative) correlation with FEV6 and therefore more 
biologically plausible.  Despite this lack of correlations between objective and 
subjective measures, there is very strong correlation between all the VAS 
scores.  One possible explanation for this discrepancy would be that little or no 
thought was given by subject 10 to the completion of the VASs, and lines were 
placed in approximately the same for all VASs to make the process as quick as 
possible.  Although a plausible explanation, this would not fit with the 
experience of those who interacted with the subject, who was considered highly 
adherent to therapies and related activities, with good educational attainment 
levels.  




Figure 4-22 Subject 10: Response Profile Plot for Sum of VASs. 
 
Figure 4-23 Subject 10: Response Profile Plot for FEV1 and FEV6  
  152 
4.2.11  Subject 11 
Subject 11 had three treated CFPEs.  The first two were treated with oral 
antibiotics, the third with IV antibiotics.  There was a clear decline in symptoms 
leading up to the start of treatment for the first CFPE, over a period of around 
50 days. This was associated with a decline in FEV1 from around 2.4 to around 
2.0L.  There followed a small response in symptoms and spirometry during the 
treatment.  However this was not sustained and both symptoms and spirometry 
worsened a little after cessation of this first course of antibiotics.  Two further 
courses of antibiotics followed, with good improvement in symptoms during the 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .938**  .943**  .924**  .968**  .163*  -.264**  -.071 
p value  .  <.001  <.001  <.001  <.001  .041  .001  .379  Breath 
VAS 
N.  160  160  159  160  159  158  157  156 
rho  .938**  1.000  .951**  .931**  .977**  .165*  -.283**  -.040 
p value  <.001  .  <.001  <.001  <.001  .038  <.001  .620  Cough 
VAS 
N.  160  160  159  160  159  158  157  156 
rho  .943**  .951**  1.000  .956**  .985**  .185*  -.249**  -.094 
p value  <.001  <.001  .  <.001  <.001  .020  .002  .246  Sputum 
VAS 
N.  159  159  159  159  159  157  156  155 
rho  .924**  .931**  .956**  1.000  .973**  .222**  -.244**  -.069 
p value  <.001  <.001  <.001  .  <.001  .005  .002  .394  GWB 
VAS 
N.  160  160  159  160  159  158  157  156 
rho  .968**  .977**  .985**  .973**  1.000  .186*  -.260**  -.076 
p value  <.001  <.001  <.001  <.001  .  .020  .001  .350  Sum of 
VASs 
N.  159  159  159  159  159  157  156  155 
rho  .163*  .165*  .185*  .222**  .186*  1.000  .589**  .039 
p value  .041  .038  .020  .005  .020  .  <.001  .626  FEV1 
N.  158  158  157  158  157  159  158  155 
rho  -.264**  -.283**  -.249**  -.244**  -.260**  .589**  1.000  .010 
p value  .001  <.001  .002  .002  .001  <.001  .  .901  FEV6 
N.  157  157  156  157  156  158  158  154 
rho  -.071  -.040  -.094  -.069  -.076  .039  .010  1.000 
p value  .379  .620  .246  .394  .350  .626  .901  .  Temp. 
N.  156  156  155  156  155  155  154  157 
Table 4-12 Subject 10: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different 
at p<0.05.  
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of IV antibiotics, symptoms had again worsened, without change in spirometry, 
suggestive of a pseudo-exacerbation.  Symptoms did eventually improve 
without additional treatment, but never returned to the nadir seen prior to the 
first CFPE.  Spirometry, however, gradually improved after the end of the last 
course of antibiotics, and by the end of the year, was close to values at the 
start. 
Overall, subject 11 appears to have very variable symptoms that only partially 
responded to treatments for CFPEs.  There was at least one and possible more 
pseudo-exacerbations.  Table 4-13 below shows the correlations between the 
various components of the CMF.  FEV1 has the strongest negative correlation 
with the General Wellbeing VAS (rho -0.348, p<0.001).  There are moderately 
good positive correlations between the individual VASs, which improve when 
combined in the Sum of VAS score.  The values for rho (0.392 to 0.656 are 
lower than for a number of other subjects.  Temperature has no significant 
correlations.  
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Figure 4-24 Subject 11: Response Profile Plot for Sum of VASs 
 
Figure 4-25 Subject 11: Response Profile Plot for FEV1 and FEV6  
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4.2.12  Subject 12 
Subject 12 was a student from the European Union studying at a local higher 
education facility.  As such he retuned home during each of the academic 
holiday periods of Christmas, Easter and summer, and thus sampling ceased 
during these periods. 
Subject 12 received treatment for four CFPEs during the study period.  There 
were additional treated CFPEs whilst away from the UK during holiday periods, 
but these were not recoded.  The first and fourth exacerbations were treated 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .576**  .392**  .619**  .836**  -.321**  -.160*  .016 
p value  .  <.001  <.001  <.001  <.001  <.001  .045  .835  Breath 
VAS 
N.  168  168  168  168  168  159  159  168 
rho  .576**  1.000  .656**  .478**  .795**  -.195*  -.145  -.070 
p value  <.001  .  <.001  <.001  <.001  .014  .069  .364  Cough 
VAS 
N.  168  168  168  168  168  159  159  168 
rho  .392**  .656**  1.000  .342**  .690**  -.179*  -.220**  -.082 
p value  <.001  <.001  .  <.001  <.001  .024  .005  .293  Sputum 
VAS 
N.  168  168  168  168  168  159  159  168 
rho  .619**  .478**  .342**  1.000  .764**  -.348**  -.127  .126 
p value  <.001  <.001  <.001  .  <.001  <.001  .112  .104  GWB 
VAS 
N.  168  168  168  168  168  159  159  168 
rho  .836**  .795**  .690**  .764**  1.000  -.315**  -.170*  .028 
p value  <.001  <.001  <.001  <.001  .  <.001  .032  .715  Sum of 
VASs 
N.  168  168  168  168  168  159  159  168 
rho  -.321**  -.195*  -.179*  -.348**  -.315**  1.000  .701**  -.039 
p value  <.001  .014  .024  <.001  <.001  .  <.001  .626  FEV1 
N.  159  159  159  159  159  159  159  159 
rho  -.160*  -.145  -.220**  -.127  -.170*  .701**  1.000  .022 
p value  .045  .069  .005  .112  .032  <.001  .  .780  FEV6 
N.  159  159  159  159  159  159  159  159 
rho  .016  -.070  -.082  .126  .028  -.039  .022  1.000 
p value  .835  .364  .293  .104  .715  .626  .780  .  Temp. 
N.  168  168  168  168  168  159  159  168 
Table 4-13 Subject 11: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different 
at p<0.05.  
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In general Subject 12’s VAS scoring was low, particularly when taking his 
pulmonary disease severity in to consideration.  For the first exacerbation, 
which started 13 days after entry in to the study, a high Sum of VASs score can 
be noted, which appears to improve with treatment.  However, the exacerbation 
occurred too close to the start of the study to allow a period of stability to be 
seen, if one existed.  There was a marked initial response to the start of 
treatment, but symptoms worsened again before the end of treatment and 
remained at this level for about 14 days.  There were also changes in 
spirometry during this time.  However, although small, the changes ran counter 
to that which would be expected with a CFPE, with a fall during treatment and a 
rise after the end of treatment.  The second and third treated CFPEs were 
associated with more modest changes in symptoms, without associated 
changes in spirometry.  The fourth treated CFPE was immediately on returning 
from overseas, and it is thus difficult to comment accurately on this time.  After a 
long summer holiday abroad, symptoms seemed to have worsened 
considerably on his return, with lung function considerably below that seen at 
the start of the study.  This may constitute a pseudo-exacerbation. 
Correlations between the components of the CMF are presented in Table 4-14 
below.  There was no correlation between any VAS value and lung function.  
The only correlation between an objective and a subjective measure was a 
weak negative correlation between FEV1 and temperature (rho -0.284, 
p=0.002).  Correlations between separate VAS components were moderately 
strong and made stronger when combined in the Sum of VAS score.  




Figure 4-26 Subject 12: Response Profile Plot for Sum of VASs 
 
Figure 4-27 Subject 12: Response Profile Plot for FEV1 and FEV6  
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Table 4-14 Subject 12: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05 
4.2.13  Subject 13 
Subject 13 generally scored his VASs at the very low end.  He reported 
memories that as a young child he had been kept in hospital for a long period of 
time on oxygen and remembered severe breathlessness at that time.  All 
breathlessness experienced since that time was mild by comparison. 
Subject 13 had four treated CFPEs during the study period.  All four were 
treated with IV antibiotics.  Despite the low level of VAS scoring all four 
episodes were associated with discernible worsening symptoms, and 
subsequent response to treatment.  At least three of the four were also clear 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .705**  .613**  .537**  .844**  -.118  -.084  .087 
p value  .  <.001  <.001  <.001  <.001  .214  .377  .358  Breath 
VAS 
N.  114  114  114  114  114  113  113  114 
rho  .705**  1.000  .682**  .583**  .850**  -.055  -.130  -.017 
p value  <.001  .  <.001  <.001  <.001  .560  .170  .861  Cough 
VAS 
N.  114  114  114  114  114  113  113  114 
rho  .613**  .682**  1.000  .688**  .865**  -.069  -.139  .055 
p value  <.001  <.001  .  <.001  <.001  .470  .142  .559  Sputum 
VAS 
N.  114  114  114  114  114  113  113  114 
rho  .537**  .583**  .688**  1.000  .794**  -.061  -.076  .060 
p value  <.001  <.001  <.001  .  <.001  .523  .424  .525  GWB 
VAS 
N.  114  114  114  114  114  113  113  114 
rho  .844**  .850**  .865**  .794**  1.000  -.084  -.129  .073 
p value  <.001  <.001  <.001  <.001  .  .376  .172  .438  Sum of 
VASs 
N.  114  114  114  114  114  113  113  114 
rho  -.118  -.055  -.069  -.061  -.084  1.000  .795**  -.284** 
p value  .214  .560  .470  .523  .376  .  <.001  .002  FEV1 
N.  113  113  113  113  113  114  114  114 
rho  -.084  -.130  -.139  -.076  -.129  .795**  1.000  -.176 
p value  .377  .170  .142  .424  .172  <.001  .  .061  FEV6 
N.  113  113  113  113  113  114  114  114 
rho  .087  -.017  .055  .060  .073  -.284**  -.176  1.000 
p value  .358  .861  .559  .525  .438  .002  .061  .  Temp. 
N.  114  114  114  114  114  114  114  115  
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were no clear pseudo-exacerbations, although there was a period at the very 
start of the study associated with higher symptom scores that resolved without 
recourse to antibiotic therapy.  However, values were high at the start of the 
study, and thus no worsening was recoded, only an improvement, and thus 
cannot be called a pseudo-exacerbation. 
Unlike the previous subject, subject 13 had good correlations between 
individual VAS scores and FEV1, with three of the four correlations being at 
rho~0.500.  There was also a weak positive correlation between temperature 
and Sputum VAS and Sum of VASs.  There was generally good correlation, 
except for General Wellbeing, which had lower correlations with the others than 
was seen for any other subject. 
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Figure 4-28 Subject 13: Response Profile Plot for Sum of VASs 
 
Figure 4-29 Subject 13: Response Profile Plot for FEV1 and FEV6  
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4.2.14  Subject 14 
Subject 14 had four treated CFPEs through the year.  All four were treated with 
IV antibiotics.  It is worth noting that the fourth and final CFPE was diagnosed 
and treated on the basis of haemoptysis, rather than on any reported 
deterioration in symptoms that could have been picked up with the VAS 
domains of the CMF.  In general FEV6 values were very close, and often 
identical to FEV1 values, suggesting incomplete effort.  However, there were 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .755**  .656**  .360**  .886**  -.494**  -.256**  .189* 
p value  .  <.001  <.001  <.001  <.001  <.001  .001  .017  Breath 
VAS 
N.  160  160  160  160  160  153  153  160 
rho  .755**  1.000  .758**  .280**  .874**  -.512**  -.230**  .255** 
p value  <.001  .  <.001  <.001  <.001  <.001  .004  .001  Cough 
VAS 
N.  160  160  160  160  160  153  153  160 
rho  .656**  .758**  1.000  .315**  .840**  -.537**  -.247**  .289** 
p value  <.001  <.001  .  <.001  <.001  <.001  .002  <.001  Sputum 
VAS 
N.  160  160  160  160  160  153  153  160 
rho  .360**  .280**  .315**  1.000  .522**  -.271**  -.528**  .078 
p value  <.001  <.001  <.001  .  <.001  .001  <.001  .328  GWB 
VAS 
N.  160  160  160  160  160  153  153  160 
rho  .886**  .874**  .840**  .522**  1.000  -.565**  -.329**  .280** 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  <.001  Sum of 
VASs 
N.  160  160  160  160  160  153  153  160 
rho  -.494**  -.512**  -.537**  -.271**  -.565**  1.000  .596**  -.127 
p value  <.001  <.001  <.001  .001  <.001  .  <.001  .117  FEV1 
N.  153  153  153  153  153  153  153  153 
rho  -.256**  -.230**  -.247**  -.528**  -.329**  .596**  1.000  .024 
p value  .001  .004  .002  <.001  <.001  <.001  .  .770  FEV6 
N.  153  153  153  153  153  153  153  153 
rho  .189*  .255**  .289**  .078  .280**  -.127  .024  1.000 
p value  .017  .001  <.001  .328  <.001  .117  .770  .  Temp. 
N.  160  160  160  160  160  153  153  160 
Table 4-15 Subject 13: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different at 
p<0.05.  
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The worst symptoms were recoded at the start of the first CFPE, and these very 
rapidly improved with treatment.  However this first CFPE was very quickly 
followed by a pseudo-exacerbation at around days 35 - 45, with high symptoms 
scores that exceeded any values seen throughout the remainder of the study.  
This first pseudo-exacerbation was also associated with some of the lowest 
lung function values during the study period.  Following this first pseudo-
exacerbation, there followed a second pseudo-exacerbation of less magnitude, 
also associated with a small but discernible decline in lung function.  At day 123 
there started treatment for the second CFPE, with a worsening in symptoms 
and lung function over the preceding 14 days.  Notably, FEV1 declined from 
around 2.4L to 1.9L.  Again there was good improvement with treatment. 
Following the second CFPE, there followed a slow decline in lung function, 
associated with stable symptom scores.  The third CFPE followed a similar 
pattern to the second.  The final CFPE, as noted above, was for haemoptysis 
rather than other symptoms, and consequently there was no noticeable change 
in symptoms at that time. 
Table 4-16 shows the correlations between the various components of the 
CMF.  FEV1 correlated well with the subjective measures, with values for rho 
ranging from -0.445 to -0.392.  FEV6 performed equally well if not better.  There 
were also weakly significant weak positive correlations with temperature that 
were in a biologically implausible direction.  The correlations of the VAS scores 
to each other were good, with the lowest rho value at 0.74.  Combining the VAS 
scores in the Sum of VAS improved the correlation such that values of rho were 
all >0.900.  




Figure 4-30 Subject 14: Response Profile Plot for Sum of VASs 
 
Figure 4-31 Subject 14: Response Profile Plot for FEV1 and FEV6  
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4.3  Relationship between Clinical Monitoring and CFPEs 
It was clear from the above plots that the components of the CMF had a 
considerable variability, with many troughs and peaks unrelated to CFPEs or 
their treatment.  Further analysis was therefore performed in order to establish 
whether fluctuations in the components of the CMF bore any relationship to the 
diagnosis of CFPE by the treating clinicians.   
For each component of the CMF, a paired analysis was performed, of values 
around the time of a CFPE diagnosis with values from a period of stability in the 












VASs  FEV1  FEV6  Temp. 
rho  1.000  .867**  .833**  .746**  .901**  -.392**  -.409**  -.108 
p value  .  <.001  <.001  <.001  <.001  <.001  <.001  .155  Breath 
VAS 
N.  174  174  174  174  174  171  171  174 
rho  .867**  1.000  .953**  .833**  .978**  -.397**  -.417**  -.047 
p value  <.001  .  <.001  <.001  <.001  <.001  <.001  .536  Cough 
VAS 
N.  174  174  174  174  174  171  171  174 
rho  .833**  .953**  1.000  .865**  .971**  -.445**  -.465**  -.034 
p value  <.001  <.001  .  <.001  <.001  <.001  <.001  .657  Sputum 
VAS 
N.  174  174  174  174  174  171  171  174 
rho  .746**  .833**  .865**  1.000  .900**  -.442**  -.461**  -.068 
p value  <.001  <.001  <.001  .  <.001  <.001  <.001  .370  GWB 
VAS 
N.  174  174  174  174  174  171  171  174 
rho  .901**  .978**  .971**  .900**  1.000  -.437**  -.460**  -.055 
p value  <.001  <.001  <.001  <.001  .  <.001  <.001  .467  Sum of 
VASs 
N.  174  174  174  174  174  171  171  174 
rho  -.392**  -.397**  -.445**  -.442**  -.437**  1.000  .926**  .175* 
p value  <.001  <.001  <.001  <.001  <.001  .  <.001  .022  FEV1 
N.  171  171  171  171  171  171  171  171 
rho  -.409**  -.417**  -.465**  -.461**  -.460**  .926**  1.000  .231** 
p value  <.001  <.001  <.001  <.001  <.001  <.001  .  .002  FEV6 
N.  171  171  171  171  171  171  171  171 
rho  -.108  -.047  -.034  -.068  -.055  .175*  .231**  1.000 
p value  .155  .536  .657  .370  .467  .022  .002  .  Temp. 
N.  174  174  174  174  174  171  171  174 
Table 4-16 Subject 14: correlation between components of Clinical Monitoring 
Form, by Spearman's rank correlation.  ** = correlations significantly different 
at p<0.05.  
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the VAS or FEV1 values in the 7 days immediately prior to the start of treatment 
for a CFPE.  Values for the period of stability were judged based on the 
appearances of the Sum of VASs response profile plot for that subject.  More 
specifically, the period of stability was assessed as the lowest 7 day period in 
the 60 days prior to treatment for a CFPE, but not including the 7 days 
immediately prior to treatment.  A CFPE was excluded if it occurred: within 21 
days of a previous CFPE; within 21 days of the start of the study; or if there was 
insufficient data due to absence or incomplete CMFs.  A period of stability could 
follow immediately on from a period of treatment for a CFPE, but could not 
include days when on treatment.  Paired averages were compared using the 
paired student t test. 
In total, there were 13 of 42 CFPEs that were excluded due to reasons outlined 
above.  Results for the remaining 29 CFPEs (28 for FEV1 data) are presented 
below in Table 4-17 below.  In general, all four VASs demonstrated a highly 
statistically significant difference between mean values at the time of 
exacerbation compared to during a period of preceding stability.   The difference 
between the medians at the two time points varied from 8 to 14.7 VAS points, 
with p values ranging from <0.0001 for Breath, Cough and Sputum VASs to 
0.002 for the General Wellbeing VAS. The difference in FEV1 was also 
significant (p = 0.005).  Further details of the above findings can be seen in 
Figure 4-32 Figure 4-33 below.  These two figures show that there is a clear 
deterioration in symptoms prior to a CFPE, and a commensurate improvement 
following the instigation of treatment.  However, both the symptoms and lung 
function continue to improve following the end of the treatment period. 
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Table 4-17 Differences in median values of CMF components at baseline and at 
CFPE.  (*= statistically significant at the 0.05 level Wilcoxon signed rank test) 
In addition to the assessment of whether the individual components of the CMF 
could detect differences between periods of CFPE and stability, the time of the 
stable period prior to the start of treatment was recorded, using the same 
criteria above.  Such analysis would cast light on the period of time where any 
aetiological agent causing a change in symptoms leading to a CFPE would be 
found, if such an agent exists). 
As might be expected, the overall values vary widely.  For the group as a whole 
there were 29 (of 42) analysable CFPEs, with a mean time of period of clinical 
stability of 24 days (±12) days prior to treatment for a CFPE.  
 






median (IQR)  p value 
13.7  21.7  <0.0001*  Br. VAS  29 
(7-21)  (15-38)   
16.0  28.0  <0.0001*  Cough VAS  29 
(7-26)  (18-37)   
13.3  28.0  <0.0001*  Sputum VAS  29 
(8-26)  (19-34)   
17.3  25.3  0.002*  GWB VAS  29 
(9-26)  (18-42)   
1.85  1.76  0.005* 
FEV1 (L.)  28 
(1.15-2.24)  (1.13-2.07)    
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Table 4-18 Last period of stability prior to CFPE, in days. 
4.4  Summary of Clinical Monitoring and CFPE 
In order to allow analysis of microbial changes before during and after CFPEs, a 
number of discrete CFPEs were selected for more detailed analysis.  Only 12 of 
the 14 subjects had a CFPE event.  One CFPE from each of these was 
selected, on the basis of temporal spacing away from other such events to allow 
each CFPE to be seen as discrete an event as possible.  Results of bacterial 
community analysis can be seen in Chapter 6 - .   Here are presented summary 
figures for the clinical monitoring during the CFPE that were selected for further 
bacterial community analysis. 
There was no variation in mean oral temperature before during and after the 12 
CFPEs.  Values at start of treatment were 36.7
oC (+0.7), compared to 36.8
oC 
(+0.39) at 21 days prior to treatment; p= ns.   
 
Subject 
No. of analysed 
exacerbations ( No. 
missing) 
Time of period of stability 
prior to CFPE in days (SD) 
1  3 (0)  13 (3) 
2  2 (1)  27 (1) 
3  N/A  N/A 
4  0 (3)  N/A 
5  4 (1)  21 (11) 
6  2 (0)  30 (7) 
7  4 (0)  24 (15) 
8  N/A  N/A 
9  1 (4)  43 
10  2 (0)  34 (2) 
11  2 (1)  44 (17) 
12  2 (2)  18 (5) 
13  4 (0)  14 (9) 
14  3 (1)  25 (8) 
  Total = 29 (missing 13)  Mean = 24 (12)  
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4.5   Discussion of Clinical Monitoring 
Few longitudinal studies in respiratory illness have used Visual Analogue 
Scales to monitor symptoms (Marshall 2004; Rosenfeld et al. 2001).  There are 







































































































Figure 4-33 Changes in Lung Function Before During and After Treatment for 
12 CFPE in 12 Subjects.  
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Score (Borg 1982).  VASs offer a much greater degree of freedom to subject, 
without imposition of artificially constraining metaphorical boxes (Gift 1989b).  
VASs have also been shown, in other clinical settings, to be more reproducible 
than either the Borg Score or the Likert Score for breathlessness (Grant et al. 
1999), and to correlate to Peak Expiratory Flow Rate in Asthmatics (Gift 1989a).  
Grant et al. showed that a VAS is also the most sensitive to changes in 
breathlessness, as quantified by full cardio-pulmonary exercise testing (Grant et 
al. 1999).  However, with this increased sensitivity to change, comes greater 
signal noise.  As these set of VASs are partially unvalidated in this longitudinal 
setting, it is unproven as to what constitutes a Minimal Clinically Important 
Difference (MCID) on an individual basis.  Ries et al. set out to determine an 
MCID for a breathlessness VAS and arrived at a figure of 10-20 mm.  However, 
it would be flawed to impose this value on results presented here.  First of all 
Ries et al. derived the value from interventional studies of Pulmonary 
Rehabilitation, with an intrinsic dichotomy that is lacking from the continuous 
variables studied here.  Secondly, imposing an objective external MCID is 
counter-intuitive to the idea that a subject sets their own internal controls for 
what is important in determining the perception of a symptom.  An example of 
this is provided by Subject 13 (see Section 4.2.13 above) who only had a total 
minimum to maximum range of 20 mm for Breathlessness VAS.  Within this 
range there were four clear CFPEs all requiring intravenous antibiotics and 
three of four being associated with a decline in FEV1.  If a MCID of 20 were 
imposed it is likely that no CFPEs would have reached the required threshold 
for a CFPE to be objectively diagnosed.  
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In addition to these concerns, the use of VASs makes inter-subject comparisons 
difficult.  As the anchor phases are interpreted subjectively by subjects, they do 
not provide a means of quantifying changes observed between subjects.  As 
can be seen from Figure 4-1 above the range of scores for any particular VAS 
varies greatly between subjects.  If FEV1 percentage of predicted is used as a 
rough approximation of object breathlessness, it can be seen that there is little 
relationship between FEV1% and the range of VAS scores.  For example, 
subject 10 has an FEV% of 86% predicted, but a median Breathlessness VAS 
of 60.  This is in contrast to subject 12, who has an FEV1% of 30% predicted 
yet a lower median Breathless VAS of around 12.  Despite this there has been 
shown to be a high degree of accuracy for the completion of VAS (see 2.7.1 
above).  In addition values for VASs are significantly higher in the week before 
treatment for a CFPE than in stable period in the preceding 60 days (see 4.3 
above).   
It can be seen from inspection of the Response Profile Plots for different 
subjects that changes in VAS appear to correlate better with the diagnosis and 
treatment of CFPE than in other subjects.  For example, VAS RPPs for subject 
10 do not appear to reflect the diagnosis and treatment of CFPEs.  In contrast, 
symptom worsening is clearly documented for most if not all CFPEs for subjects 
1, 5, and 14.  The reasons for such discrepancies between subjects are not 
clear. 
Thus, VASs appear to provide a good intra-subject record of symptoms, but a 
less good means of comparison between subjects. 
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Chapter 5 -  Results: Periodic Sampling at Times of 
Clinical Stability 
Bacterial diversity in CF airways has been demonstrated in previous studies 
(Bittar et al. 2008; Rogers et al. 2004).  Some researchers have studied 
temporal changes in bacteria using culture independent techniques (Sibley et 
al. 2008g) over short periods focusing on particular species.  No study however 
has taken a temporal approach to analysing if or how bacterial community 
diversity changes.  Thus, it has not been possible to understand the significance 
of differences in the bacteria detected in different patients.  Before studying 
CFPEs in relation to changes in the bacteria present, it was necessary to 
analyse the degree of flux in bacterial communities across time when subjects 
were clinically stable.  Through a better understanding the fluctuations seen in 
bacterial communities over the whole study period, the fluctuations seen around 
periods of greatest clinical instability (CFPEs) could be put in context and 
interpreted. 
In order to ensure that analysed samples came only from periods of stability, it 
was planned to analyse samples that were at least 30 days before the start, and 
30 days after the end of systemic antibiotics.  However, for some subjects that 
had more frequent exacerbations this was not possible.  Table 5-1 below gives 
details of the times that the ‘stable’ samples were taken with respect to the start 
of the study and to periods of systemic antibiotics before and afterwards.  The 
longest gap from ‘Last systemic antibiotics’ to analysed sputum sample was 
1195 days (Subject 03, sample iv).  The longest applicable gap from sample to 
‘Next systemic antibiotics’ was 265 days (Subject 08, sample i; antibiotics given 
for unrelated non-pulmonary reason).  Other subjects had no further recorded  
  172 
systemic antibiotics.  The shortest gap from ‘Last systemic antibiotics’ to 
analysed sputum sample was 5 days (Subject 05, sample ii).  The shortest 
applicable gap from sample to ‘Next systemic antibiotics’ was 6 days (also 
Subject 05, sample iii).  Due to the frequent CFPEs suffered by Subject 05, 
there were no samples which were more suitable for analysis.  
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Table 5-1 Times of Sputum Sampling at Times of Clinical Stability, With 
Reference to Periods of Systemic Antibiotics.  (Abx = antibiotics; N/A = not 
applicable). 
Patient number  Sample  Day  Days Since Last Systemic Abx  Days until next Systemic Abx 
1  i  5  > 30  81 
  ii  194  32  44 
  iii  296  39  n/a 
  iv  345  88  n/a 
2  i  64  49  29 
  ii  157  51  97 
  iii  304  35  n/a 
  iv  360  56  n/a 
3  i  15  851  n/a 
  ii  122  958  n/a 
  iii  243  1079  n/a 
  iv  360  1196  n/a 
4  i  1  41  175 
  ii  103  115  73 
  iii  318  57  32 
5  i  13  ?  52 
  ii  111  5  16 
  iii  148  12  6 
  iv  190  22  26 
  v  283  43  40 
  vi  290  50  33 
6  i  20  892  204 
  ii  146  1018  65 
  iii  288  26  n/a 
  iv  351  89  n/a 
7  i  27  218  149 
  ii  137  342  20 
  iii  218  57  20 
  iv  363  28  n/a 
8  i  10  > 30  265 (elective) 
  ii  127  > 30  148 (elective) 
  iii  255  > 30  21 (elective) 
  iv  362  81 (elective)  n/a 
9  i  5  18  128 
  ii  44  35  97 
  iii  100  91  39 
  iv  307  27  30 
10  i  19  31  89 (elective) 
  ii  103  86  3 (elective) 
  iii  234  97 (elective)  21 
  iv  316  52  20 
11  i  1  2989  79 
  ii  129  35  49 
  iii  255  32  n/a 
  iv  365  142  n/a 
12  i  69  33  50 
  ii  238  69  21 
  iii  371  166  n/a 
  iv  504  299  n/a 
13  i  1  267  39 
  ii  139  55  35 
  iii  297  35 (elective)  n/a 
  iv  365  103 (elective)  n/a 
14  i  64  36  59 
  ii  167  32  71 
  iii  204  69  34 
  iv  356  46 (elective)  n/a  
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It became apparent during preliminary analysis that the results were highly 
complex.  It was noted that they shared similarities with ecological results from 
other non-clinical studies.  Such studies have measured diverse communities 
(fish species in the Bristol Channel (Magurran & Henderson 2003)) and 
identified a division between species that are resident (core species) in the 
habitat in question, and a second group that can be identified as transient 
species (satellite species).  Such techniques were applied to the data in this 
study in order to better understand the species. 
In addition to core/satellite analysis, ecologists have used multivariate methods 
such as Principle Component Analysis to investigate complex data (Henderson 
& Seaby 2008).  Others have applied such techniques to other clinical 
microbiological studies, of the bacterial community of the human gut for 
example (Engelbrektson et al. 2006), but not to Cystic Fibrosis respiratory 
samples. 
5.1  Bacterial Clone Sequence Analysis 
As outlined in Section 1.3.2 above, each culture independent molecular 
technique has its strengths and weaknesses.  In brief T-RFLP is sensitive but 
does not provide an absolute species identification.  However, it is relatively 
inexpensive and rapid, enabling the analysis of a large numbers of samples.  
There is also the theoretical risk that it may underestimate the number of 
species due to co-migration of two species with the same T-RF band length.  
However, it should be noted that this unlikely as there a median of 7.5 bands 
detected, spread over a possible range of more than 900 positions.  In contrast, 
bacterial 16S clone sequence analysis is extremely specific, giving as exact a  
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speciation as is possible, but using current technologies, is extremely labour 
and cost intensive.  In an attempt to improve the resolution of species/bands 
detected by T-RFLP during the longitudinal analysis, clone sequence analysis 
was employed on one sample from each subject.  To some extent this allowed 
validation of the diversity detected by T-RFLP.  It also allowed bands detected 
by T-RFLP to be assigned species names with a far greater degree of certainty, 
particularly in cases where the T-RFs of different species co-migrate to occupy 
the same band length position. 
One sample from each of the 14 subjects was subjected to bacterial clone 
sequence analysis.  Samples were chosen as close to the start of the study 
period as possible, at a time of clinical stability.  A total of 2137 clones were 
analysed, with the number of clones per patient ranged from 90 to 258 (mean 
153). The closest species matches to these sequences (at the level of 97% 
similarity) represented a total of 82 different bacterial species. These species 
were from four bacterial groups and 35 separate genera. 
The number of different bacterial species identified per patient, as indicated by 
their closest species match, ranged from 2 to 42 (median 7.5; IQR 5.75-17.75)). 
It should, however, be noted that the similarity of the sequences to the 
published sequence data from particular bacterial species differed in many 
cases between clones. Further, in some cases the sequence similarity to the 
closest species match was as low as 82%, and 86% (Alistipes shahii, Sample 
14 and Barnesiella viscericola, Sample 1, respectively).  Given that many 
accept a genetic similarity level of 97% or greater to confer a species (Hey 
2001), this would suggest that these are in fact new, previously undescribed 
species.  
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Sequences that most closely matched P. aeruginosa were detected in 13 of the 
14 samples (the only sample in which it was not represented was Subject 01). 
P. aeruginosa clones represented a mean of 78.5% (SD±21.6) of the clones in 
samples in which it was detected, and represented the numerically dominant 
species in all of these 13 samples.  
Of the other recognised CF pathogens (namely S. aureus, H.  influenzae, 
Burkholderia cepacia complex, and S. maltophilia (Gilligan 1991; Lyczak, 
Cannon, & Pier 2002) only S. aureus, H. influenzae and S. maltophilia were 
detected in any of the cloned sequences, with each detected in one sample 
only. One sequence derived from S. aureus was detected in the sample from 
Subject 01, representing 0.78% of the sequences from that sample.  Five 
sequences derived from H. influenzae were detected in the sample from 
Subject 14, representing 1.9% of the sequences from that sample.  Four 
sequences derived from S. maltophilia were detected in the sample from 
Subject 01, representing 3.1% of the sequences from that sample. 
The same samples were also subject to standard bacterial culture as described 
in Section 2.2.1 above, to allow comparison of species detected and identified.  
The results of selective bacterial culture are presented in Table 5-2.  In 11 of the 
13 subjects for whom results from the comparable sputum sample were 
available, P. aeruginosa was identified.  From 10 of 13 subjects ‘Oral flora’ was 
detected.  In 6 of the 13 subjects a fungus was detected.  MRSA was identified 
in one subject.   
Within the sequence set there were 16 genera, from four different Groups, that 
have not been reported in the literature as having been detected, either by 
culture-based analysis of molecular-based analysis, within CF lung infections.  
  177 
The 17 species that this represents, the samples from which they were derived, 
and the number of clones per species, are shown in Table 5-2 below. 
Figure 5-1 Rank abundance for species detected by bacterial clone sequence 
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Table 5 2 Bacterial species identified by clone sequencing that have not 
previously been reported in CF respiratory infections. 
 
Species  Subject 
Number of 
clones 
Alistipes shahii  14  1 
Alishewanella fetalis  8  1 
Barnesiella viscericola  1  1 
Catonella morbi  1  9 
  6  2 
Clostridium metallolevans  13  1 
Dialister invisus  1  1 
Dorea longicatena  12  1 
Gemella haemolysans  5  2 
  6  3 
  14  1 
Megasphaera micronuciformis  1  3 
  6  4 
Mogibacterium neglectum  1  2 
Oribacterium sinus  6  1 
Rothia dentocariosa, Rothia proteobacteria  9  1 
  14  1 
Selenomonas infelix  14  3 
Tannerella forsythensis  1  1 
Terrahaemophilus aromaticivorans  1  8 
  6  5  
  179 
Table 5-2 Semi-quantitative bacterial culture result for samples also subjected to bacterial clone sequencing. 
Subject  “Species” 1  “Species” 2  “Species” 3  Species 4 
01  Oral Flora (+)       
02  P. aeruginosa (+++)  Pseudomonas spp. (+++)  Oral flora (++)  Aspergillus fumigatus (+++) 
03  Oral Flora (+)  P. aeruginosa mucoid (++)  Pseudomonas spp. (++)   
04  MRSA (S. aureus) (+)  Oral flora (+++)     
05  Pseudomonas spp. (+++)  Oral flora (+++)  P. aeruginosa mucoid (+++)  Aspergillus fumigatus (+++) 
06  Pseudomonas spp. (+++)  Yeasts (Scanty Growth)  Oral Flora (+++)  P. aeruginosa (+++) 
07  P. aeruginosa (+++)  P. aeruginosa mucoid (+++)     
08  Pseudomonas spp.  (+++)  Aspergillus fumigatus (+)  Yeasts (+)  Oral Flora (+++) 
09  Pseudomonas spp.  (+++)  Pseudomonas spp.  (+++)  Pseudomonas spp.  (+++)  Oral Flora (+++) 
10  Data Missing 
11  P. aeruginosa (+++)  Pseudomonas spp. (+++)  Yeasts (+)  Aspergillus fumigatus (+) 
12  Pseudomonas spp.  (+++)  Pseudomonas spp.  (+++)  Pseudomonas spp.  (+++)  Oral Flora (+++) 
13  P. aeruginosa mucoid (+++)  Pseudomonas spp. (+++)     
14  Pseudomonas spp. (+++)  Pseudomonas spp. (+++)  Oral Flora (+++)    
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5.1.1 Classification of Bacteria Detected by Clone Sequence 
Analysis 
5.1.1.1  Aerobes vs. Anaerobes 
The full list and identity of bacterial clones has been included in the Appendix 
(Table 9-1 below).  In summary there are a total of 82 species, 36 (44%) of 
which have been considered to be obligate anaerobes.  The remaining species 
(n=46, 56%) can be classified as aerobes, which includes microaerophiles, 
facultative anaerobes and aerobes (Brenner et al. 2005) 
5.1.1.2  Bacteria Associated with the Human Oropharynx 
Bacterial clone sequence analysis allows accurate speciation of clones.  In 
Appendix Table 9-1, it can be seen that 59 of 82 (72%) of identified bacterial 
species are associated with the human oropharynx based on an analysis of the 
literature available (Aas et al. 2005; Brenner et al. 2005; Gibbons et al. 1963; 
Igarashi et al. 2009; Sakamoto, Umeda, & Benno 2005).  This includes species 
from the genera Prevotella , Porphyromonas, Veillonella and Rothia.  Other 
bacterial groups have been associated with other parts of the human 
microbiota, such bacteria from the genus Bacteroides, which are associated 
with the normal human gastrointestinal tract flora (Brenner et al. 2005).   
5.2  TRFLP Sampling Overview 
5.2.1  TRFLP 
Results of periodic analysis of samples from each subject at periods outside of 
treatment for CFPEs are presented below.  The mean bacterial species 
richness by T-RFLP compared to species detected by culture are presented in 
Figure 5-4 and Table 5-4.  Across the four time points in the study, the mean  
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number of species detected by T-RFLP ranged between 5.4 species (SD±2.5) 
and 6.4 species (SD±2.7).  Mean bacterial species richness as detected by 
culture varied from 1.6 to 2.0 species (SD±0.49-0.67).  Using the unpaired 
student t test, differences in the means for species richness by T-RFLP and 
culture was highly statistically significant (p<0.0001) at all time points.  In 
addition to this difference, there was no correlation between the number of 
species detected by culture and the number of species detected by T-TFLP 
(Spearman’s rho 0.675; p=NS). 
In order to assess the similarity between consecutive samples, the Sorensen 
Index of Similarity was used as described in Section 2.5 above.  The results for 
both T-RFLP and culture are presented, for all subjects in Figure 5-5 below.  
The lines representing the mean Sorensen Index for the 14 subjects at each 
time point for both culture and T-RFLP are not statistically different, even 
though the actual number of species detected by the two techniques was 
different (see above).  This shows that the likelihood of two consecutive 
samples being bacteriologically similar are the same whether the means of 
testing is culture based or by T-RFLP.   
The individual fluctuations in bacterial profiles by T-RFLP over the 12 months 
are presented  Figure 5-2 and Figure 5-3 below.  It can be seen that some 
subjects showed remarkable consistency, with species detected across long 
periods of time (e.g. subjects 1, 2, 3, 6, 7, 11, 13 and 14), despite courses of 
antibiotics for CFPEs in most cases, and long term antibiotic therapy in all.  In 
others however, there is considerable flux of species across the time points (4, 
5, 8, 9, 10 and 12).  There is no correlation between disease severity and mean  
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Sorensen Index (Pearson correlation coefficient; data not shown), although the 
low numbers of subjects limits the power to detect a real difference.   
Table 5-3 Top three most dominant species/bands by T-RFLP.  'S' and 'U' = 
Stable and Unstable bacterial communities over time. 
 
Subject  Stable or Unstable   Most Dominant  Second Dominant  Third Dominant 
1  S  Sp. 17  T. forsythensis / A. 
shahii / C. gracilis  Sp. 27 
2  S  P. aeruginosa  R. dentocariosa  Sp. 39 
3  S  P. aeruginosa  R. dentocariosa 
Porphyromonas. / 
Prevotella. / Bacteroides 
sp. 
4  U  Prevotella  sp.  Sp. 17  Sp.1 
5  U  P. aeruginosa  Sp. 17  Prevotella mel. 
6  S  P. aeruginosa  H. parainfluenzae  Megasphaera m. 
7  S  P. aeruginosa  R. dentocariosa  Sp. 23 
8  S  P. aeruginosa  Veillonella spp.  Prevotella spp. 
9  U  T-RF 212  P. aeruginosa  H. parainfluenzae 
10  U  P. aeruginosa  H. parainfluenzae  H. parahaemolyticus 
11  S  Sp.17  T. forsythensis / A. 
shahii / C. gracilis  P. aeruginosa 
12  U  Sp. 17  Sp. 19  Sp. 10 
13  S  Sp. 17  T. forsythensis / A. 
shahii / C. gracilis  P. aeruginosa 
14  S  Sp. 17  P. catoniae  P. aeruginosa  
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Figure 5-2 Bacterial Community Stability over Study Period (Time – X axis), for 
Subjects (S.) 01-08.   Y axis is percentage of community.  Black triangles 
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Figure 5-3 Bacterial Community Stability (DNA) over Study Period (Time – X 
axis), for Subjects (S.) 09-14.   Y axis is percentage of community.  Black 
triangles represent percentage of P. aeruginosa.  Values represent PMA treated 
T-RFLP results. 
Figure 5-4 Mean bacterial species richness, measured by T-RFLP and culture.  
*p<0.0001 across all time points by unpaired student t test.  Y-axis error bars 
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Figure 5-5 Similarity between bacteria in samples at four time points of clinical 
stability using Sorensen Index , by T-RFLP and culture. Y-axis error bars 
represent 95% confidence intervals. There was no significant difference between 
the methods of bacterial detection. 
. 
Table 5-4 Species richness and similarity between samples during periods of 
clinical stability.  *=statistically significant difference between the means by 






































Bacterial Species Richness  Sorensen Similarity Index 
Subject  Culture  T-RFLP  Culture  T-RFLP 
1  2.50  5.50  0.79  0.89 
2  2.00  3.25  0.88  0.93 
3  1.75  3.50  0.83  0.96 
4  1.67  2.33  0.33  0.60 
5  1.50  5.50  0.67  0.80 
6  1.25  10.00  0.89  1.00 
7  1.50  3.25  0.83  0.96 
8  2.25  5.75  0.83  0.69 
9  1.75  9.00  0.83  0.58 
10  2.00  8.25  1.00  0.79 
11  1.75  5.25  0.83  0.93 
12  2.00  5.50  1.00  0.90 
13  1.75  7.25  0.92  0.89 
14  2.00  6.50  1.00  0.75 
Total  1.83*  5.77*  0.83  0.83  
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5.2.2 Comparison of Bacterial Community Structure by 
Genotype 
In order to investigate whether Cystic Fibrosis genotype exerted an influence on 
bacterial community structure, subjects were divided into those who were 
known to be homozygous for the F508 mutation, and those who were 
heterozygous for the F508 mutation, with the second allele being another, non-
F508, mutation.  The results are presented in Figure 5-6 below.   
Figure 5-6 Comparison of bacterial community slope by CF genotype over four 
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Figure 5-7 Comparison of bacterial community similarity by CF genotype, using 
Sorensen Index (=Sor.). 
Figure 5-8 Bray-Curtis Similarity Index by CF genotype. 
It can be seen that there are significant differences between heterozygotes and 
homozygotes by similarity indices.  For heterozygotes and homozygotes, the 
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were statistically different (p=0.01) as were the comparable findings for the 
mean Bray-Curtis Index i.e. 0.78 (±0.18) vs. 0.60 (±0.29) respectively (p=0.03). 
 
5.2.3 Comparison of Bacterial Community Structure by Lung 
Function 
In order to determine if interplay between lung function and bacterial community 
structure, the 14 subjects were divided in to two groups on the basis of their 
stable lung function at the start of the study.  The chosen cut off for lung 
function was an FEV1 of 50% of the predicted value.  Using this classification 
two groups were 6 ‘Low’ lung function (FEV1 <50% predicted), and 8 ‘High’ lung 
function (FEV1 >50%).  These groups are as shown in Table 5.8 with low lung 
function patients including subjects 3, 4, 5, 6, 9 and 12 and high function 
patients including subjects 1, 2, 7, 8, 10, 11, 13 and 14. 
  Subject 
Low Lung Function (FEV1 <50%)  3, 4 , 5 , 6 , 9 ,12 
High Lung Function (FEV1 >50%)  1 , 2 , 7 , 8 , 10 , 11 , 13 , 14 
Table 5-5 Division of Subjects by Lung Function during a period of clinical 
stability at the start of the study 
The mean bacterial community slope was calculated for each of the four stable 
time points.  In the low lung function group the mean (±SD) slope was 0.46 
(±0.33), compared to a mean slope of -0.27 (±0.31) for the high lung function 
group (The results are presented in Figure 5-9 below).  It can be seen that  
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subjects with lower (worse) lung function have a statistically significantly steeper 
bacterial community slope, with the difference between the two groups giving a 
p value of 0.02.   
The relationship between similarity indices and lung function was assessed. As 
described in Methods Section (see 2.5 above) the Sorensen Index and the 
Bray-Curtis Index both measure the similarity between two ecological 
communities, using binary and quantification values respectively.  The amount 
of flux between subjects with high and low lung function, as measured using 
both the Sorensen and Bray-Curtis Index, and presented in Figure 5-10 below.  
Sorensen Index mean (±SD) for Low FEV1 0.74 (±0.24) and for the High FEV1 
group 0.82 (±0.17); p=NS.  The Bray-Curtis Index was 0.58 (±0.34) for the Low 






































Figure 5-9 Comparison of bacterial community evenness by Lung Function.   * 
p value = 0.02.  
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One further analysis between the high and low lung function groups was 
undertaken.  The results of the comparison of bacterial diversity between High 
and Low FEV1 groups are presented in Figure 5-11 below.  The overall mean 
for the high lung function group was 6 (SD± 0.7) species per sample.  The 
overall mean for the low lung function group was lower at 5.25 (±0.70) species 
per sample.  The difference between the two groups was statistically significant 






























Figure 5-10 Similarity indexes by Lung Function.  Sor.= Sorensen Index; 
B-C = Bray-Curtis Index.  Difference between Sorensen Index = NS; 
diffierence between groups by Bray-Curtis Index p = 0.036, using 
unpaired t test.  
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5.2.4 Comparison of Bacterial Community Structure by Gender 
In order to determine if there existed interplay between lung function and 
bacterial community structure, the 14 subjects were divided on the basis of their 
gender.  There were 8 females and 8 males (see Section 3.1.1 above). 
Results for bacterial community structure by gender are presented in Figure 
5-12 below.  The mean (+SD) slopes for females and males respectively were -
0.48 (+0.04), and -0.26 (+0.05).  This difference was statistically significant (p= 



































Figure 5-11 Species richness for 4 stable samples from each subject, 
separated by Lung Function. *  p = 0.048, using unpaired t test.  
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Further assessment of the bacterial community differences between genders 
was done, using measures of similarity between consecutive samples. 
Results separated by gender for the Similarity Indexes are presented in Figure 
5-13  below.  The mean values (+SD) for the Sorensen Index for females and 
males respectively are 0.79 (+ 0.09) and 0.78 (+0.03); p = NS.  The mean 
values (+SD) for the Bray-Curtis Index for females and males respectively are 
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Figure 5-12 Bacterial community slope for 4 stable samples from each 
subject, separated by gender. *  p = 0.0004, using unpaired t test. Error 
bars represent standard deviation.  
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In order to assess the differences in bacterial communities between males and 
females further, the results of bacterial community profiles from the stables 
samples were analysed using Principle Component Analysis.  The results are 
presented in Figure 5-14 below.  There is no significant clustering by gender.  
This shows that there are no major underlying patterns in the structure of the 
bacterial community in terms of its composition between males and females.  

































Figure 5-13 Similarity Indexes (Sor. = Sorensen Index; B-C = Bray-Curtis Index) for 4 
samples from each subject during clinical stability, separated by gender.  # p=NS; * p 
= 0.01, using student unpaired T Test.  Error bars represent standard deviation.  
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5.3  Core/Satellite Analysis of Species Detected 
As previously discussed, not all subjects had sufficiently large numbers of 
samples analysed over the whole study period to allow such analysis.  
However, Subject 09 had 125 samples analysed, the core-satellite analysis of 
which are presented in Figure 5-15 below. 
 
Figure 5-14 Principle Component Analysis of 4 stable samples from each subject, 
differentiated by gender. Filled-in squares = female; white triangles = males.  
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From this, in Figure 5-15 above, it can be seen that a total of four bands 
constitute the core species, each of which was detected in at least 80% of 
samples. These can be seen to the right of the dividing black arrow.  These four 
core species of the bacterial community for Subject 09 were: 
1.  T-RF band length 104 (derived from either Porphyromonas 
veroralis or melaninogenica, or Prevotella pallens). 
2.  T-RF band length 634 (derived from Porphyromonas 
melaninogenica). 
3.  T-RF band length 212: a less specific band length, associated with 
at least six different species/genera (possible matches include 
Neisseria meningitidis, S. maltophilia, N. chinerea, and 
Actinomyces naeslundii and viscosus) 
4.  T-RF band length 155: P. aeruginosa. 
70
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Figure 5-15 Subject 09: Species-Frequency chart to determine constituents of core species 
(DNA).  Numbers above bars represent actual values for each bar. Species to the right of 
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The same analysis was performed on results from RT-T-RFLP, with similar 
results (data not shown).   
5.4  Discussion 
Different culture independent techniques were employed to analyse bacterial 
diversity in CF sputum over a 12 month period.  The results from 16S ribosomal 
RNA gene clone sequence analysis confirm findings from previous studies 
(Bittar et al. 2008; Rogers et al. 2005; Sibley et al. 2008d) demonstrating higher 
levels of bacterial diversity than are detected by culture.  Interestingly, however, 
such levels of diversity are in fact much lower than those seen elsewhere.  For 
example, other natural environments may harbour 6000-12,000 different 
species per gram, depending on the environment (Torsvik, Ovreas, & Thingstad 
2002).   
The results of the periodic sputum sample analysis by T-RFLP demonstrate two 
patterns of bacterial community stability over time.  Such stability over time has 
not previously been described in CF respiratory samples.  Others in non-clinical 
studies have however, found similar degrees of stability over time.  In bacterial 
communities from oceanic sediments, Pringault et al. (Pringault et al. 2007) 
described quantitative similarity indices over time of over 0.6 (or 60%).  This 
compares to an over all value 0.68 (or 68%) in the subjects of this study.  There 
are a number of subjects who have very stable bacterial communities over time.  
In these nine “stable” subjects the species hierarchy in the rank abundance 
curve remaining unchanged in both position and relative proportions.  This is 
despite all but one of them experiencing CFPEs and receiving antibiotics during 
the study period.  Six of this group of eight also received intravenous antibiotics  
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at least once for a CFPE.  In contrast, subjects 4, 5, 9, 10 and, to a lesser 
extent, 8 and 12, show a high degree of bacterial community instability during 
the study period.  This group included three of the subjects with the worst 
respiratory function (5, 9 and 12) who had frequent prolonged courses of 
intravenous antibiotics.  However, it also included subjects 8 (who had no 
CFPEs) and subject 10 who had the least impaired respiratory function of the 
cohort. 
This data can be contrasted to other situations.  In an interventional study to 
assess the effects of 7 days of oral clindamycin on normal faecal gut bacterial 
communities, Jernberg et al. demonstrated large changes at 7 and 21 days 
after administration of clindamycin, as assessed by Correspondence Analysis 
(Jernberg et al. 2007).  These changes persisted in the Bacteroides species 
population for up to two years, but not for when assessing the overall wider 
bacterial community.  However, more recently Dethlefsen et al. reported that, 
using high a throughput pyrosequencing technique, a short course of oral 
ciprofloxacin reduced antibiotic diversity for a few weeks only (Dethlefsen et al. 
2008).  By four weeks after treatment bacterial communities structure had 
recovered to be similar to pre-treatment structure.  In a similar finding to 
Jernberg et al., Dethlefsen et al. also noted that some taxa failed to return to 
pre-treatment levels by 6 months.  Thus it appears that the effects of antibiotics 
on established bacterial communities are short lived, although effects on 
individual groups of bacteria may be more persistent.   
In non-clinical environmental situations, there is little that is comparable to the 
concept of a CFPE.  However, Pringault et al. studied microbial communities, 
using T-RFLP, from tropical marine sediments in summer and winter found no  
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seasonal fluctuations of bacterial diversity (Bahrani-Mougeot et al. 2008; 
Colombo et al. 2009; Tunney et al. 2008). 
Pseudomonas. aeruginosa was found, by T-RFLP, to be in the top most 
abundant in 11 of the 14 subjects and was the most consistently dominant 
species in only 7 of those 11 in which it is found.  Thus in 7 of 14 subjects 
(50%), species other than P. aeruginosa were most dominant.  None of these 
other species have been identified as typical CF respiratory pathogens (Lyczak, 
Cannon, & Pier 2002).  The species detected in this study  include Species 17 
at band length 268, which is otherwise uncharacterised, and was the dominant 
species in 5 of the 14 subjects.  Prevotella species were also prominent, being 
the most dominant species in one subject, and present in the top three species 
for two other subjects, and a possible candidate in one other.  Prevotella  
species are strictly anaerobic (Brenner et al. 2005), and frequently found in the 
gingival crevice in humans, particularly in periodontitis (Aas et al. 2005).  They 
are less well characterised as a pathogen beyond the oral cavity, but have been 
reported in high numbers from the CF lung previously (Tunney et al. 2008; 
Worlitzsch et al. 2009) using culture independent and anaerobic culture 
techniques.  Its role as a pathogen in the aetiology of CFPEs and CF lung 
disease has not been established.  Another genus detected that is also a 
recognised oral inhabitant was Veillonella (Bittar et al. 2008; Tunney et al. 
2008).  Interestingly, species from this genus have been shown to be capable of 
forming biofilms and communicating and influencing other bacterial species 
(Egland, Palmer, Jr., & Kolenbrander 2004).  In addition species from the genus 
Porphyromonas also appeared twice in the list of top three species.  Species 
from the genus Porphyromonas are also associated with periodontal diseases  
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(Faveri et al. 2009), and have been previously reported from the CF lung (Bittar 
et al. 2008; Tunney et al. 2008). 
Another frequently detected species was Rothia dentocariosa.  R. dentocariosa 
is another typical inhabitant of the upper respiratory tract (Aas et al. 2005).  
Species from the genus Rothia have been previously detected from airway 
samples from CF subjects (Bittar et al. 2008; Tunney et al. 2008).  In three 
subjects it occupied one of the top three positions, each time in the second 
most dominant position.  It is an anaerobe or facultative aerobe (Brenner et al. 
2005), and has been associated with disease distant to the upper respiratory 
tract and lung, but only infrequently (Morris et al. 2004; Sadhu, Loewenstein, & 
Klotz 2005).   
It is note-worthy that the two subjects that appeared to have the greatest 
bacterial species “instability” over time were subjects 05 and 09.  They were the 
most frequent exacerbators, had the worst lung function, and both have since 
gone on to be assessed for possible lung transplantation.  It not possible to 
determine cause and effect, but there are a number of possible explanations for 
this link between pulmonary disease severity and bacterial community 
instability.  First, it is possible that the frequent courses of intravenous 
antibiotics (5 and 6 courses of IV antibiotics respectively) that these two 
individuals received drove the flux in bacterial species seen.  Although 
plausible, there is little evidence from the work presented here, or other 
published work (Dethlefsen et al. 2008; Jernberg et al. 2007) that IV antibiotics 
(and other associated treatments) do in fact have any dramatic long term effect 
on bacterial communities.  A second possible explanation is that such flux is in 
fact the driving factor behind the worse pulmonary health.  This may be a partial  
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explanation as there is a correlation between lung function and structure of the 
bacterial community (see Figure 5-11 above).  Additionally there may be a 
relationship between lower lung function and less similarity between adjacent 
samples using the quantitative Bray-Curtis Index (see Figure 5-10).  There is a 
further explanation based on heterogeneous lung damage and mucociliary 
clearance.  The CF lung becomes damaged in a heterogeneous way: some 
parts of the lung are more damaged than others.  With the heterogeneity comes 
the possibility that separated, or partially separated communities exist with a 
given set of lungs.  These separate environments may develop due to different 
amounts of ventilation (Gustafsson et al. 2008) and perfusion that may produce 
different habitats.  In addition stochastic processes are known to be important in 
the composition of bacterial communities (van der Gast, Ager, & Lilley 2008).  
This is likely to lead to different communities of bacterial in different parts of the 
damaged lung.  In addition, as more areas of the lung become less well 
ventilated, inhaled antimicrobial therapies will not reach the worst affected parts, 
particularly those areas distal to impacted inspissated secretions.  As lung 
function worsens this increased heterogeneity of lung habitats may result in 
sputum samples containing a more varied composition of bacteria, from 
different parts of the damaged lung.  Support for a heterogeneous distribution of 
inflammation during CF pulmonary exacerbations comes from studies using 
recent advances in imaging (Klein et al. 2009), as well bronchoscopic studies 
assessing inflammation and microbiology from different lobes (Gutierrez et al. 
2001) Additional support for a theory of regional bacterial heterogeneity comes 
from studies of serial induced sputum in CF.  Rogers et al showed that in any 
one given induced sputum sample an average of 58% of the total expectorated  
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bacterial community, as detected by T-RFLP, could be detected (Rogers et al. 
2010). 
The significance of bacterial community stability over time is unclear.  The first 
point is that it is surprising that the bacterial communities are so persistent over 
time.  Clinicians and patients make vigorous, expensive and time-consuming 
attempts to treat, disrupt and challenge the bacteria of the lower airway in CF  
(Elkins et al. 2006; Fuchs et al. 1994; Ramsey et al. 1999).  Despite this effort, 
relatively little impact appears to be made on these bacterial communities of the 
lower airways during the course of one year.  However, it should be made clear 
that all subjects were on long term antimicrobial therapy, and thus it is possible 
that treatment is contributing to the stability of the bacterial community, perhaps 
by preventing the establishment of new species in the pre-existing bacterial 
community. 
The differences in bacterial communities seen between the genders are of 
interest.  The evenness, or slope, of the bacterial community was found to be 
statistically steeper in females than males (see Section 5.2.4 above).  There is 
no evidence to support an explanation for such a finding, but it is interest that 
females with CF are reported to have a faster rate of decline in lung function 
than males, and thus a shorter overall life expectancy (Corey et al. 1997; Liou et 
al. 2001).  In addition there are significant differences in similarity over time 
between those with a more severe genotype, and those with a milder genotype.  
Those with a milder genotype maintain greater similarity over time than do 
those with a more severe genotype (Corey et al. 1997; McKone, Goss, & Aitken 
2006).  Given that those with a more severe genotype have more severe 
pulmonary disease and shorter life expectancy, this could suggest that a more  
  202 
stable community is associated with less severe disease.  However, those with 
more severe disease may also receive more antimicrobial therapy. 
The presence of large quantities of anaerobic bacteria identified by clone 
sequence analysis and also detected longitudinally by T-RFLP is unsurprising 
when reviewing recent literature.  Many other researchers have produced 
similar findings.  It is noteworthy that  wide range of techniques for detection 
have been employed, including culture of at least some samples obtained 
bronchoscopically from the lower respiratory tract secretions (Harris et al. 2007; 
Tunney et al. 2008).  This point is of importance because the oropharynx is well 
known to be an environment that harbours many species of anaerobic bacteria, 
and samples obtained by passage of secretions directly through the 
oropharynx, as is the case with spontaneously expectorated samples, have the 
theoretical potential to be contaminated with these bacteria.  Samples obtained 
bronchoscopically avoid this potential, and thus this work, along with work 
comparing sputum and mouthwash samples (Tunney et al. 2008) demonstrates 
that anaerobic bacteria in sputum samples really are from the lower respiratory 
tract and not contamination from the oropharynx. 
Once this point is accepted, that anaerobic bacteria really are present in the 
lower airways of patients with CF, the question arises as to where they 
originated from.  Answers to such questions might provide opportunities to 
intervene therapeutically to prevent, delay or reduce the immigration of bacteria 
to the lower airways, and potentially reduce bacterial induced lung damage. 
  
  203 
Chapter 6 -  Results: Flux around treated CF Pulmonary 
Exacerbations 
Due to the very large number of samples collected in the course of this study, 
and the involved and labour intensive process by which samples were analysed 
by T-RFLP and RT-T-RFLP, it was not possible to analyse all samples received.  
For patients experiencing a CFPE, one example from each was studied.  At 
least three samples prior to each CFPE, and from at least 21 days before the 
start of systemic treatment, were analysed.  At least three samples from during 
the treatment period were analysed.  If possible, one or more samples were 
analysed from after the end of systemic antibiotics.  The analysis of samples 
starting 21 days before the treatment period was chosen as a clinical and 
microbiological decision based on experience of the time course in fluctuations 
in symptoms.  Additional time points were chosen in an attempt to capture a 
range of variations across the whole course of a CFPE, before, during and after 
treatment.  The antibiotics used for each of the analysed exacerbations are 
presented in Table 6-1 below.  When a subject had more than one CFPE, the 
decision as to which one to analyse was taken on the basis that the driving 
forces for change leading to a CFPE would be the same, irrespective of the type 
of treatment given for that CFPE (i.e. oral or intravenous antibiotics).  
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Table 6-1 Antibiotics used in each of the CFPEs analysed in chapter 6. 
In addition to the analysis of one CFPE from each subject, three subjects were 
selected to have all of their CFPEs analysed.  These three subjects were 
representative of three different clinical phenotypes: subject 02, subject 09 and 
subject 14. 
There are other chronic respiratory conditions such as COPD in which bacteria 
persist in the lower airways. In COPD Patel et al. demonstrated that it is useful 
and valid to divide patients into frequent exacerbators and infrequent 
exacerbators (Patel et al. 2002).  Such an approach was adopted here to 
determine if any bacterial community characteristics pre-disposed to more 
frequent CFPEs.  In the work of Patel et al., the division between frequent vs. 
infrequent exacerbations was determined to be 2.58.  For the practicality 
necessities of this study, subjects were defined as Frequent Exacerbators if 
they had >3CFPEs per annum (in the study period), and infrequent if they had 
less than three CFPEs.  See Table 6-2 below. 
Subject 
Number  Antibiotic One  Antibiotic Two  Antibiotic Three 
1 
Ciprofloxacin 
PO     
2  Colomycin IV  Tobramycin IV   
4  Doxycycline     
5  Meropenem IV  Amikacin IV  Ciprofloxacin PO 
6  Ceftazidime IV  Gentamycin IV   
7  Doxycycline     
9  Meropenem IV  Colomycin IV   
10  Ceftazidime IV  Gentamycin IV   





PO   
13  Ceftazidime IV  Gentamycin IV   
14  Meropenem IV  Tobramycin IV    
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Table 6-2 Classification of Subjects by Frequent vs. Infrequent Exacerbators 
6.1  Variations in Species Richness 
6.1.1 Single CFPE from Each Subject 
Species richness varied over time.  Time Point Zero is for samples taken 
immediately before the commencement of therapy for a CFPE.  At 21 days 
before the start of treatment, mean (±SD) bacterial species richness was 6.67 
(±3.25) per sample, compared to 4.42 (±2.60) per sample at day zero (p= 0.04 
by paired t test).  Figure 6-1 below shows these variations.  There is no clear 
recovery in species number either during or after treatment. 
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Figure 6-1. Bacterial species richness before, during and after 
antibiotic treatment for CFPE.  
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Table 6-3 Comparison of mean species richness between time points before 
CFPE, using paired t test.  *= statistically significant at 0.05 level. 
Species richness at Day-14 before the start of a CFPE was 6.3 (±3.5) per 
sample (p=0.03 compared to Day-0; paired t test), and at Day-7 was 6.6 (±3.3) 
per sample (p=0.08 compared to Day-0; paired t test).   
Four periods were grouped (Pre-CFPE; day zero (pre-antibiotics); during 
antibiotics; and Post-antibiotics), the mean number of species detected per 
sample were as follows 5.9 (n=36; SD 3.4), 3.6 (n=12; SD=2.2), 4.8 (n=23; SD 
3.1).   Mean bacterial species richness was statistically higher in the pre-CFPE 
period than at the time of CFPE (p=0.03).  No other significant differences 
between the periods in relation to bacterial species richness were observed.  
See Figure 6-2 below. 
  Mean species number 
(±S.D.) 
Comparison of mean to day zero;  
p value 
Day -21  6.67 (+3.25)  0.04* 
Day -14  6.34 (+3.47)  0.03* 
Day -7  6.58 (+3.34)  0.08 
Day 
Zero 
4.42(+2.60)  N.A.  
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Figure 6-2 Species Richness before during and after antibiotic treatment for 
CFPE.  * = p value significant at 0.05 value.  All other pairings p=N.S., using 












































































































































Figure 6-3 Bacterial Community Richness for Subject 09.  Results are from DNA 
profiles not treated with PMA.  Boxed areas denote systemic antibiotics, the first 
four (‘stippled’) areas were clinician defined CFPEs, whilst the fifth (‘hatched’) 
area denotes elective antibiotics. 
p=0.03*  
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In order to ascertain if similar patterns of perturbations in the bacterial 
community to those seen in one CFPE from 12 different subjects would also 
occur in CFPEs from just one subject, all the analysable CFPEs from subject 09 
were analysed (CFPE n=4).  Species richness in the three periods before during 
and after treatment for a CFPE, mean (+SD) species richness was 10.2 (+4.5), 
7.5 (+3.8), and 11.6 (+2.2) species respectively.  Using the student’s unpaired t 
test, the probability of the differences between groups being significant was: Pre 
vs. during, p= 0.007; pre vs. post p=ns; during vs. post p<0.0001.  This 
suggests that the number of species detected before antibiotic and after 
antibiotics are given is much higher than during a period of systemic antibiotics. 
6.2  Variations in Species Evenness 
In order to assess the evenness of the bacterial community, the slope of the 
logged values of the ranked abundances was calculated (see 2.6 above).  Mean 
values for at various time points before, during and after the start of treatment 
for a CFPE, are presented in Figure 6-4 below, with a mean FEV1 plotted for 
comparison. 
In Figure 6-4 a trend towards a steeper slope in the bacterial community at the 
time of CFPE compared to the preceding 21 days was observed.  This was not 
statistically significant with p>0.05 in all comparisons.  
In the time periods both during and following the administration of antibiotics, no 
clear trend was observed.  However, it is worth noting that the introduction of 
treatment for a CFPE has not resulted in the return of community evenness to 
pre-CFPE levels.  
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Figure 6-4.  Changes in Bacterial Community Slope Before, During and After 
Treatment for a CFPE.  Error bars represent 95% Confidence Intervals.  --▲--= 
mean FEV1 for same time period.  All samples treated with PMA.  
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Subject 09 
In order to ascertain if similar perturbations in bacterial community slope, seen 
in one CFPE from 12 different subjects, would also occur in CFPEs from just 
one subject, all the CFPEs from subject 09 were analysed (CFPE n=4).  Results 
are presented in Figure 6-5 above.  It was seen that bacterial community slope 
in the three periods before during and after treatment for a CFPE, mean slope 
of the bacterial community (±SD) was -0.28 (± 0.31), -0.54 (± 0.56), and -0.16 (± 
0.02) respectively.  Using the student’s unpaired t test, the probability of the 
differences between groups being significant was: Pre vs. during, p= 0.02; pre 
vs. post p= 0.02; during vs. post p= 0.0004.  It can also be seen that between 
each course of antibiotics, the Slope is consistently around a value of 
approximately -0.2..  Other patterns are less consistent:  In some CFPEs the 
slope becomes noticeably less even prior to the start of treatment (above: 2
nd 
CFPE, marked with black arrow), whereas overall the mean slope in the three 


































Figure 6-5 Changes in bacterial community slope for Subject 09.  Stippled areas 
denote treatment periods for CFPEs; hatched area denotes 'elective' treatment 
including antibiotics.  Results are from DNA profiles (without PMA treatment).  
Black arrow – see text.  
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6.3  Variations in Flux between Samples 
It was hypothesised that there may be greater flux in bacterial species and 
within the bacterial community around the time of a CFPE.  In Figure 6-6 below 
is shown the results of Sorensen Similarity Index for the periods of time before a 
CFPE (days -7 to -21), for the day of CFPE compared to the pre-CFPE period, 
and for the period during treatment.  Mean (±SD) Sorensen Index for the three 
time periods were 0.63 (±0.20), 0.51 (±0.25), and 0.48 (±0.29).  All differences 
were not statistically significant.  
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6.4  Variations in Key Species 
Pseudomonas aeruginosa has been considered a key pathogen in CF (Lyczak, 
Cannon, & Pier 2002).  The changes in the proportions of P. aeruginosa present 
in sputum samples taken before during and after CFPE treatment for 12 CFPEs 
is presented below inFigure 6-8.  It can be seen that proportions of P. 
aeruginosa are relatively low in the time preceding a CFPE (mean 42±5.6%), 
and rise during (mean 58.6±7.8%) and after treatment (mean 68.1±10.9%).  
These differences were not statistically significant.  This is also presented in 
Figure 6-7 below. 
 
Figure 6-6 Box plot of Sorensen Similarity Index around time of CFPE.  
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It can be seen that, in contrast to P. aeruginosa, levels of Prevotella are higher 
before treatment for a CFPE, decline rapidly on treatment, and remain low after 
treatment.  The differences between the three time categories was found to be 
highly significant by one way ANOVA (p=0.0002). 
 
Figure 6-7 Box plot of proportions of P. aeruginosa around CFPE.  Between 
groups difference p= ns (one way ANOVA).  
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Figure 6-7 Fluctuations in proportion of Pseudomonas aeruginosa and Prevotella 
species present before during and after CFPE treatment.  Error bars represent 
95% confidence intervals 
 
Prevotella spp. were not the only obligate anaerobes detected.  In Figure 6-9 
below, bands that are associated with species that are known to be obligate 
anaerobes (Brenner et al. 2005) are plotted against changes in P. aeruginosa.  
A strict definition of which bands were from obligate anaerobes was applied.  
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Pseudomonas aeruginosa Prevotella sp.  
 
Figure 6-8 Box plot of proportions of Prevotella spp. around CFPE.  
Between groups difference p=0.0002  (one way ANOVA).  
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with them, but not exclusively so.  These band lengths also had other species 
not considered obligate anaerobes associated with them and were thus 
excluded from this definition of bands derived from obligate anaerobes.  This 
strict definition of which data to include in this analysis may well have resulted in 
the proportions of obligate anaerobes being an underestimation of the true 
proportions of anaerobes.  The proportion of anaerobes fall from a mean of 25% 
(±20.4) on the day prior to CFPE treatment, to 6.35% (±7.7) at the end of 
antibiotics (p= 0.03 by paired t test).  This difference persists after the end of the 
treatment. 
Figure 6-9 Proportions of obligate anaerobes and P. aeruginosa around CFPE. ▲ 
= P. aeruginosa.  █ = Anaerobe.  Error bars represent SD. 
Subject 09 
The effect of antimicrobial therapy on Prevotella spp. proportions throughout a 
whole year, including CFPEs is shown in Figure 6-10 below.  It can be seen that 
reduced relative abundance of Prevotella species has a temporal relationship 
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effect of systemic antibiotics on the proportions of Prevotella spp..  The first 
CFPE was the only one in which the intravenous antibiotic Meropenem was not 
a part. 
Figure 6-10 Effects of periodic antimicrobial therapy on relative abundance of 
Prevotella species for one Subject (09).  Grey areas represent periods of 
systemic antimicrobial therapy. 
 
T-RF Band 268, identified by PCA as an important species in the differentiation 
between frequent and infrequent exacerbators in samples analysed as part of 
the stability analysis.  In this analysis of samples around the time of an 
exacerbation, Band 268 was almost never detected (only identified in Subject 
12).   
6.5  Multivariate Analysis 
Using results from samples taken from subjects when clinically stable (see 
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as per Table 6-2 above, it was possible to analyse bacterial community 
similarities in samples using Principle Components Analysis 
 In Figure 6-13 above, it can be seen that samples from infrequent exacerbators 
(blue triangles) cluster together, where as the frequent exacerbators (red 
triangles) are more widely distributed.   The two Principle Components 
responsible for this clustering are an unknown species (T-RF 268), and P. 
aeruginosa.  Finally it is of note that a third component, band 104 – a Prevotella 
species, is also a Principle Component of the differentiation between samples.  
On further statistical testing using Wilcoxon rank sum test, the median 
proportions of P. aeruginosa, for ‘frequent exacerbators’ and ‘infrequent 
exacerbators’ respectively were: 6.6% vs. 12.1% (p= 0.187); Prevotella  spp. 
were 0.0% vs. 0.30% (p= 0.006), and T-RF 268 4.5% vs. 0.0% (p<0.001) 
 
Pseudomonas aeruginosa Unknown Species
Prevotella veroralis
Pseudomonas aeruginosa Unknown Species
Prevotella veroralis
 
Figure 6-13 Principle Component Analysis of samples from subjects 
when stable, divided in to infrequent CFPEs (‘point down’ triangles) 
and frequent CFPEs (‘point up’ triangles).  





Exacerbators  p  value 





 (38.5%)  0.187 
T-RF 104 




(4%)  0.006* 




0.0%  < 0.0001* 
Table 6-4 Comparison of median values for bands identified as principle 
components by PCA.  Statistical analysis by Wilcoxon rank sum test. * = 
statistically significant result. 
 
6.6  Discussion 
A number of pertinent findings emerge from these data, relating primarily to two 
key areas, namely to bacterial community structure, and key species.  
6.6.1 Bacterial community structure 
Of the twelve subjects who experienced a CFPE during the study period, a clear 
effect of treatment on bacterial community structure can be seen.  Species 
richness falls significantly during treatment.  This is unexpected and not in 
keeping with studies of the effects of antibiotics on other bacterial communities.  
Robinson et al. assessed the effects of antibiotics on bacterial communities 
using a butterfly larval model and noted marked increases in bacterial species 
detected during treatment (Robinson et al. 2009).  Bacterial community slope 
becomes significantly steeper during treatment compared to both the immediate 
pre-treatment period, and in the case of Subject 09, compared to the longer 
term baseline too.  However the changes in values of both bacterial species 
richness and community evenness during treatment return to pre-treatment  
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values.  Given that treatment ends due to a symptomatic improvement, which 
persists, it is a little perplexing that the apparent effects of treatment, including 
intensive antibacterial treatment, are so quick to dissipate.  However, in all 
cases, some form of less intensive long term antimicrobial therapy continued.  It 
has also been shown that bacterial community evenness offers advantages to 
the persistence of the bacterial community under pressure in a theoretical 
model (Wittebolle et al. 2009). 
It was found that, during treatment, both the number of species detected and 
the evenness of the bacteria fall.  This is to be expected.  For example, as a 
community becomes more dominated by a single species, giving a steeper 
slope, many of the rarer species may fall below the lower limit of detection, 
resulting in a fall in the number of species detected (Ager et al. 2009). 
The fall in species richness and increase in the steepness of the slope during 
treatment for CFPEs is at least in part due to a rise in the relative abundance of 
P. aeruginosa and fall in the relative abundance of other species, notably 
Prevotella spp. (see Figure 6-7).  Prevotella spp. have been previously detected 
and identified by both culture-based (Tunney et al. 2008) and sequence based, 
culture-independent techniques (Bittar et al. 2008).  Tunney et al. found 
Prevotella spp. as the most frequent detected anaerobe in samples obtained by 
bronchoscopic lavage and spontaneous sputum from adult CF subjects (Tunney 
et al. 2008).  Harris et al. also found a number of Prevotella species in CF 
subjects , but from a younger population with a mean age of 9.1 years (Harris et 
al. 2007).  Both of the afore-mentioned studies were horizontal descriptive 
studies, with no evidence to support the importance or otherwise of the diversity 
of species detected.   
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The finding that treatment for CFPEs, of which intensive antimicrobial therapy is 
the mainstay, results in a rise in the relative quantity of P. aeruginosa compared 
to other species runs counter to the prevailing understanding of CFPE 
treatment.  Gibson et al. reviewed the management of CFPEs in 2003, 
highlighting that the only strategy for selection of antibiotics was based on the 
presence and resistance patterns of P. aeruginosa  (Gibson, Burns, & Ramsey 
2003).  As previously discussed in the Introduction(see Section 1.1) others have 
highlighted both the lack of correlation of these resistance patterns to clinical 
outcomes (Smith et al. 2003), and the lack of internal consistency of the result 
from antibiotic resistance pattern results to P. aeruginosa  (Foweraker et al. 
2005; Foweraker et al. 2009).  However, it should be stressed that the results 
presented in this work only show a relative increase in P. aeruginosa levels and 
that it entirely possible, and indeed clinically likely, that absolute quantity of P. 
aeruginosa fall during CFPE treatment (Regelmann et al. 1990).  Were it to be 
demonstrated that absolute P. aeruginosa levels fall, this work demonstrates 
that the effects of treatment on other species than on P. aeruginosa. 
The results of Principle Component Analysis and the resulting comparison of 
means of the principal components identified is important.  As can be seen from 
Table 6-4 above, there were significant differences between species in the 
frequent exacerbators vs. infrequent exacerbators.  There was significantly 
more Prevotella spp. and significantly less (=none) of T-RF 268 in the infrequent 
exacerbators.  There was also a non-significant trend towards more P. 
aeruginosa in the infrequent exacerbators.  The finding of key species that 
contribute to exacerbation frequency would of of importance in identifying  
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mechanisms behind CFPEs, which are such significant events for people with 
CF. 
Another group of bacteria that have been implicated in the development of 
CFPEs has been the Streptococcus milleri group (SMG).  This work has found 
no evidence to lend support to the hypothesis that bacteria from the SMG play 
any significant role in CFPEs.  However, in work done within this research 
group, samples from a CF centre in the USA were compared to samples from 
CF patients in Southampton.  Samples from the two groups were significantly 
different to each other and clustered geographically (unpublished data).  This 
might offer an explanation as to why bacteria from SMG were found in one 
centre but not another. 
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Chapter 7 -  Inflammatory Mediators 
Although it is certainly true that the presence of large quantities of bacteria in 
the lower airways of patients with CF is an important driver in the pathological 
destruction of the lung parenchyma that leads to morbidity and ultimately death, 
the link between fluctuations in the structure of that bacterial community and the 
aforementioned lung damage is not clear. In order to link measures of bacterial 
community structure, and the fluctuations therein, to the response of the host to 
their presence, sputum inflammatory mediators were measured as outlined in 
Section 2.4 above.  As the sample handling requirements were more exacting 
for samples for inflammatory mediator measurements (Ordonez et al. 2003) 
compared to samples for microbiology analysis (Mayer-Hamblett et al. 2007), a 
separate sample set was collected which was delivered straight to a -80
oC 
freezer within two hours of expectoration.  In total, 70 analysed samples were 
collected from the fourteen subjects.  A number of samples that were collected 
were subsequently excluded from parts of the analysis as they were not 
obtained at times that were easily differentiated in to ‘CFPE (pre-treatment)’, 
and stable.  For the purposes of the study, stable was defined as at least three 
weeks before or after a CFPE. 
A summary of the results are presented in Table 7-1 below. In general there was 
wide variability in results both within and between subjects.  There were also 
generally low numbers of samples for each subject and category (stable/CFPE).  
From Table 7-1 it can be seen that there were only three occasions in which a 
subject had more than two samples in both stable and CFPE in any given 
inflammatory mediator (Subject 09: NE; Subject 12: NE and ECP).  In addition, 
paired samples were not obtained.  In other words, samples were not obtained  
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before and after a given CFPE, but instead before one CFPE but perhaps after 
an additional CFPE.  This was due to the difficulty in obtaining appropriate 
samples, given the more exacting sample handling requirements, in what was 
essentially a community based study. 
During the measurement of the inflammatory mediators in the soluble phase of 
the sputum supernatant, it was necessary to estimate the expected range for 
results in order to allow the result to fall within the standard curve.  
Unfortunately, on a number of occasions values were much higher than had 
been predicted and fell above the standard curve, preventing acceptably 
accurate measurements.  These results were excluded. This occurred for four 
results for IL-8. 
From Table 7-1 it can be seen that the median value for all three measured 
inflammatory mediators was higher during a CFPE than at times of clinical 
stability.  However, it can be seen that none of the differences reached 
statistical significance (analysed using non-parametric tests due to the non-
parametric distribution of the data). 
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Stable  Exacerbation 











 (ng/ µL) 
1.51  25.2  1.93  2.04  101.3  10.2  1.      
mean 
             (N)  (2)  (2)  (2)  (2)  (2)  (2) 
5.86  40.8  5.61  3.36  47.1  9.08  2.      
mean 
             (N)  (3)  (3)  (2)  (2)  (1)  (2) 
3.11  62.4  3.08  N/A  N/A  N/A  3.      
mean 
             (N)  (6)  (4)  (4)  (0)  (0)  (0) 
2.73  92.2  N/A  0.441  11  0.12  4.      
mean 
             (N)  (1)  (1)  (0)  (1)  (1)  (1) 
3.01  41.5  N/A  1.64  33.6  3.01  5.      
mean 
             (N)  (1)  (1)  (0)  (2)  (1)  (2) 
2.97  19.80  5.49  2.56  54.30  7.07  6.      
mean 
             (N)  (3)  (2)  (1)  (2)  (2)  (2) 
7.61  63.70  1.96  4.10  77.90  6.29  7.      
mean 
             (N)  (1)  (2)  (1)  (3)  (2)  (2) 
1.78  34.50  4.88  N/A  N/A  N/A  8.      
mean 
             (N)  (3)  (3)  (1)  (0)  (0)  (0) 
14.30  89.90  13.19  20.32  209.65  12.82  9.      
mean 
             (N)  (3)  (2)  (2)  (7)  (7)  (5) 
9.77  3.67  13.207  0.424  35.2  5.37  10.    
mean 
             (N)  (1)  (1)  (1)  (1)  (1)  (1) 
2.46  56.55  12.12  0.98  N/A  1.93  11.    
mean 
             (N)  (2)  (2)  (2)  (1)  (0)  (1) 
3.30  52.88  3.03  3.14  64.05  4.89  12.    
mean 
             (N)  (6)  (5)  (6)  (3)  (2)  (3) 
1.23  53.80  6.30  3.20  50.50  6.83  13.    
mean 
             (N)  (1)  (2)  (2)  (3)  (2)  (3) 
0.54  21.15  2.11  1.23  39.23  2.77  14.    
mean 
             (N)  (2)  (2)  (2)  (3)  (3)  (3) 
2.71  43.60  3.81  2.80  56.90  5.65  Overall 
Median  p=0.071  p=0.211  p=0.101       
Table 7-1 Inflammatory Mediator results for samples taken during Pulmonary 
Exacerbations and in periods of clinical stability.  Difference between mean 
values for each mediator at the two time points assessed using Wilcoxon signed 
rank test. 
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7.1.1 Inflammatory Mediators vs. Bacterial Community 
Measures 
If fluctuations in the structure of the complex bacterial community present in CF 
sputum were to have some bearing on the well being of the host, then it might 
be expected that changes in sputum inflammation might correlate with 
measures of community structure.  In Table 7-2 (below) are presented 
correlations between a number of different measures of bacterial community 
structure and the inflammatory mediators measured from the same samples.  
For more details see Section 2.5 above. 
The measures of species evenness used were the slope of the log values of the 
ranked species dominance plot, in addition to the percentage abundance of the 
most dominant species in each sample, and the percentage abundance of P. 
aeruginosa in each sample.  The measure of bacterial community richness was 
number of species.  These measures were performed for both T-RFLP results 
(bacterial DNA) and RT-T-RFLP results (bacterial RNA). 
Values presented are for all samples from all subjects, irrespective of whether 
samples could be clearly delineated into or out with periods of CFPE.  Values 
were not normally distributed, and thus non-parametric Spearman’s rank 
correlation was used.  When assessing correlations between DNA (T-RFLP) 
and inflammatory mediator results there were no statistically significant 
correlations between measures community structure, either evenness or 
richness, and measured sputum inflammatory mediators.  However, when 
looking at RNA results (RT-T-RFLP), which theoretically is a marker of bacterial 
activity rather than merely bacterial presence or absence, there were two  
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correlations that were statistically significant which are described in more detail 
below.  Values of Spearman’s rho were not large (max value -0.346). 
For RNA (RT-T-RFLP) results there were two significant correlations, although 
both weak.  There was a weak correlation between the slope of the ranked 
bacterial community and measures of ECP.  A less steep (more even) bacterial 
community correlated with more inflammation (rho 0.346; p=0.014).  Additionally 
the percentage abundance of the most dominant species (be that P. aeruginosa 
or another species) had a negative correlation with ECP.  This too suggests that 
a less even community is associated with less inflammation and vice versa.  
Finally species richness (RNA) and values for Neutrophil Elastase approached 
statistical significance (rho 0.227; p= 0.063).  Were this to be a real correlation, 
then it too would favour the same direction of change between bacterial 
community and inflammation as those previously mentioned, namely a more 
diverse community being associated with more inflammation. 
The low number of samples obtained per subject in each disease state, 
combined with many samples not collected pair wise before and after particular 
CFPEs, meant that a more detailed analysis of intra-subject variations could not 
be undertaken.   
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DNA  RNA 
Species Evenness  Species 
richness  Species Evenness  Species 
richness 
 
Slope  % of Pa  % dom. 
species  No. of species  Slope  % of Pa  % dom. 
species  No. of species 
NE:   rho  -0.104  0.157  0.096  -0.115  0.147  -0.086  -0.154  0.227 
p value  0.403  0.216  0.438  0.390  0.243  0.510  0.210  0.063 
N.  67  64  68  68  65  61  68  68 
IL-8: rho  0.064  0.067  -0.022  0.002  0.112  0.007  0.099  0.086 
p value  0.631  0.623  0.866  0.985  0.402  0.960  0.451  0.516 
N.  59  56  60  60  58  53  60  60 
ECP: rho  0.071  -0.059  -0.133  0.043  0.346*  -0.172  -0.340*  0.196 
p value  0.618  0.685  0.342  0.760  0.014  0.238  0.013  0.159 
N.  52  50  53  53  50  49  53  53 
Table 7-2 Correlation between measures of species evenness and richness and inflammatory mediators, using Spearman's rank correlation (rho).  
Correlation considered statistically significant if p 0.05 (*); N = number of samples  
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7.1.2 Inflammatory Mediators vs. Clinical Data 
Visual analogue scales used in a longitudinal fashion in CF is novel.  Sputum 
inflammatory mediators, although well established as a research tool, do not 
have a well defined role in clinical management or as a surrogate end point for 
clinical trials.  It has been shown that inflammatory mediators are responsive to 
intravenous antibiotic therapy (Becker et al. 2009; Rottner, Freyssinet, & 
Martinez 2009; Teichgraber et al. 2008).  However, a prospective evaluation of 
their relationship to symptoms has not previously been undertaken.  As subjects 
provided frequent assessments of the clinical health using the CMF, which 
included the four VAS domains as well as spirometric readings, an assessment 
of the correlation between sputum inflammatory mediators and measures of 
clinical well being, through VAS scores and spirometry, was undertaken.   
The results are presented in Table 7-3 below.  It should be noted that samples 
taken on days for which there was no CMF (e.g. CMF/sample days 
Monday/Wednesday/Friday, but clinic visit on Tuesday or Thursday) were 
excluded from this analysis.  When the analysis was repeated to include these 
excluded samples, with extrapolation of the nearest CMF results received 
(within +/- 2 days), all significant correlations disappeared (results not shown). 
Between VAS values and sputum inflammatory mediators, there was no 
significant correlation.  Between FEV1 and both IL-8 and Neutrophil Elastase 
there was a statistically significant negative correlation (rho -0.358, p=0.028 for 
FEV1 with NE; rho=-0.418, p=0.014 for FEV1 with IL-8).  There was no 
correlation between ECP and any of the clinical measures.  
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As with other work based on the samples for sputum inflammatory mediators, 
there were insufficient samples per subject, and insufficient samples taken at 
appropriately paired time points before and after particular antibiotic therapy, to 
allow a more details analysis. 
 
Table 7-3 Correlation between clinical measures and sputum inflammatory 
mediators, using Spearman's rank correlation (rho); considered statistically 
significant if p<0.05; N = number of samples. 
 
7.2  Discussion 
Sputum inflammatory mediators have been studied in CF previously (Al et al. 
2009; Amitani et al. 1991).  Ordonez et al. demonstrated that treatment with 
intravenous antibiotics for physician defined CFPEs was associated with a fall in 
IL-8 and NE, with a rise in FEV1, and a fall in density of P. aeruginosa or S. 
aureus by culture (Ordonez et al. 2003).  Results presented here do not provide 
statistical support for this, as, although there were lower levels during stable 
periods than at CFPE they were not statistically significant.  However the results 











VASs  FEV1 
NE:       
rho 
-0.215  -0.114  -0.075  -0.168  -0.171  -0.358* 
p value  0.196  0.495  0.654  0.314  0.304  0.028 
N.  38  38  38  38  38  38 
IL-8:     rho  -0.249  -0.059  -0.067  -0.198  -0.165  -0.418* 
p value  0.156  0.740  0.705  0.261  0.352  0.014 
N.  34  34  34  34  34  34 
ECP:     
rho 
0.156  0.179  0.164  0.229  0.182  -0.126 
p value  0.402  0.334  0.379  0.215  0.326  0.501 
N.  31  31  31  31  31  31  
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namely samples compared in this study were taken at various time points 
throughout the 12 month study period that were either identified as periods of 
stability or at the time of CFPE, prior to commencement of antibiotic therapy.  
Ordonez et al. and others have previously noted that inflammatory mediators 
are poorly reproducible (Ordonez, Kartashov, & Wohl 2004).  In their study they 
found large variations in IL-8 and Neutrophil Elastase in induced sputum 
samples in young stable CF children, in three samples obtained on three 
consecutive weeks.  Many of the samples in the work presented here were 
obtained at intervals greater than the weekly intervals reported by Ordonez et 
al..  This intrinsic variability may contribute to the findings presented here.  In 
other studies, which have found a significant change in inflammatory mediators 
with treatment for CFPE, minimising the time interval between sampling and 
maximising the intervention in that time, may have contributed to the significant 
results found by other researchers.  It is worth noting the large degree of 
variation over time in clinical symptoms reported by the subjects of this study 
(see Section 4.2 above).  Some of this variability may represent, to a greater or 
lesser degree, pseudo-exacerbations.  The occurrence of such pseudo-
exacerbations has the potential to impact on the results of inflammatory 
mediators presented here, some of which may not have been from time periods 
which were not as clinically stable as would first have appeared without the 
symptom information provided from the CMFs.  Two other points of difference to 
note between this work and the work by Ordonez et al. are: 1) their sample size 
was 55 subjects and 55 CFPEs compared to exacerbations in only 12 subjects 
here; 2) all of the subjects in the Ordonez study received IV antibiotics, which is 
not true for the CFPEs presented here  (Ordonez et al. 2003).  
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In addition to the comparison between inflammatory mediators at times of CFPE 
and clinical stability, comparison was made with results from the Clinical 
Monitoring Forms.  These forms were completed by subjects at the time of 
producing samples for microbiological analysis, which often coincided with the 
collection of samples for inflammatory mediator analysis.  This analysis showed 
a weak but statistically significant correlation between IL-8 and FEV1 (rho -
0.418, p= 0.018) and between NE and FEV1 (rho -0.358, p= 0.028).  There no 
significant correlations between ECP and any clinical measures, nor between 
any of the Visual Analogue Scale scores and inflammatory mediators.  The 
correlation of FEV1 with NE is similar to that reported by Mayer-Hamblett et al.  
(Mayer-Hamblett et al. 2007) in a much larger cohort of 269 subjects, who 
reported a rho value of -0.35.  They also reported a correlation between IL-8 
and FEV1 (rho -0.28).  Due to the larger cohort in their study, they were able to 
use the more robust confidence interval technique of boot strapping.  It is also 
worth noting that their study reported correlations between FEV1% predicted 
rather than absolute FEV1. 
It is shown here that there were no strong correlations between inflammatory 
mediators and bacterial community measures.  In Table 7-2 above it can be 
seen that there were weak correlations between ECP and bacterial community 
slope.  The direction of these changes suggest that, as the bacterial community 
became more even, there was more ECP.  This finding is noted consistently, 
whether assessing slope, or proportion of the dominant species.  There was no 
correlation with the proportion of P. aeruginosa.  The nature of the connection 
between ECP and community is not clear.  Koller et al. found a clear 
relationship between IL-8 and ECP levels in CF (Koller et al. 1997).  However  
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IL-8 did not show the same relationship with RNA bacterial community 
measures as ECP here.  It is possible that there are other explanations for the 
association, such as additional roles for ECP and eosinophils in CF, as yet to be 
elucidated.  However, it is also possible that the association may relate to a 
genuine relationship between the bacterial community and ECP.  Further 
studies would be needed to answer these questions.   
There only limited association between measures of bacterial community 
structure and inflammatory markers is at odds with the pre-study hypothesis.  
Perhaps, however, it should come as little surprise, as there is growing 
evidence for the intrinsic pro-inflammatory nature of the CF airway in addition to 
inflammation that is driven by bacterial presence (Rottner, Freyssinet, & 
Martinez 2009).  In addition, there are other drivers of airway inflammation other 
than bacteria.  It has recently been noted that there is a very large diversity of 
viruses in the CF airway (Willner et al. 2009).  A similar finding of previously 
undetected microbial diversity has been made when detecting of fungi from the 
CF airway using culture independent molecular techniques (Nagano et al. 
2009).  It should however be made clear that these findings are from single time 
point studies, and the clinical significance of such findings is yet to be 
ascertained.  However, if the bacterial community is of importance in lung 
inflammation and damage, then either directly or indirectly, the wider microbial 
community is also likely to play a role. 
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Chapter 8 -  Discussion 
This study has attempted to extensively analyse some of the complexity 
inherent within the pathology of Cystic Fibrosis pulmonary disease.  Previous 
attempts to understand the mechanisms of pulmonary exacerbations inCF lung 
disease and associated symptoms have met with partial success.  The clinical 
relevance of P. aeruginosa detection by culture has been well described 
(Frederiksen, Koch, & Hoiby 1997; Littlewood et al. 1985), but targeted therapy 
has not been effective at altering established infection, nor explaining the 
heterogeneity of clinical outcomes (Liou et al. 2001).  Bacterial diversity beyond 
those species easily detected by culture has been documented (Rogers et al. 
2004; Rogers et al. 2008), but the relevance of such diversity to CFPEs, and the 
accepted dominance of P. aeruginosa has not been challenged.  This study has 
attempted to move the scientific conversation forward from descriptive studies 
of diversity to a more in depth assessment and linkage of these changes to the 
underlying pathology. 
The fourteen subjects in this study were a heterogeneous group, with wide 
variation in baseline lung function, genotype and diabetic state.  Although 
patients who chose to participant in research studies may not be representative 
of socio-economic status across all CF patients (Goss et al. 2006), it was felt 
that in terms of a UK population the subjects were broadly representative of the 
type of patients seen by clinicians in adult CF clinics (Cystic Fibrosis Trust 
2009b).  
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8.1  Clinical Monitoring 
Patients’ perception of symptoms is an important part of their lives with Cystic 
Fibrosis.  Symptom reporting is integral in determining a clinicians decision to 
diagnose and instigate treatment for a CFPE.  CFPEs have, in turn, been 
shown to independently predict long term (5 year) survival (Liou et al. 2001), 
and to correlate with quality of life (Britto et al. 2002).  As above, there is still no 
accepted definition of what constitutes a CFPE, however (Marshall 2004).  Most 
definitions are based on new symptoms or changes in pre-existing symptoms 
(Rosenfeld et al. 2001).  See Figure 1-1.  Few definitions take account of day to 
day fluctuations in symptoms that occur without recourse to intervention from a 
clinician.  Such variability has not previously been quantified.  The VASs used in 
this study fulfil most but not all of the criteria for a valid PRO, as laid out by 
Goss and Quittner (Goss & Quittner 2007).  The area in which they fail the test 
is in the lack of a validated minimum clinically important difference (MCID).  A.L. 
Ries  ( 2005) attempted to estimate this for VASs, giving a MCID range of 10-20 
based on studies of Pulmonary Rehabilitation in COPD.  However, it can be 
seen in this review, that the MCID is dependant on the baseline starting value, 
with higher baseline values having a higher MCID and vice versa.  Thus it is 
possible that each subject may need to set their own internal MCID, a strategy 
that would be impractical for most clinical studies.   
The Visual Analogue Scales showed marked variability on a day to day basis in 
all individuals. However, when compared to each other there was good 
correlation between symptoms.  For example, in Figure 4-3 above it can be 
seen that Cough and Sputum VAS scores have a very strong correlation with 
each other with an r value of 0.858.  Symptomatically and physiologically these  
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two domains are closely linked, and thus this result is not unexpected although 
has not been previously reported.  As such, they may not be considered 
independent variables, although hey are distinct symptoms in proposed 
definitions of CFPE (Fuchs et al. 1994; Ramsey et al. 1999).  As any subject 
with extensive bronchiectasis coughs more they, in turn, expectorate a greater 
volume of sputum and vice versa. The General Wellbeing VAS score correlated 
best with the Breathlessness VAS score (r = 0.733), which reflects the 
importance of exercise capacity and dyspnoea on quality of life.  Increased 
cough or sputum, with less strong correlations with general wellbeing, affects 
QoL less than does breathlessness.  The weaker correlations between the more 
specific respiratory symptoms of cough and sputum with GWB suggest that 
these symptoms have less impact on day to day quality of life.  This partly 
agrees with other studies, which have found exercise capacity, along with 
sputum output, accounts for 54% of the variance in QoL as measured by the 
Chronic Respiratory Diseases Questionnaire (Bradley, McAlister, & Elborn 
2001). 
On inspection of the individual Response Profile Plots for each subject (see 
Appendix - 9.4 below), it can be seen that in these are marked day to day 
variability.  Given the lack of visual anchors available (for example, there were 
unable to see how they had scored on the previous CMF, as it had already 
been collected by the courier), it is perhaps not surprising to see such variation. 
However, there are trends that emerge.  A number of subjects have recorded 
changes in their symptoms that are of the same magnitude as other times when 
they received treatment for a CFPE (e.g. Subject 01, ~day 300).  Subsequent to 
both diagnosed CFPEs and ‘pseudo-CFPE’ events there is a return to a  
  236 
previously lower level, which has lead to these untreated deteriorations in 
symptoms to be termed as pseudo-exacerbations.  Such a phenomenon is not 
new in respiratory illnesses.  Wilkinson et al.  (Wilkinson et al. 2004) described 
1077 exacerbations in COPD of which only 658 were reported to a physician.  
Their study used simpler Likert scale-type diary monitoring than the VASs 
employed in this study, with all the advantages and disadvantages previously 
discussed.  The Wilkinson study demonstrated that COPD exacerbations that 
were not reported to a physician took longer for symptoms and lung function to 
return to baseline, and were more likely to be hospitalised for treatment for their 
illness.  The mechanisms behind such pseudo-exacerbations are unknown.  It is 
possible, given the microbial lower airway colonisation that is a frequent and 
important feature of both diseases, that there may be similar processes at work 
in both.  However, as yet the cause of many exacerbations remains unclear, 
and more work is required.  
There is undoubtedly a significant psychological and social element in a 
patient’s perception of their symptoms (Conway et al. 1996).  For example, 
some of the subjects in this study were in part time or full time employment or 
education (Subjects 01, 05, 06, 07, 08, 10, 12).  Subject 01 was a teacher, and 
may have been somewhat reluctant to seek medical assistance during school 
term time, and may try to time treatment for CFPEs with school holidays or half 
term (Hodson & Geddes 2007). 
Lung function is an important determinant of outcomes in CF, although it is 
recognised that is not a key component in the diagnosis of CFPEs (Rosenfeld et 
al. 2001).  By inspection of Table 4-2 above, it can be seen that there is a range 
of strengths of correlation between symptoms and FEV1.  This ranged from a  
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strong correlation (r = -0.565, p<0.001) for Subject 13, to no correlation at for 
Subject 12 (r = -0.086, p=0.376).  Such correlations have not previously been 
described in such a way.  For those without a correlation, it may be worth 
exploring some explanations.  Subject 09 will not be discussed here as there 
were insufficient paired data points to allow a valid comparison to be made 
(N=3; see Table 4-2).  For Subject 08, it is necessary to review the individual 
RPPs in the Appendix (See Section 9.4.8 below).  Through the time of the 
study, the individual RPPs for Cough and Sputum both show a gradual 
improvement, but General Wellbeing and Breathlessness showed a gradual 
worsening.  During this time FEV1 remained remarkably stable.  Thus, it 
appears that there may have been other factors at play in influencing the 
changes seen in the VAS and the Sum of VAS scores.  It is possible that there 
was a lack of recall in how this subject rated their symptoms.  Perhaps, over 
time, this subject’s perception of their previous breathlessness was diminished.  
Yet the opposite occurred with cough and sputum.  It is of course possible that 
the changes recorded were in fact measuring a real change in symptoms, not 
detected by FEV1, and not explained by symptom domains captured by these 
VASs.  There is evidence that changes in spirometric values are an insensitive 
marker for underlying lung damage when compared to Computerised 
Tomography of the lungs (de Jong et al. 2004). 
The other study subject, in whom no significant correlation between Sum of 
VAS scores and FEV1 was seen, was Subject 12.  Although Subject 12 was in 
higher education, their first language was not English.  In addition to this, there 
were a number of prolonged periods during the study where they were not 
resident in the UK, and were not recording symptom scores or providing sputum  
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samples.  These factors may at least in part explain why this subject did not 
show the expected correlations. 
The use of FEV6 as a surrogate measure of the vital capacity, as used in this 
study,  is not universally accepted (American Thoracic Society 1991).  However 
its use in this way offers a number of important potential benefits.  Firstly, it is 
reported to be more reproducible than Forced Vital Capacity (Swanney et al. 
2000).  In addition, it offers a reduced duration of effort for subjects with 
significant airflow obstruction.  Finally it offers a more objective and explicit 
marker for the end of the test.  It has been shown to be equally valid to FVC in 
measurement of airflow limitation in COPD (Akpinar-Elci, Fedan, & Enright 
2006), although its use in CF does not appear to have been previously reported.  
There were correlations seen with symptoms as measured by Visual Analogue 
Scales (see Table 4-2 above).  In 11 Subjects there was a significant correlation 
between spirometric values and VAS scores; in 4 of these 11 the correlation 
between FEV6 and symptoms was stronger than the correlation between FEV1 
and symptoms.  This suggests that FEV 6 is a valid marker of symptoms, but 
may not be as good as FEV1. 
8.1.1 Limitations of Clinical Monitoring 
Most symptoms are most accurately described as continuous rather than 
discrete variables.  Despite this many longitudinal studies of lung health use 
categorical variables to capture data about pulmonary exacerbations 
(Seemungal et al. 2000; Wilkinson et al. 2004).  The most obvious advantages 
of this categorical approach are that analyses are somewhat simpler and some 
of the subjectivity is removed.  By removing the part of the subjectivity, it allows  
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a more valid comparison between subjects.  The use of Visual Analogue Scales 
is well described.  Gift et al. (Gift 1989a) validated their use for the assessment 
of dyspnoea in asthma and COPD, whilst Smith et al. (Smith et al. 2006b) 
demonstrated good correlation of a cough VAS to objective sound recording 
measures of cough. In addition to the validated use of breathlessness and 
cough VASs in this study, sputum and ‘General wellbeing’ VASs were used, 
which to the best of knowledge, have not been previously validated. However 
the internal consistency of the measures was demonstrated (Section 2.1.4.2 
above), and strong correlations were seen between the different symptom 
domains.  See Figure 4-3 above.  The fact remains, though, that VAS data were 
highly variable both within and between subjects.  This can be best seen in 
Figure 4-1 above.  Overall the median (IQR) for breathlessness VAS was 
20(19).  These results can be compared to others (best summarised in Ries, 
A.L. ( 2005)).  In interventional studies in COPD, Reardon et al. found a mean 
(±SD) baseline VAS of 74.4 (±18.9), whilst Alvisi et al. found values of 25.0 (± 
18) (Alvisi et al. 2003; Reardon et al. 1994).  With regard to Cough VAS, the 
results presented here showed a median Cough VAS of 22 (IQR 22).  Smith et 
al. showed similar results, with a median Cough VAS of 18 (IQR 41) after 
treatment for a pulmonary exacerbation.  However no study has shown the 
longitudinal variation over time in CF as has been presented here.  The form of 
the data captured allows insight in to the day to day fluctuations in symptoms 
which to a very large extent go unreported to the clinical team. 
To quantify and compare the changes in symptoms between subjects is clearly 
going to be skewed by subjects who report a wider range and higher values of 
VAS.  However, the alternative approach would be to in some way standardise  
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the range of responses seen in different subjects.  One way to do this would 
have been to standardise raw VAS scores by converting the minimum score for 
a particular subject’s VAS to zero%, and converting the maximum score to 
100%.  This too comes with considerable statistical problems.  For example, it 
would mean that, in subject 13, a single point change in Breathlessness VAS 
would equate to a ((1/3)x100=) 33% rise in breathlessness, compared to a 
single point change in subject 10 equating to a ((1/28)x100=) 3.6% increase in 
relative breathlessness.  There was no precedent identified in the literature for 
normalising or standardising VAS scores, and thus the decision was made to 
work with the raw scores.  In addition changes in VAS scores only weakly 
correlated with the occurrence of CFPE.  This may be a weakness in the VAS 
method of monitoring, in so much as it is inherently going to have large intra- 
and inter-subject variability, but may also truly be a reflection of the wellbeing of 
the subjects over time.  
There are no validated definitions of what constitutes a CFPE.  In common with 
a number of other observational studies (Ordonez et al. 2003; Sibley et al. 
2008c), a clinician-based definition of a CFPE was used here.  Many other 
studies have only defined CFPEs for which intravenous antibiotics have been 
used.  It was the practise in SGH to use oral antibiotic therapy for many CFPEs, 
thus reducing the treatment burden for patients and conserving the greater 
health resource that is utilised when treatment is with intravenous therapy.  
Although this allowed the analysis of many more CFPEs than would have been 
possible if analysis had been limited to IV courses, it means that many of the 
CFPEs studied may have been less severe than those in other cohorts 
(Ordonez et al. 2003; Smith et al. 2003).   
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Much consideration was given to which symptoms and with what wording 
should be included for monitoring in the Clinical Monitoring Form.  With 
hindsight, there were two additional areas that could have been incorporated to 
provide a more robust assessment of pulmonary health in CF.  There were 
occasions when haemoptysis was the precipitant for treatment for a CFPE, and 
the CMF provided no mechanism for capturing these data.  In addition there are 
changes to the qualities of sputum, beyond its volume, that contribute to clinical 
decision making.  This is apparent in the subtle difference in wording seen 
between the definitions of CFPE used by Fuchs et al. ( 1994), and by Ramsey 
et al. ( 1999) with regard to the role of sputum in CFPEs (see Figure 1-1 above).  
The earlier study by Fuchs et al. includes the less specific ‘Change in sputum’, 
whereas the latter study by Ramsey et al. includes the more specific ‘Increased 
sputum volume (increase of 50%)’. 
There are additional signs and symptoms which may be important in indicating 
a pulmonary exacerbation that were not included in the clinical monitoring.  
These included sputum viscosity (Serisier et al. 2009), sputum colour 
(Anthonisen et al. 1987), and taste (Barker et al. 2006).  However, given the 
repetitive and long term nature of the study, the inclusion of such additional 
information for subjects to complete would have had a significant negative 
impact on the time required.  Hence the likelihood of study protocol adherence 
would have been diminished (Kehoe et al. 2009). 
There are results from some subjects that require additional discussion to allow 
a fuller understanding of their results.  
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Subject 04  
This subject was enrolled in to the study with the understanding that they were 
regular and frequent sputum producers (see Inclusion Criteria Section 2.1.3).  
However it can be seen from the sampling frequency from this subject that the 
minimum sampling frequency was not achieved, with only 43 samples in 52 
weeks.  After enrolment and the start of the study it became apparent that they 
did not expectorate sputum on most days, but at a much reduced frequency, 
averaging les than one sample per week, and fewer when there were no 
exacerbations.  Because the study was designed so that clinical monitoring only 
occurred when a sputum sample was produced, this resulted in a very hit and 
miss record of their symptoms and microbiology, in comparison to the other 
subjects.  This reduced sampling frequency, with a potential bias towards 
sputum samples at the time of exacerbation had a negative impact on the 
quality of the results from this subject. 
 Subject 09 
Subject 09 also deviated from the study monitoring protocol, but for very 
different reasons to Subject 04.  These are now discussed in more detail. 
The Clinical Monitoring Form was tested for subject acceptability by patients 
receiving in patient care, with positive feedback about the ease of use.  
However, it became apparent during the study that one Subject (09) was having 
difficulty in completing the CMF correctly.  The VAS results from Subject 09 
were all reporting no or minimal symptoms in any VAS domain, and yet it was 
known, clinically, that Subject 09 was severely disabled by their lung disease.  
Subsequently a meeting was held with Subject 09, who confirmed that the  
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VASs were being completed incorrectly.  After further training on the process all 
future VASs were adequately completed.  The decision was taken to exclude all 
VAS data from Subject 09 prior to the re-education (about 6 months of data).  
As well as the direct loss of data, this was unfortunate for two other reasons.  It 
was at about the same time that this Subject stopped performing CMF 
spirometry, due excessive dyspnoea (FEV1 often recoded as <0.5L).  In 
addition, due to frequent CFPEs, this Subject had already been chosen as one 
whose samples would be analysed more extensively.  It was thus not possible 
to link microbiological changes to symptom scores so well (see Figure 4-20 
above). 
Thus two of 14 subjects provided sub-optimal data, but 12 of 14 provided 
acceptable data.  It is known and accepted that incomplete adherence to clinical 
trial protocols occurs.  For example there was a 10% drop out rate for subjects 
in a 6 month RCT of inhaled tobramycin in CF (Ramsey et al. 1999). 
8.2  Sputum Culture 
Previous work has suggested a role for bacteria from the Streptococcus milleri 
group (SMG)  (Sibley et al. 2008b).  Bacterial sputum culture detected bacteria 
from Group F streptococci, which includes the SMG.  However, in the one 
subject from who it was identified, no temporal correlation with the occurrence 
or treatment of CFPE cold be discerned. 
The number of bacterial species detected and identified by culture remained 
stable over time at just less than two per sample (see Figure 5-4 above ).  This 
is slightly fewer than the 2.8 pathological species detected per sample in a large  
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cohort of American CF patients (Burns et al. 1998), but the data are not directly 
comparable as the American results included fungal species in the count. 
8.2.1 Limitations of Bacterial Culture 
The limitations of selective bacterial culture in its ability to discern bacterial 
diversity in CF sputum has been well described (Rogers et al. 2004; Rogers et 
al. 2008).  The methods employed in this study were a little different to those 
employed in other studies that employed bacterial culture.  Overall this study 
looked to undertake bacterial culture in a manner identical to that used in every 
day clinical practice (Cystic Fibrosis Trust 2001), which uses semi-quantitative 
estimates of bacteria detected.  Other studies have used quantitative methods, 
such as colony forming units (Regelmann et al. 1985; Regelmann et al. 1990).  
In addition, although not a weakness of culture per se, fungal cultures were 
performed.  This was not mirrored in the methodology in the culture 
independent work, due to the different molecular techniques required. 
8.3  Inflammatory Mediators 
Significant correlations were seen between the pro-inflammatory cytokine IL-8 
and changes in FEV1, in keeping with the findings of others (Mayer-Hamblett et 
al. 2007).  Given the underlying pro-inflammatory state of the infected CF lungs 
this is not unexpected.  However, values of NE, IL-8 and ECP were not 
statistically different at a clinically stable baseline compared to the start of a 
CFPE.  Possible explanations for this surprising negative finding are discussed 
above.  
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The lack of association between inflammatory markers and measures of 
symptoms is interesting.  It might have been expected that more inflammation 
would have been associated with worse (higher values) symptom scores.  More 
inflammation is certainly associated with significantly worse lung function, which 
in turn is strongly linked with worsening dyspnoea.  However, the data 
presented here have failed to complete the triangle.  This may be because 
inflammation does not directly drive dyspnoea, and the only indirect link 
between the two is the effect of inflammation on worsening lung function 
through tissue breakdown (Hilliard et al. 2007).  In fact this is more biologically 
plausible than inflammation itself having a direct causal link to dyspnoea.  
Despite this, if the sampling size was large enough one still might have 
expected to find an association between inflammation and symptoms, even if 
only because increased inflammation is associated with CFPEs, without 
implying a direct causal link.  However, the nature of the VAS as a tool to 
measure symptoms is intrinsically subjective and, between subjects, scores 
ranged without a clear link to their underlying disease severity. Taken together, 
this would suggest that the VAS is not a tool that is well suited to this kind of 
between-subject analysis.  
In the comparison of inflammatory mediators with measures of bacterial 
community structure, there were only two results of significance.  Both related to 
ECP, a little studied protein in CF.  Previous findings of raised levels of ECP 
correlating with CF disease severity were in themselves surprising, as 
eosinophils are not a feature of the CF airway (Koller et al. 1996).  No 
relationship to bacteriology has previously been noted.  The significance of the 
current findings is unclear.  It may be that the host immune responses to the  
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changes in the bacterial community structure are led by an eosinophilic driven 
process. Although the association is not strong, the direction of change is in 
keeping with results from other parts of this thesis, which have noted that there 
a more even community is seen during treatment for CFPE than before 
treatment. 
8.3.1 Limitations of Inflammatory mediators  
Inflammatory mediators were collected from the 14 subjects at various time 
points throughout the study period.  Subjects gave a median of 5 samples 
(range 2-10).  Samples were given at times of clinic attendance, which limited 
the ability to obtain samples at the optimum times around CFPEs.  It was not 
possible to obtain paired samples before and after a CFPE.  This limited the 
ability to correlate changes in inflammatory mediators that would be expected 
as a result of antibiotic treatment (Ordonez et al. 2003).  Changes seen in 
inflammatory mediators from times of CFPE to times of clinical stability may 
have had many other events between the intervention and the measurement 
that would make any change less reliable.  As can be seen from the results of 
symptoms using the clinical monitoring forms, there may be pseudo-CFPE, or 
other inflammatory airway events that were not diagnosed as CFPE.   
It was unfortunate that the degree of inflammation in some subjects was 
unexpectedly high.  This meant that some results, that could not be repeated, 
fell above the upper limit of the standard curve and thus could not be accepted 
as reliable results.  This negatively impacted on the results of inflammatory 
mediator measurements.    
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8.4  Culture independent bacterial analysis 
8.4.1 Periodic Stable Sampling 
Periodic stable sampling was undertaken in an attempt to understand what 
happens to the bacteria in the CF airway during the study period, without the 
periods of what were hypothesised to be the greatest fluctuations, CFPEs.  
Such a large scale longitudinal analysis of bacteria in the CF airway has not 
previously been attempted, although longitudinal analysis of bacteria by culture 
independent techniques in the human gastrointestinal tract (De La Cochetiere et 
al. 2008; Dethlefsen et al. 2008; Mackie, Sghir, & Gaskins 1999), and other 
non-clinical settings have been performed (Bell et al. 2008; Hongoh et al. 2005; 
Robinson et al. 2009).  The findings presented here show a high degree of 
bacterial community stability over time, with 10 of 14 having the same basic 
community of bacteria (i.e. the same dominant species in the top few positions 
of the species rank abundance plot) at the end as at the beginning.  This is 
despite, or possibly because of, the panoply of antibacterial treatments received 
by the subjects of the course of the study.  It would be well accepted by most 
clinicians that P. aeruginosa becomes dominant in the airway of most CF 
patients and would remain permanently as such (Cystic Fibrosis Trust 2009a), 
eradication attempts not withstanding (Taccetti et al. 2005).  Thus, by culture 
based techniques P. aeruginosa would achieve stability over time.  However, 
the result presented here show more than stability of one species, but of a 
community of bacteria.  In a number of subjects species or bands other than P. 
aeruginosa achieve the same level of stability over time (e.g. subject 01).  In 
addition the species further down the rank abundance curve are also relatively 
stable.  Such stability over time has been seen in other environmental  
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communities, despite marked temporal perturbations (Lacap, Barraquio, & 
Pointing 2007).  There a number of possible explanations for this.  This might 
suggest that the established community of bacteria has not been challenged by 
new species.  This seems unlikely, given the widespread abundance (Curtis, 
Sloan, & Scannell 2002) of microbes in the mouth (Aas et al. 2005; Socransky 
et al. 1963), and in the air (Fierer et al. 2008; Wainwright et al. 2009).  Others 
have assessed factors responsible for colonisation of new and established 
biofilms, albeit in an in vitro stream model, and found that both physical and 
biological factors influence the likelihood of colonisation (Augspurger et al. 
2010).  It thus seems likely that the bacterial community has some intrinsic 
stability, in which it has some characteristics that make it resistant to intrusion 
by other bacteria.  In terms of biological reasons for this, it may be due to 
limitations in supply of key nutrients, or substrate, upon which a given bacteria 
is dependent in order to make a living.  Availability of nitrate has been shown to 
affect the gene expression of P. aeruginosa (Hoffman et al. 2010), whilst the 
ability to utilise iron may be important for bacterial fitness (Harrison & Buckling 
2009).  There may also be physical barriers, in the amount of secretions in the 
lower airway that prevent new bacterial species entering the established 
bacterial biofilm communities that exist (Donlan & Costerton 2002).  The clinical 
significance of stability, and lack of it in some subjects, is not clear.  it is 
possible that the stability is, in part, driven by the antimicrobial therapy, with 
inhaled aminoglycoside therapy (Ramsey et al. 1999) resulting in increased 
propensity of bacteria such as P. aeruginosa to form biofilms (Hoffman et al. 
2005)   
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From the ribosomal gene clone sequence analysis it is possible to accurately 
establish that a considerable proportion (44%) of the bacteria in the CF lower 
airway are obligate anaerobes (see 5.1.1.1 above and Table 9-1 below).  This is 
in keeping with a number of previous studies that utilised both culture 
dependent and culture independent techniques.  Rogers et al (Bittar et al. 2008; 
Rogers et al. 2004; Rogers et al. 2005; Rogers et al. 2008; Tunney et al. 2008).  
Tunney et al. described large numbers of anaerobes by culture, with anaerobic 
species in 42 of 66 samples (64%).  Using 16S bacterial clone sequence 
analysis Bittar et al. identified 736 clones, of which 119 (16%) were considered 
obligate anaerobes. 
In addition to bacteria that are only capable of anaerobic respiration, there are 
some species which have been shown to be facultative anaerobes in the CF 
airway, e.g. P. aeruginosa (Worlitzsch et al. 2002).   This has potentially 
important implications in a number of ways.  Firstly, antibiotic strategies that 
target P. aeruginosa alone, without targeting other anaerobic bacteria will not 
provide optimum anti-bacterial spectrum cover.  In addition, culture based 
antibiotic sensitivity testing results, are based on aerobic culture of P. 
aeruginosa cells not growing as a biofilm.  It has been previously shown that P. 
aeruginosa in a planktonic form is intrinsically less resistant to antibiotics than 
the biofilm form that is more akin to the in vivo mode of growth (Hill et al. 2005).  
Additionally, it opens up the possibility that there may be other ways to add 
physiological stress to the growth of anaerobic bacteria beyond the use of 
antibiotics and the associated side effects (Cystic Fibrosis Trust 2009a).  One 
possible therapy that may be worth future study is supplemental oxygen.  
Increased oxygen concentrations in the CF airway would reduce the amount of  
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anaerobic secretions in which anaerobic bacteria flourish (Worlitzsch et al. 
2002).  Supplemental oxygen is already used to reduce complications of 
advanced CF lung disease associated with chronic hypoxaemia (Cystic Fibrosis 
Trust 2001).  In addition to these potential benefits there is evidence that 
alveolar hypoxia may contribute to the pro-inflammatory milieu of the CF airway 
(Leeper-Woodford & Detmer 1999).  Thus the use supplemental oxygen may 
theoretically have a role to play in reducing the vicious cycle of inflammation 
and infection, as well as perturbing the anaerobic bacterial community. 
The presence of such large number of bacterial species that are associated with 
the human oropharynx is of interest.  They have been shown to be not just 
‘passing through’, but members of the core community of bacteria. This is an 
important point, as Magurran and Henderson made clear in 2003 (Magurran & 
Henderson 2003).  In their paper, which studied fish species and number in the 
Bristol Channel over a twenty year period, they showed that it was possible to 
differentiate between species that are transient in the sampling environment, 
and those that are resident species.  In the context of the CF lung and the 
mucociliary escalator, these resident species are analogous to the core species 
of the lung, and the satellite species are analogous to the transient fish species 
that were found in the Bristol Channel after storms out in the Atlantic Ocean.  
This raises another question.  What is the source of these two populations of 
lung bacteria?  Both core and satellite communities have ‘oral’ bacteria in them.  
It is known that the mucociliary escalator is a crucial part of lung host defence 
(Regnis et al. 1994), and that clearance is impaired in CF (Robinson & Bye 
2002).  In addition it has been shown that micro-aspiration of gastro-
oesophageal contents occurs in to the CF airway in significant amounts (Ledson  
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et al. 1998; Ledson, Tran, & Walshaw 1998b).  Finally the mechanisms that 
drive whether a species moves from transient to resident, satellite to core 
species has been shown to be at least partly stochastic (van der Gast, Ager, & 
Lilley 2008).  Thus, this situation combines the predisposition of the CF airways 
to persistent infection, the ongoing mechanism by which such oral and gastro-
intestinal bacteria could reach the lower airways and evidence for why some 
become core species and others do not.  The work presented here 
demonstrates that such bacteria, which have previously not been considered as 
part of the usual CF respiratory bacteria and only demonstrated as present by 
molecular techniques in single time point studies, are present over long periods. 
A number of different measures were employed to elucidate differences in 
bacterial community structure in repeated samples from periods of stability 
during the study (Section 5.2).  A number of significant findings were made.  In 
Section 5.2, it was shown that subjects with more severe CF pulmonary 
disease, as determined by FEV1 percentage predicted, had significantly more 
uneven bacterial communities and fewer species detected.  This could be 
explained in a number of ways.  Firstly, FEV1% is an independent risk factor for 
CFPE (Block et al. 2006).  Thus, those with more severe CF pulmonary disease 
are likely to have had more frequent courses of antibiotics, as well as more 
lifetime antibiotics.  In turn, these antibiotics may have applied selective 
pressures to the bacterial community resulting in a reduction in the number of 
persistent species, increased dominance of those species that did persist and a 
commensurate increase in the unevenness of the bacterial community.  An 
additional explanation for this finding, and not necessarily one in which is 
mutually exclusive to the first, is that a less even community is one that results  
  252 
in greater potential for lung damage.  Support for such an idea comes from in 
vitro  work on P. aeruginosa and decreased virulence in the presence of a more 
diverse community (Harrison et al. 2006).  Thus the presence of such an 
uneven community and reduction in bacterial diversity may be a contributory 
factor to the pathological process. 
In addition to differences in the bacterial community between subjects with high 
and low lung function when assessed by bacterial community evenness, 
differences were seen between the groups when assessing similarity between 
samples.  A significant difference was seen when assessing using the Bray-
Curtis Index.  There was a greater difference between consecutive samples 
with lower lung function, a finding that would be consistent with the theory that 
different parts of the more damaged and ecologically heterogeneous lungs 
harbours distinct bacterial communities.  This would offer an explanation as to 
why Subjects 5 and 9 had Periodic Stable T-RFLP plots that were so much 
more variable than other subjects.  However, this theory would be out of 
keeping with previous work (Gutierrez et al. 2001), where multiple lobes of CF 
lungs under went bronchoscopic lavage.  However, this work was culture based 
and thus not comparable to the work presented here.  Furthermore the 
comparability of such findings is further hampered as the work was in children 
(age range 1.5 – 57 months). 
In addition to differences seen between subjects grouped by lung function, there 
were significant differences between subjects grouped by gender.  This is an 
area of interest to clinicians, as there is an as yet unexplained difference in 
survival between females and males with CF (Corey et al. 1997; Liou et al. 
2001; Rosenfeld et al. 1997).   In this work there was a significantly more  
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uneven bacterial community in female subjects than in males.  This is despite 
the males having on average a lower FEV1% (49% vs. 58%), which has been 
shown to favour a steeper slope.  There other baseline characteristics and 
factors not accounted for in this association, such as course of antibiotics, 
baseline therapy, and adherence to therapy to name but a few, but this is a new 
finding and warrants further attention.  In addition to the differences in bacterial 
community evenness, differences in the data emerging from the similarity 
indices used was noted.  There was no difference in similarity when measured 
by the Sorensen Index, but there was a difference when the Bray-Curtis Index 
was used (see Figure 5-13).  This disparity between the two indices is perhaps 
unsurprising as the Sorensen Index is a less sensitive measure of bacterial 
community fluctuations as it uses binary species abundance data (i.e. species 
present or absent), whereas the Bray-Curtis Index uses quantitative proportion 
of bacteria present in each sample.  The use of the Sorensen Index helped to 
detect the presence (or lack) of new species in the community.  Given the 
stability of species present in the communities over time, yet fluctuations in 
proportions of bacteria present, it is perhaps no surprise that the Bray-Curtis 
Index appears more sensitive than the Sorensen Index to detecting changes.   It 
remains possible that the difference in slope between genders may contribute to 
the cause of the gender mortality gap through being associated with more 
inflammation and lung damage.  It is equally possible that it is due to a third, as 
yet unaccounted for factor that is responsible for the mortality gap and the 
difference in bacterial community evenness.  It has previously been suggested 
that hormonal differences may play a role (Gurwitz et al. 1979).  More recent 
studies have refuted this however, as the mortality gap was at its most 
pronounced before puberty (Rosenfeld et al. 1997).  The Rosenfeld database  
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study from 1997 (Rosenfeld et al. 1997) examined over 20,000 American CF 
patients, and no associations to explain the gender gap were found.  Only one 
study has suggested a microbiological explanation for the gap (Demko, Byard, 
& Davis 1995).  Demko et al. found that females had earlier acquisition of 
mucoid P. aeruginosa , but both males and females had the same rate of 
decline in lung function after acquisition.  In addition the gender mortality gap 
persisted even among subjects with only the non-mucoid form of P. aeruginosa.  
The authors concluded that factors other than P. aeruginosa may play a role.  
The work presented here offers new insights in to possible linkage between 
bacterial community structure and the gender mortality gap in CF.  It is also of 
interest that the mortality gender gap may not be limited to CF, as recent work 
has suggested that females with COPD may do worse than males (Ekström, 
Franklin, & Ström 2010). 
Another finding with potential significance is the observation that there is a 
association between the presence of band 268 (‘Unknown species 17’) and 
subjects being frequent exacerbators (Figure 6-13 above.  This finding is of 
great potential significance, particularly as this band does not appear to be P. 
aeruginosa.  If confirmed by larger studies, it would offer the hope that targeted 
therapy at this species might reduce rates of CFPEs with all the associated 
negative health, QoL and cost implications (Britto et al. 2002; Liou et al. 2001; 
Weiner et al. 2008).  As such it is unfortunate that clone sequence analysis, 
undertaken on one sample from each subject at the start of the study, did not 
reveal any species that may have been responsible for band 268.  It is thus of 
great importance to identify the origins of band 268.  
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8.4.2 Culture Independent Microbiological Analysis of CFPEs 
The cause of CFPEs is as yet unknown.  In COPD, exacerbations have been 
linked to the acquisition of new bacterial strains, albeit bacteria grown from 
sputum by culture based techniques (Sethi et al. 2002). It has previously been 
suggested that CFPEs may be due to the acquisition of new strains of P. 
aeruginosa, but there is now convincing evidence that this is not the case 
(Aaron et al. 2004).  It is likely that, if there is a proceeding trigger that causes 
the change in respiratory symptoms in CF, it is multi-factorial (Goss & Burns 
2007).   
When reviewing the effects of antimicrobial therapy on airway microbiology in 
CF, the evidence for clear benefit is not as convincing as might be assumed 
(Wolter, Bowler, & McCormack 1999).  P. aeruginosa is consistently found by 
culture before and after both IV antibiotic therapy targeted at P. aeruginosa 
(Gold et al. 1985; Gold et al. 1987; Regelmann et al. 1990) at CFPE, and during 
long term oral (Saiman et al. 2003; Wolter et al. 2002) and inhaled antibiotics 
(Mccoy et al. 2008; Ramsey et al. 1999; Retsch-Bogart et al. 2009) in 
chronically P. aeruginosa infected subjects.  There is thus little evidence to 
suggest that antimicrobial therapy is ‘treating’ these pulmonary infections in the 
same way that an acute infection in a sterile environment is treated.  Thus 
antimicrobial therapy for pulmonary exacerbations in CF may be having 
alternative or additional modes of action beyond an effect of P. aeruginosa. 
The results presented here cast more light on the “murky” world of bacteria in 
the CF airways before, during and after CFPEs.  Others has previously 
identified significant quantities of anaerobic bacteria in cohorts of CF subjects 
(Bittar et al. 2008; Tunney et al. 2008; Worlitzsch et al. 2009).  Figure 6-2 and  
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Figure 6-4 above show changes in bacterial community richness and evenness 
around the time of CFPE.  The mean number of species detected at day zero 
(prior to antibiotic treatment) is lower than at the time points measured in the 
preceding three weeks.  This reduction in diversity is maintained for the duration 
of the treatment and beyond, although significantly outlying results were 
observed.  Figure 6-7 shows that bacterial community evenness, as measured 
by the slope of the rank abundance for curve, also changes in a similar pattern.  
At day zero (prior to treatment for CFPE) the slope becomes steeper, a change 
that is reflected by the dip in FEV1 that occurs at around the same time.  This 
change in slope would be expected, given the aforementioned reduction in 
diversity seen mentioned above.  However, the introduction of treatment 
including antibiotics for the CFPE, do not then alter this reduction in richness 
and evenness.  The changes also typically persist after the end of treatment.  It 
would suggest that the reduction in diversity may play some role in the aetiology 
of the CFPE rather than being a response to treatment.  However this reduction 
in diversity prior but not more than 6 days before treatment may be at odds with 
the change in symptoms that appears to occur a number of weeks prior to the 
start of treatment (see Table 4-18).  After the end of treatment, lung function 
continues to improve, but no consistent changes are seen in bacterial 
community evenness and richness, although levels remain lower than in the 
three weeks leading up to treatment. 
Other researchers have investigated the effects of antibiotics on bacterial 
communities, with conflicting results.  Recently, and with most in common to the 
short term longitudinal effects studied here, Robinson et al. (Robinson et al. 
2009) looked at the effects of antibiotics and nutrient changes on the bacterial  
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ecology of the Cabbage White butterfly larval midgut using culture independent 
strategies.  Their study showed that caterpillars ingesting antibiotic impregnated 
feed resulted in a marked increase in the means species richness (from 14 to 
43 species).  This suggested that antibiotics were allowing the detection of more 
species by suppressing the previously most dominant species.  The results from 
the CF airway presented here are at marked odds to this finding.  However this 
may be, of course, because of the marked physiological and ecological 
differences that exist between the healthy Cabbage White butterfly larva, and 
the CF lung.  Firstly, the caterpillar gut is an environment that has evolved, like 
all gastro-intestinal tracts, to harbour a normal community of bacteria that co-
exist symbiotically with the host.  The healthy gut does not mount an immune 
response to a normal bacteria community, in contrast to the CF lung which is in 
response, at least partly, to the presence of bacteria (Armstrong et al. 1997).  A 
second important difference between the two situations is that antibiotics in CF 
were given in response to some change in the clinical situation, which may in 
turn have been driven by some change(s) in the bacterial community.  Finally 
the CF lung is not an antibiotic naïve environment, but in fact quite the reverse, 
with continuous oral and topical (inhaled) antimicrobial therapy the norm in most 
cases, plus episodic IV antibiotics over many years.  This will already have had 
major effects on the bacterial community structure for many years, and this 
study is assessing the situation many years after the first antimicrobial 
intervention. 
Given the previous controversy around the effects of antibiotics on P. 
aeruginosa (Wolter, Bowler, & McCormack 1999) and other bacteria species  
(Worlitzsch et al. 2009) during treatment for CFPEs, work was done to assess  
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the effects of treatment during this study.  In Figure 4-32 and Figure 4-33 
above, it can be seen that treatment was clinically effective with returns to 
baseline levels in spirometry and symptom scores.  The effects of treatment on 
key airway bacteria is shown in Figure 6-8 and Figure 6-9 above.  For example, 
across the 12 CFPEs analysed, the proportion of Prevotella spp. prior to 
antibiotics was 25%, which had fallen to 6.35% by the end of the antibiotic 
course, whist the proportion of P. aeruginosa was 42.8% prior to antibiotics, 
compared to 68.1% after antibiotics.  Here it was shown that therapy for CFPEs 
is preferentially reducing the proportions of anaerobes whilst increasing the 
proportions of P. aeruginosa.  It is of interest there is a non-significant trend 
towards an increase in proportions of anaerobes in the 21 days preceding the 
start of CFPE treatment.   In addition, the effects of treatment in reducing 
anaerobe proportions persist beyond the end of treatment.  It is worth 
speculating whether there was a rise in the relative abundance in the anaerobic 
population even further before each CFPE, perhaps even leading as far back as 
the last systemic antibiotic course.  In addition to the suggestion of a 
disproportionate effect of treatment on proportions of anaerobes, it should be 
noted that the proportion of P. aeruginosa rises during treatment, a finding that 
is counter to any that is seen in studies that have employed culture based 
techniques.  Regelmann et al. ( 1990) showed a reduction in density of P. 
aeruginosa, as measured by colony forming units (cfu), attributable to antibiotic 
treatment alone.  This fall was proportional to clinical improvement.  Are these 
two pieces of work contradictory or is there a unifying explanation?  Both 
techniques offer only a relative change in bacterial quantities, as there is no 
indirect way of quantifying the total number of bacteria within the lungs.  Both 
techniques attempt to take account of bacterial cell viability, T-RFLP by using  
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PMA (Rogers et al. 2008) and culture by the fact that only live cells can form 
colonies.  However, it may be possible to reconcile the two findings.  It is 
possible that the total bacterial load per aliquot of sputum has been reduced by 
antibiotics (including the total P. aeruginosa content), but that a proportionately 
greater fall in the amount of anaerobes has occurred, as T-RFLP reports a 
percentage of a species in the total community. 
This finding of a significant effect of treatment of proportions of obligate 
anaerobes is contrary to the only other longitudinal study of anaerobes during 
CFPE treatment.  Worlitzch et al. (Worlitzsch et al. 2009) study anaerobes in 
sputa in 12 adult subjects with CF by using culture based techniques.  They 
found no fall in quantitative colony counts of anaerobes between start and end 
of therapy for CFPE.  The subjects in their study also received IV antibiotics in 
hospital or at home.  Such differences in findings may well reflect the 
techniques used for detection and identification of anaerobes.  For P. 
aeruginosa, culture based techniques have been shown to be poorly 
reproducible and of doubtful clinical significance (Foweraker et al. 2005; Smith 
et al. 2003).  Given that many of the same short comings of selective culture 
techniques apply equally well whatever the species being cultured, this is 
perhaps no surprise.  
It is worth mentioning that it is not possible from the current work to 
demonstrate what has driven the changes in bacterial communities that occur 
during treatment for a CFPE.  Treatment consists of much more than just 
antibiotic treatment.  Airway clearance techniques, nutrition, improved 
adherence to other prescribed therapies and supplemental oxygen therapy are 
all likely to play some part.  Indeed oxygen therapy is worth further discussion.   
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It is well described that bacteria in the CF airway live in an oxygen depleted 
environment (Worlitzsch et al. 2002; Yoon et al. 2002).  In the work presented 
here it has been shown that proportions of obligate anaerobes, including 
Prevotella sp fall during treatment, that often includes supplemental oxygen 
therapy in the acutely hypoxic patient (Cystic Fibrosis Trust 2001).   It is 
therefore of great interest that there is in vitro work to show that oxygen may be 
directly toxic to Prevotella species (Takumi et al. 2008) as well as to strict 
anaerobes generally.  As a result of the findings presented here, and the 
published work of others, new treatment strategies may become available. 
In addition to the accepted wisdom of the importance of P. aeruginosa and 
CFPEs, others have suggested a role for the Streptococcus Milleri group (SMG) 
(Sibley et al. 2008a).  It has been noted in Section 5.1 that almost no bacterial 
clones from this group were detected from sputum samples at times of stability.  
In this data using T-RFLP before, during and after CFPEs, no evidence for a 
role for bacteria from the SMG was found. 
8.4.3 Polymicrobial diversity in the CF airways: beyond bacteria 
Despite the significant attempts to unravel the complexity of symptoms and 
microbiology of the CF airway, much remains unclear. Since the inception of 
this study, a number of key pieces of research have been published, some of 
which have already been alluded to.  Crucially, even greater microbial diversity 
has been reported.  Nagano et al. have shown that there are large numbers of 
diverse fungal species present in the CF airway (Nagano et al. 2009).  This is 
interesting from an ecological point of view, as fungi and bacteria are capable of 
communicating and interacting.  Kerr et al. showed that a number of P.  
  261 
aeruginosa- derived compounds inhibited growth of Candida albicans and 
Aspergillus fumigatus in vitro (Kerr et al. 1999).  Such a finding is in keeping 
with clinical observations in CF (Hughes & Kim 1973).  In addition, Candida  
albicans has been shown to be capable of producing chemicals that can inhibit 
the quorum sensing signals in P. aeruginosa that are so important fin biofilm 
production (Cugini et al. 2007).  In addition there is also increasing evidence 
notably from a recent observational study (Amin et al. 2010) that the persistent 
presence of Aspergillus spp. in CF sputum, without evidence of Allergic 
Bronchopulmonary Aspergillosis (ABPA), is a strong risk factor for admission to 
hospital with a relative risk of 1.94.  It is worth noting that it is now known that A. 
fumigatus is capable of growing as a biofilm (Loussert et al. 2009). 
The other work to open up new kingdoms of microbial diversity in CF showed 
that there may be an enormous diversity of DNA viral communities in the CF 
airways (Willner et al. 2009).  Virus have been previously implicated in the 
pathogenesis of CFPEs (Efthimiou et al. 1984; Hiatt et al. 1999; Hordvik et al. 
1989; Wat et al. 2008b).  In subjects with preceding established airway infection 
it is possible that the airborne arrival of sufficient quantities of a virus contribute 
to perturbing the established balance of a bacterial community, thus contributing 
to the pathogenesis of a CFPE.  To date no work presented here is able to 
confirm of refute such a hypothesis, but it provides an interesting future avenue 
for investigation.  In addition to these potentially negative effects of viruses in 
the CF airway, there is also the possibility that viruses may be able to play a 
role in a more positive way through the role of bacteriophages which have been 
shown to be able to modulate biofilms and influence P. aeruginosa phenotypes 
(Azeredo & Sutherland 2008; Brockhurst, Buckling, & Rainey 2005).    
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One prominent finding from this work is that bacteria that are typically 
considered part of the oral microbiota can be permanent and important 
constituents of the bacterial community in the CF airway.  In order to inform the 
direction of future studies it is of great interest to ascertain the origins of the 
bacteria that constitute the CF airway bacterial community.  The work presented 
here would add support to the hypothesis that a significant proportion of the CF 
bacterial community originated in the oropharynx.  It seems very likely that 
micro-aspiration occurs from the oropharynx in both healthy subjects and 
patients with CF from a young age (Blondeau et al. 2009; Ledson et al. 1998; 
Ledson, Tran, & Walshaw 1998a).  The healthy subject would be able to 
withstand small quantities of erosive and infective material, but the same may 
not be true of subjects with CF.  This gives rise to at least two potential areas 
for future study.  The first is the role of reducing the reflux and aspiration of 
gastric contents, irrespective of its pH.  The second is the role of oral health.  
The teeth are well known to harbour a diverse community of bacteria, including 
many anaerobes (Filoche, Wong, & Sissons 2009; Gibbons et al. 1963).  As 
such both gastric refluxate and oral micro-aspirates may be a source of the 
bacterial diversity identified in this work. 
Another situation where lower respiratory tract infection is a major cause of 
morbidity and health care cost is in Ventilator Associated Pneumonia (VAP).  In 
VAP, a patient who is immuno-suppressed by the nature of their acute illness, is 
ventilated using an endotracheal tube (ETT).  This ETT may act as a ladder to 
allow the migration of bacteria from the chronically colonised upper respiratory 
tract through the usually impregnable “doors” to the LRT that constitute the 
vocal cords.  A number of microbiological interventions to reduce the incidence  
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of VAP have been subject to large scale RCTs.  These include the use of 
chlorhexidine mouth care around the time of intubation (DeRiso et al. 1996; 
Segers et al. 2006), and the use of ETTs impregnated with silver as an 
antimicrobial agent (Kollef et al. 2008).  Such studies suggest that it may be 
worth considering similar strategies for CF patients.  As yet, it has not been 
documented whether subjects with worse oral hygiene have earlier or more 
rapidly progressive lung disease.  One final point to conclude on the connection 
between the oral cavity and the lower airway bacterial community in CF, is that 
in mouse models of CF is noted that the CFTR protein has been found to bind 
and phagocytose P. aeruginosa in wild type but not CFTR
-/
-  knockout mice, 
leading to lower airway colonisation (Coleman et al. 2003).  This might suggest 
that the long established and important CF pathogen P. aeruginosa may early 
persistence in the oral cavity as a stepping stone to the lower airways.  Indeed 
there are to date no convincing clinical data to suggest exactly by what route P. 
aeruginosa enters the lung, by inhalation (Wainwright et al. 2009), or by oral 
micro-aspiration (Button et al. 1997). 
8.4.4 Limitations of Culture Independent Techniques 
Culture-independent microbiology techniques offer many potential advantages 
over traditional selective culture based techniques such as lack of selection 
bias.  As with all methods each has advantages and disadvantages, as outlined 
in Section 2.3 above (Nocker, Burr, & Camper 2007).  For bacterial community 
profiling and compared to earlier molecular methods such as DNA:DNA re-
association kinetics (Torsvik 1980; Torsvik, Goksoyr, & Daae 1990), T-RFLP 
offers many advantages, such as relatively quick results, relatively high 
throughput and also some approximate speciation (Liu et al. 1997).  It also  
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offers better reproducibility and higher measures of diversity than Length 
Heterogeneity PCR (Rogers et al. 2003).  An additional potential concern with 
T-TFLP as a technique is that the number of copies of the 16S ribosomal RNA 
gene varies between species, and thus there may be a bias in the apparent 
relative abundances detected (Farrelly, Rainey, & Stackebrandt 1995).  
Due to the limitations of T-RFLP listed above, an additional technique was 
employed to add specificity to the identification of bacteria.  Here, 16S 
ribosomal RNA clone sequence analysis, considered the ‘gold standard’ for 
bacterial identification (Dowd et al. 2008) was also carried out.  Such analysis 
was performed on a sample from each subject, from a time distant to treatment 
for a CFPE.  It was not possible to undertake this on more than one sample due 
to the additional time and cost involved in this technique, but in terms of the 
objectives of this study, such an approach was deemed to be appropriate.  The 
results are presented in Section 5.1.  In summary a median of 7.5 species per 
subject were detected (IQR 5.75-17.75).  In addition 15 species not previously 
described in CF samples were identified.  This is also in keeping with previous 
work and confirms previously described bacterial diversity in CF respiratory 
secretions (Bittar et al. 2008; Rogers et al. 2004).  This clone sequence analysis 
serves a number of purposes in this study.  Firstly, it confirms the previous 
findings of higher bacterial diversity than that detected by culture based 
methods.  Secondly, it allows greater certainty in the speciation of recognised T-
RF bands detected by T-RFLP.  Finally it allows greater certainty when 
assigning a species name to a T-RF band.  As previously discussed it not 
possible to ascribe a species name to each T-RF band with absolute certainty, 
due to between 36,000 to 2 million bacterial species, and ‘only’ ~900 bases  
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within the 16S RNA gene.  Thus 16S ribosomal gene clone sequence analysis 
allows more accurate speciation of T-RF bands that cannot be assigned to 
species by in silico analysis of the T-RFLP results. 
The results of clone sequence analysis can be used to review the results of T-
RFLP.  It is noted from Principle Component Analysis of stable samples that a 
species with a band length of 268 bases appears to be an important in 
differentiation between frequent and infrequent exacerbators (see Figure 6-13).  
The source and identity of this band would be of great importance as there is 
data here to suggest that it may play a significant role in CFPEs.  However, the 
results of bacterial clone sequence analysis fail to provide clues or answers as 
to the identity of this band, as no species is identified that would give rise to a 
predicted cut point at this length.  Given that it can be seen from Table 5-3 that 
T-RF 268 constitutes the dominant band in 5 of the 14 subjects and is in the top 
three species in two others, this is somewhat surprising.  It is possible that a 
new species did indeed become dominant following the start of the study (the 
time that the clone sequence analysis).  Another possibility is that it is derived 
from a species that was detected by clone sequencing but that does not have a 
predicted cut in 268 bases, as currently registered online with the BLAST 
database (see Section 2.3.2).  However, it is a possibility that band 268 is in fact 
derived from another, more dominant, species such as P. aeruginosa, as has 
been shown to be a possibility with band 567, as outlined in Section 2.3.2.1 
above.  If this is the case, the genetic sequence of the rRNA gene that is the 
target of T-RFLP may have altered in some way.  Significant evolutionary 
changes in P. aeruginosa have been seen to take place in chronic infection of  
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the CF airway  (Smith et al. 2006a) favouring decreased virulence and 
increased persistence. 
A large proportion (44%) of the species both detected by T-RFLP and clone 
sequencing were identified as obligate anaerobes as well as constituents of the 
normal oral bacterial community.  Given that all the samples in this study were 
spontaneously expectorated samples, this might give rise to a potential 
criticism.  It is a theoretical possibility that the anaerobic bacteria detected are 
not, in fact, members of the bacterial community in the lungs but merely 
contaminants of the sputum bolus acquired in its passage through the 
oropharyngeal cavity.  However, such criticisms have been comprehensively 
dealt with in many ways in previous publications, and with additional evidence in 
this work.  Firstly, paired mouthwash and sputum samples show very poor 
species concordance, although there was some similarity (Rogers et al. 2006).  
To counter the claim more robustly, others have obtained samples without the 
risk of oropharyngeal contamination, with samples obtained by fibreoptic 
bronchoscopy.  For the multiple repeated samples required for this study, such 
invasive sampling methods were not appropriate.  Samples obtained in such a 
way have been subject to anaerobic culture (Tunney et al. 2008), and ribosomal 
gene clone sequence analysis (Bittar et al. 2008).  In addition, this present 
study has shown that bacteria from e.g. the genus Prevotella are members of 
the core species in the community of bacteria in the lower respiratory tract, and 
not merely detected as a result of occasionally poorly prepared sputum 
samples.  
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Propidium monoazide 
As previously discussed, a new method of preparing the samples prior to T-
RFLP became available during the course of the study (Nocker et al. 2007).  
The use of PMA allows the removal of extracellular nucleic acid material, and is 
able to bind and remove from further analysis the nucleic acid from within non-
viable cells.  This allowed the T-RFLP process to be refined so that the step of 
RT-T-TFLP (used to demonstrate the presence of metabolically active, viable 
bacteria) was no longer required.  T-RFLP on samples that had undergone 
PMA treatment would only amplify nucleic acid from bacterial cells that were 
intact and viable.  All results presented in the molecular CFPE analysis 
(Chapter 6) were subject to treatment with PMA.  All samples in the Periodic 
Stable Sampling analysis Chapter 5) were analysed by T-RFLP and RT-T-
RFLP, without the benefit of PMA treatment.  
8.5  Future Directions 
The work presented here has revealed a large amount about the complexity of 
CF pulmonary disease.  There are many different directions to take and a 
number are discussed below. 
Clinical Monitoring 
The work presented here shows previously unsuspected complexity and day to 
day variability in symptoms in adults with CF.  This findings clearly demonstrate 
that these components, that constitute a major proportion of the plethora of 
symptoms that constitute a CFPE (Fuchs et al. 1994; Ramsey et al. 1999; 
Rosenfeld et al. 2001), are part of a continuum with no clear way to determine a  
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CFPE.  This goes some way to help understand why defining a CFPE has 
proved so difficult (Marshall 2004).   
The data presented here suggests that VASs are a good tool for monitoring 
changes in individual patients or subjects, but do not allow for easy comparison 
between patients or subjects.  One suggestion for the future is that VASs may 
provide a useful tool in the clinical setting to allow different clinicians to monitor 
symptoms changes between clinic visits in a more objective manner than is 
currently possible.  For example it would allow a clinician to attach a numerical 
value to the answer to the oft asked question “How are you today compared to 
last visit?”.  Providing an objective measure of a subjective phenomena is likely 
to become more important as the number of clinicians involved in CF care 
continue to rise in line with the expanding adult CF population (Dodge et al. 
2006). 
Sputum Inflammatory Mediators 
Sputum inflammatory mediators are a challenging area.  The findings presented 
here show that sputum ECP correlate to indices of bacterial community 
structure.  The findings suggest that the more even the community, the greater 
the amount of ECP.  This finding is in keeping with others within this study, 
notably that there are fewer species detected, with a less even community 
structure during treatment for a CFPE, than in the preceding three weeks.  
However, the biochemical link between ECP, derived from the host 
inflammatory cells, and these bacterial community structure indices is not clear.  
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Microbiology 
The somewhat unexpected observation that treatment for CFPEs results in a 
dramatic fall in the proportions of anaerobic bacteria, but no significant change 
in the proportion of P. aeruginosa leads to a number of further possible avenues 
for investigation.  Given the increasing predicted life expectancy of people with 
CF (Dodge et al. 2006) side effects from treatment are becoming increasingly 
important and serious for patients (Al-Aloul et al. 2005; Bertenshaw et al. 2007).  
Thus strategies aimed at reducing the reliance on toxic antimicrobial therapy 
are needed.  Oxygen therapy targeting anaerobes such as Prevotella (Takumi 
et al. 2008) may be able to play such a role.   
 
New Insights in to Mechanisms of Action for Established Therapies 
The findings that are presented here suggest additional explanations to the 
accepted mechanisms of action for proven therapies for CF.  Hypertonic saline, 
for example, has been shown to be beneficial in large RCTs in CF (Elkins et al. 
2006).  It is hypothesised to work by correcting the defective dehydration in the 
airway surface liquid in CF, thus allowing more effective mucociliary clearance 
(Boucher 2007).  Thus may indeed be true, but the evidence presented here 
suggests that there is another possibility: that hypertonic saline is influencing 
the microbial community.  This may be either by reducing the passage of 
bacteria from upper to lower airway akin to mouthwash in VAP (Koeman et al. 
2006), or by altering the microbial habitat such that the microbial residents are 
changed in composition or activity.  
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There are at least two other important proven therapies in CF that may exert an 
effect though influencing the microbial community.  The first is Azithromycin, 
which has been shown to have considerable beneficial effects in long term 
therapy, in reducing exacerbations, and increasing lung function and weight 
(Jaffe et al. 1998; Saiman et al. 2003; Wolter et al. 2002).  Putative mechanisms 
of action include as an anti-inflammatory agent (Ianaro et al. 2000), as a 
quorum sensing blocker (Hoffmann et al. 2007), and as an anti-biofilm agent 
(Gillis & Iglewski 2004) among others.  Which ever of these are involved, it 
would seem likely that previous studies of the effects of azithromycin on airway 
microbiology using culture dependent techniques (Saiman et al. 2003; Wolter et 
al. 2002) would have been insensitive to the types of changes seen in this work. 
Secondly, Dornase alpha is commercially available DNAse that has been 
shown to be beneficial in CF (Fuchs et al. 1994).  It is thought to work by 
thinning what is presumed to be hyper viscous sputum, allowing more efficient 
expectoration and less damage to the airways as a result of the inflammatory 
cytokine milieu that is present in the sputum.   In addition to this Dornase alpha 
may have an ecological impact on the bacterial community.  It has been shown 
that a more viscous medium has been shown to encourage co-operation 
between strains of P. aeruginosa (Kummerli et al. 2009)  and promote biofilm 
formation (Matsui et al. 2006).  Thus, by thinning the viscous lower airway 
secretions, treatment with Dornase alpha may alter the microbial community in 
the lower airways in CF in a beneficial manner. 
A more thorough study of the ecological effects of such treatments in vivo would 
allow greater insights in to mechanisms and open up new avenues of other 
such therapies.   
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A Possible Connection between the Upper and Lower Airway in CF 
As discussed in the preceding section, the work presented here suggests there 
may be bacterial colonisation from the oropharynx to the lower airway in CF.  
There is good evidence that bacterial colonisation of the LRT occurs early in 
CF, perhaps shortly after birth, and is associated with inflammation (Armstrong 
et al. 1997; Armstrong et al. 1995; Armstrong et al. 2005).  This early stage of 
CF pulmonary disease is when there is the most potential to limit future 
damage, and thus reduce morbidity and mortality.  Before embarking on a RCT 
of any intervention to improve oral hygiene with the proposed outcome of 
reducing bacterial migration to the lower airways, it would be useful to 
demonstrate a link between poor oral hygiene, either by dental caries measures 
(Macnab et al. 2008), or by assessment of adherence to standard dental 
hygiene (Narang et al. 2003) (brushing teeth, visits to the dentist etc.).  It might 
be expected that those more dental caries, and those with poorer adherence to 
standard dental hygiene techniques, would have worse pulmonary health.  If 
such a study were to add additional evidence to the hypothesis that oral 
bacteria contribute to the early infection and subsequent lung damage in CF, 
then a large scale RCT would be warranted.   
One observation that does not have a satisfactory explanation is the marked 
temporal variation in bacterial community composition and structure seen in 
some subject, particularly subjects 05 and 09.  These are two of the three 
subjects with the most severe (obstructive) pulmonary disease.  As such this 
offers one possible explanation.  As lung disease severity progresses the total 
amount of ventilated lung decreases, thus increasing the proportion of the lung 
that is not ventilated.  These under ventilated portions of the lung may provide  
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heterogeneous habitats that may harbour bacterial communities that differ from 
the communities in other parts of the lung.  Different communities may in fact be 
responsible, in part, for both the heterogeneous damage that is seen in advance 
CF lung disease (de Jong & Tiddens 2007), and the heterogeneous “hot spots” 
of inflammation seen in CF lungs during CFPEs (Klein et al. 2009).  To 
adequately investigate this idea of heterogeneous communities in different parts 
of the CF lung further would require more study.  Fibreoptic bronchoscopy with 
BAL would be one means of sampling, but may be sub-optimal due to failure of 
saline to remove adherent biofilms in the very distal small airway that are the 
primary area of infection in CF.  Additionally there would be high clinical risk due 
to the multiple areas that would need to be washed out.  A more satisfactory 
study would involve sampling the whole lungs, ex vivo, at the time of lung 
transplantation.  Such a solution would also help add strong support to the body 
of evidence showing that of oral contamination is not a suitable explanation for 
the high numbers of anaerobic bacteria found in respiratory secretions in CF 
(Bittar et al. 2008; Rogers et al. 2006; Tunney et al. 2008; Worlitzsch et al. 
2009). 
8.6  Summary 
The extended body of work presented here covers a wide range of diverse 
areas in CF pulmonary disease.  It has revealed new complexities in symptoms, 
and cast doubt on current paradigms in understanding what constitutes a 
clinical diagnosis of a CF pulmonary exacerbation.  The finding of fluctuations in 
symptoms that mimic clinician defined CFPEs suggests that there is an 
unaddressed burden of disease in CF adults.    
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The culture independent molecular techniques results have revealed that 
Prevotella sp and other anaerobes may have a crucial role in interacting with P. 
aeruginosa around the time of CFPE.  This in turn opens up new avenues for 
future research, and may influence current medical practise. 
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Chapter 9 -  Appendices 
 
9.1  Clinical Monitoring Form 
Figure 9-1 Clinical Monitoring Form 
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Figure 9-3 Distribution of Age  
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9.3  Box and Whisker Plot for FEV6 Values for All Subjects 
 
Figure 9-4 FEV6 box and whisker plot 
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9.3.1 Distribution of Spirometric Values 
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9.4  Individual Response Profile Plots  
9.4.1 Subject 01 
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9.4.3 Subject 03 
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9.4.4 Subject 04 
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9.4.5 Subject 05 
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9.4.9 Subject 09 
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9.4.10  Subject 10 
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9.4.11  Subject 11 
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9.4.12  Subject 12 
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9.4.13  Subject 13 
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9.4.14  Subject 14 
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9.5  Bacterial Clone Sequence Results 
Family  Genus & Species id  Aerobe/Anaerobe  Oral  
Actinomycetaceae  Actinomyces graevenitzii (98%)   Ae     O 
  Actinomyces lingnae (98%)   Ae     O 
  Actinomyces naeslundii   Ae     O 
  Actinomyces naeslundii/viscosus (98%)   Ae     O 
Micrococcineae  Rothia dentocariosa (97%)   Ae     O 
  Rothia mucilaginosa   Ae     O 
Bacteroidaceae  Bacteroides acidofaciens (88%)   An    
  Bacteroides eggerthii (88%)   An    
  Bacteroides uniformis (87%)   An    
  Bacteroides uniformis (88%)   An    
  Bacteroides viscericola (86%)   An    
Porphyromonadaceae  Porphyromonas catoniae (92%)   An     O 
  Tannerella forsythensis (94%)   An     O 
Prevotellaceae  Prevotella loescheii (98%)   An     O 
  Prevotella melaninogenica   An     O 
  Prevotella nanceiensis   An    
  Prevotella nigrescens   An     O 
  Prevotella oris (98%)   An     O 
  Prevotella oulora   An     O 
  Prevotella pallens   An     O 
  Prevotella pleuritidis   An    
  Prevotella salivae   An     O 
  Prevotella tannerae   An     O 
  Prevotella veroralis   An     O 
Rikenellaceae  Alistipes shahii (82%)   An     O 
Flavobacteriaceae  Capnocytophaga gingivalis   Ae     O 
  Capnocytophaga granulosa (98%)   Ae     O 
  Capnocytophaga leadbetteri (98%)   Ae     O 
  Capnocytophaga sputigena   Ae     O 
Staphylococcaceae  Gemella haemolysans   Ae     O 
  Staphylococcus aureus   Ae   
Aerococcaceae  Abiotrophia defectiva   Ae     O 
Carnobacteriaceae  Granulicatella adiacens   Ae     O 
  Granulicatella para-adiacens   Ae     O 
Streptococcaceae  Streptococcus infantis   Ae     O 
  Streptococcus intermedius/constellatus   Ae     O 
  Streptococcus mitis   Ae     O 
  Streptococcus mitis/pneumoniae   Ae     O 
  Streptococcus oralis   Ae     O 
  Streptococcus parasanguis   Ae     O 
  Streptococcus parasanguis/oralis/mitis   Ae     O 
  Streptococcus pneumoniae   Ae   
  Streptococcus salivarius   Ae     O 
  Strep.  salivarius/vestibularis/thermophilus   Ae     O 
  Streptococcus sanguinis   Ae     O 
Clostridiaceae  Clostridium metallolevans (98%)   Ae    
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Family  Genus & Species id  Aerobe/Anaerobe  Oral  
Eubacteriaceae  Mogibacterium neglectum   Ae     O 
Lachnospiraceae  Catonella morbi (98%)   An     O 
  Dorea longicatena   An    
  Eubacterium spp. 'Smarlab BioMol-2301166'   An    
  Eubacterium spp. 'Smarlab BioMol-2301231'   An    
  Oribacterium sinus (98%)   An    
  Butyrate-producer SR1/1 (97%)   An    
Veillonellaceae  Veillonella atypica   An     O 
  Veillonella dispar   An     O 
  Veillonella parvula   An     O 
  Veillonella ratti (96%)   An     O 
  Dialister invisus   An     O 
  Megasphaera micronuciformis   An     O 
  Selenomonas infelix   An     O 
Fusobacteriaceae  Fusobacterium naviforme/nucleatum   An     O 
  Fusobacterium nucleatum   An     O 
  Leptotrichia trevisanii (97%)   An     O 
Alcaligenaceae  Achromobacter xylosoxidans/insolitus   Ae   
Neisseriales  Eikenella corrodens   Ae     O 
  Neisseria cinerea   Ae     O 
  Neisseria elongata   Ae     O 
  Neisseria flava/sicca/mucosa/pharyngis   Ae     O 
  Neisseria flavescens (98%)   Ae     O 
  Neisseria meningitidis (95%)   Ae     O 
  Neisseria meningitidis (98%)   Ae     O 
Campylobacteraceae  Campylobacter concisus   Ae     O 
  Campylobacter gracilis   Ae     O 
Altermonadaceae  Alishewanella fetalis   Ae   
Pastuerellaceae  Haemophilus haemolyticus (98%)   Ae     O 
  Haemophilus influenzae   Ae     O 
  Haemophilus parahaemolyticus   Ae   
  Haemophilus parainfluenzae (97%)   Ae   
  Terrahaemophilus aromaticivorans   An    
Moraxellaceae  Acinetobacter lwoffii   Ae   
Pseudomonadaceae  Pseudomonas aeruginosa   Ae   
Xanthomonadaceae  Stenotrophomonas maltophilia   Ae   
  Total Species  82  82 
  Total aerobes (%)  46 (56%)   
  Total Anaerobes (%)  36 (44%)   
  Number associated with oral microbiota (%)    59(72%) 
Table 9-1 Microbiological classification of species identified by clone sequence 
analysis. Percentage values after species names refer percentage similarity of 
sequence to closest related species.  Metabolic classification An = Anaerobic; 
Ae = Aerobic.  Note: only strict anaerobes are classified as such; all other 
species, including micro-aerophiles, facultative anaerobes and aerobes are 
classified as aerobes.  
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Glossary 
Asymptotic:   Being in a state of having reached a plateau 
Community:   A conglomeration of species or individuals which can be said 
to interact with each other. 
Core species:   Species within a diverse community which can be said to be 
resident within a given environment. Opp Satelite species. 
Diversity:   Range of different species within an environment 
Eutrophic:   Relating to habitat with high levels of key nutrients 
In silico :     Performed on or with the help of a computer. 
Kingdom:   Highest taxonomic group into which organisms are grouped; 
one of six biological categories: Archeae, Bacteria, Plantae, 
Fungi, Animalia 
Oligotrophic:   relating to habitat with low levels of key nutrients 
Phylogenetic:  Evolutionary relatedness of species 
Planktonic:   Relating to mode of living that involves individual motion.  
Opp. sessile 
Rizosphere:   That part of the environment in close proximity and relating to 
plant roots  
Satellite species:   Species within a diverse community which are not considered 
to resident.  Such species can be said to be transient to a 
given environment (Opp. Core species). 
Species evenness: Measure of the abundance of species relative to other 
species within a given community.   
Species richness: Number of species detected in a given sample by a given 
technique 
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